Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
a106c28de0575ae3c459fbb751c3fb05c64a6e87e689129761a3a3cc5c8d0677.png
complex
<table><tr><td>Outcome</td><td>RCN (monetized)</td><td>ASBL (monetized)</td><td>SER (monetized)</td><td>ASBL + SER (monetized)</td></tr><tr><td>Cycling mode share by 2051 (%)</td><td>5</td><td>20</td><td>5</td><td>40</td></tr><tr><td>LV mode share by 2051 (%)</td><td>75</td><td>65</td><td>55</td><td>40</td></tr><tr><td>Proportion of people considering cycling always/mostly safe by 2040</td><td>0.4</td><td>0.7</td><td>0.3</td><td>0.9</td></tr><tr><td>LVKT (billion km)</td><td>&#8211;3.5</td><td>&#8211;7</td><td>&#8211;10</td><td>&#8211;18.5</td></tr><tr><td>Cyclist injuries </td></tr><tr><td>Fatalities</td><td>200 (620)</td><td>360 (1,100)</td><td>85 (250)</td><td>250 (850)</td></tr><tr><td>Serious injuries</td><td>4,000 (1,300)</td><td>7,000 (2,300)</td><td>1,600 (500)</td><td>5,000 (1,600)</td></tr><tr><td>Car crashes</td></tr><tr><td>Car occupant fatalities</td><td>&#8211;70 (&#8211;220)</td><td>&#8211;120 (&#8211;370)</td><td>&#8211;170 (&#8211;527)</td><td>&#8211;340 (&#8211;1,000)</td></tr><tr><td>Air pollution</td></tr><tr><td>Mortality</td><td>&#8211;10 (&#8211;7.5)</td><td>&#8211;20 (&#8211;15)</td><td>&#8211;40 (&#8211;30)</td><td>&#8211;80 (&#8211;60)</td></tr><tr><td>Hospitalizations</td><td>&#8211;5 (&#8211;0.02)</td><td>&#8211;15 (&#8211;0.04)</td><td>&#8211;20 (&#8211;0.06)</td><td>&#8211;40 (&#8211;0.12)</td></tr><tr><td>COPD incidence</td><td>&#8211;10 (&#8211;0.75)</td><td>&#8211;30 (&#8211;2.25)</td><td>&#8211;55 (&#8211;4)</td><td>&#8211;90 (&#8211;6.75)</td></tr><tr><td>Restricted activity days</td><td>&#8211;12,500 (&#8211;1)</td><td>&#8211;37,200 (&#8211;4)</td><td>&#8211;57,700 (&#8211;6)</td><td>&#8211;112,200 (&#8211;11)</td></tr><tr><td>Air pollution total</td><td>(&#8211;9)</td><td>(&#8211;21)</td><td>(&#8211;40)</td><td>(&#8211;78)</td></tr><tr><td>All-cause mortality</td><td>&#8211;650 (&#8211;2,000)</td><td>&#8211;1,850 (&#8211;5,700)</td><td>&#8211;650 (&#8211;2,000)</td><td>&#8211;4,000 (&#8211;12,400)</td></tr><tr><td>Greenhouse gas emissions (megatons)</td><td>&#8211;3 (&#8211;120)</td><td>&#8211;8 (&#8211;360)</td><td>&#8211;13 (&#8211;520)</td><td>&#8211;26 (&#8211;1040)</td></tr><tr><td>Fuel cost ($NZ million)</td><td>(&#8211;600)</td><td>(&#8211;1,800)</td><td>(&#8211;600)</td><td>(&#8211;3,900)</td></tr><tr><td>Infrastructure cost ($NZ million)</td><td>(45)</td><td>(250)</td><td>(380)</td><td>(630)</td></tr><tr><td>Net benefit ($NZ million)</td><td>&#8211;770</td><td>&#8211;2,550</td><td>&#8211;1,780</td><td>&#8211;13,090</td></tr><tr><td>Benefit&#8211;cost ratio</td><td>18</td><td>18</td><td>6</td><td>24</td></tr><tr><td colspan="5">Abbreviations: LV, light vehicle; LVKT, light vehicle kilometers travelled. Numbers with a negative sign represent &#173;savings. Monetized figures are given in parentheses and are in millions of New Zealand dollars. Benefit&#8211;cost ratios are calculated from the net public health benefits and infrastructure costs shown.</td></tr></table>
99faf7de717a3c898451b5a014e7817e23914e61571094256118fd37207b5a63.png
complex
<table><tr><td>Independent variables</td><td>&#946; coefficient(Standardized &#946; coefficient)</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age</td><td>0.061 (0.082)</td><td>- 0.101 &#8211; 0.222</td><td>0.461</td></tr><tr><td>BMI</td><td>1.509 (0.230)</td><td>1.056&#8211;1.961</td><td><i>&lt; 0.001</i><sup>&#8224;</sup></td></tr><tr><td>Fasting blood glucose</td><td>0.044 (0.044)</td><td>- 0.042 &#8211; 0.131</td><td>0.315</td></tr><tr><td>Dyslipidemia (Yes vs. No)</td><td>- 1.014 (1.497)</td><td>- 3.961 &#8211; 1.934</td><td>0.499</td></tr><tr><td>High risk alcohol drinking habit (Yes vs. No)</td><td>- 0.851 (1.412)</td><td>- 3.630 &#8211; 1.929</td><td>0.547</td></tr><tr><td>Smoking status (Yes vs. No)</td><td>- 1.244 (1.446)</td><td>- 4.091 &#8211; 1.602</td><td>0.390</td></tr><tr><td>Adequate exercise (Yes vs. No)</td><td>- 2.324 (1.396)</td><td>- 5.073 &#8211; 0.425</td><td>0.097</td></tr><tr><td>Family history of hypertension (Yes vs. No)</td><td>4.066 (2.304)</td><td>- 0.469 &#8211; 8.601</td><td>0.079</td></tr><tr><td>Per doubling of blood cadmium<sup>a</sup></td><td>2.171 (0.855)</td><td>0.487&#8211;3.854</td><td><i>0.012</i><sup>&#8224;</sup></td></tr><tr><td>Per doubling of blood lead<sup>a</sup></td><td>- 0.636 (1.029)</td><td>- 2.661 &#8211; 1.389</td><td>0.537</td></tr><tr><td colspan="4">R<sup>2</sup> = 0.212 (<i>p</i> <i>&lt; 0.001</i>)</td></tr></table>
d1033a313e5d91d8587f2d128734387682b4e30081084bf5a069678cdcd969ad.png
complex
<table><tr><td></td><td>All</td><td colspan="3">Followed the advices</td><td colspan="3">Contacted GP</td><td colspan="3">Re-contact Casualty clinic</td></tr><tr><td></td><td>N = 100</td><td>YesN = 93</td><td>NoN = 7</td><td>p-value</td><td>YesN = 22</td><td>NoN = 78</td><td>p-value</td><td>YesN = 11</td><td>NoN = 89</td><td>p-value</td></tr><tr><td>Origin of caller</td><td></td><td></td><td></td><td>0.08</td><td></td><td></td><td>&gt; 0.99</td><td></td><td></td><td>&gt; 0.99</td></tr><tr><td>Native Norwegian</td><td>84</td><td>80</td><td>4</td><td></td><td>19</td><td>65</td><td></td><td>10</td><td>74</td><td></td></tr><tr><td>Others</td><td>16</td><td>13</td><td>3</td><td></td><td>3</td><td>13</td><td></td><td>1</td><td>15</td><td></td></tr><tr><td>Gender of caller</td><td></td><td></td><td></td><td>0.34</td><td></td><td></td><td>&gt; 0.99</td><td></td><td></td><td>0.07</td></tr><tr><td>Men</td><td>22</td><td>22</td><td>0</td><td></td><td>5</td><td>17</td><td></td><td>5</td><td>17</td><td></td></tr><tr><td>Women</td><td>78</td><td>71</td><td>7</td><td></td><td>17</td><td>61</td><td></td><td>6</td><td>72</td><td></td></tr><tr><td>Time of day</td><td></td><td></td><td></td><td>0.009</td><td></td><td></td><td>0.47</td><td></td><td></td><td>&gt; 0.99</td></tr><tr><td>Daytime</td><td>37</td><td>34</td><td>3</td><td></td><td>9</td><td>28</td><td></td><td>4</td><td>33</td><td></td></tr><tr><td>Afternoon</td><td>42</td><td>42</td><td>0</td><td></td><td>7</td><td>35</td><td></td><td>5</td><td>37</td><td></td></tr><tr><td>Night</td><td>21</td><td>17</td><td>4</td><td></td><td>6</td><td>15</td><td></td><td>2</td><td>19</td><td></td></tr><tr><td>Got enough time</td><td></td><td></td><td></td><td>0.06</td><td></td><td></td><td>0.39</td><td></td><td></td><td>&gt; 0.99</td></tr><tr><td>Yes</td><td>94</td><td>89</td><td>5</td><td></td><td>20</td><td>74</td><td></td><td>11</td><td>83</td><td></td></tr><tr><td>No</td><td>3</td><td>2</td><td>1</td><td></td><td>1</td><td>2</td><td></td><td>0</td><td>3</td><td></td></tr><tr><td>Partly</td><td>3</td><td>2</td><td>1</td><td></td><td>1</td><td>2</td><td></td><td>0</td><td>3</td><td></td></tr><tr><td>Got worse</td><td></td><td></td><td></td><td>0.53</td><td></td><td></td><td>0.039</td><td></td><td></td><td>0.012</td></tr><tr><td>Yes</td><td>10</td><td>9</td><td>1</td><td></td><td>5</td><td>5</td><td></td><td>4</td><td>6</td><td></td></tr><tr><td>No</td><td>90</td><td>84</td><td>6</td><td></td><td>17</td><td>73</td><td></td><td>7</td><td>83</td><td></td></tr><tr><td>Got answers to the questions</td><td></td><td></td><td></td><td>&lt; 0.0001</td><td></td><td></td><td>0.024</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>79</td><td>79</td><td>0</td><td></td><td>13</td><td>66</td><td></td><td>10</td><td>69</td><td>&gt; 0.99</td></tr><tr><td>No</td><td>6</td><td>3</td><td>3</td><td></td><td>2</td><td>4</td><td></td><td>0</td><td>6</td><td></td></tr><tr><td>Partly</td><td>15</td><td>11</td><td>4</td><td></td><td>7</td><td>8</td><td></td><td>1</td><td>14</td><td></td></tr><tr><td>Trusted the nurse</td><td></td><td></td><td></td><td>&lt; 0.0001</td><td></td><td></td><td>0.32</td><td></td><td></td><td>0.64</td></tr><tr><td>Yes</td><td>74</td><td>74</td><td>0</td><td></td><td>14</td><td>60</td><td></td><td>10</td><td>64</td><td></td></tr><tr><td>No</td><td>8</td><td>6</td><td>2</td><td></td><td>3</td><td>5</td><td></td><td>0</td><td>8</td><td></td></tr><tr><td>Partly</td><td>18</td><td>13</td><td>5</td><td></td><td>5</td><td>13</td><td></td><td>1</td><td>17</td><td></td></tr></table>
d909183fece0ad0682b89ea0bdb471baaca835592aeaac3cff31027268d1728b.png
simple
<table><tr><td>Protein Symbol</td><td>Protein Name</td><td>Organism</td><td>Function</td><td>Swiss Prot ID</td></tr><tr><td>OPN (SSP1)</td><td>Osteopontin, secreted phosphoprotein 1</td><td><i>Homo sapiens</i></td><td>Matrix mineralization, immunity</td><td>P10451</td></tr><tr><td>DMP1</td><td>Dentin matrix protein 1</td><td><i>Homo sapiens</i></td><td>Osteoblast differentiation, nucleation of hydroxyapatite</td><td>Q13316</td></tr><tr><td>MEPE</td><td>Matrix extracellular phosphoglycoprotein</td><td><i>Homo sapiens</i></td><td>Phosphate excretion, mineralization</td><td>Q9NQ76</td></tr><tr><td>BSP</td><td>Bone sialoprotein</td><td><i>Homo sapiens</i></td><td>Matrix mineralization, hydroxyapatite binding, cell attachment</td><td>P21815</td></tr><tr><td>DSPP</td><td>Dentin sialophosphoprotein</td><td><i>Homo sapiens</i></td><td>Dentinogenesis</td><td>Q9NZW4</td></tr><tr><td>AMELX</td><td>Amylogenin</td><td><i>Homo sapiens</i></td><td>Enamel formation; extracellular scaffold, crystal growth</td><td>Q99217</td></tr><tr><td>Stm</td><td>Starmaker</td><td><i>Danio rerio</i> (zebrafish)</td><td>Otolith formation</td><td>A2VD23</td></tr><tr><td>OMM-64</td><td>Otolith matrix macromolecule-64</td><td><i>Oncorhynchus mykiss</i> (rainbow trout)</td><td>Otolith formation</td><td>B1Q2L9</td></tr></table>
18c1626fbc970126a013e8862893d3d71cf952273ba3a5ad87db2edd1d85fed0.png
simple
<table><tr><td>Question</td><td>Response rate (percentage; <i>n</i> = 86)</td></tr><tr><td>14. How did you usually use the video clips in PHARMACY 301?</td><td>79</td></tr><tr><td>15. How did watching the Pharmville clips help you in PHARMACY 301?</td><td>64</td></tr><tr><td>16. Which families are the most realistic and why?</td><td>35</td></tr><tr><td>17. Which are the most unrealistic and why?</td><td>28</td></tr><tr><td>18. Do you have any suggestions for improving Pharmville?</td><td>48</td></tr><tr><td>19. Do you have any suggestions for where else the Pharmville families could be included in the BPharm programme?</td><td>19</td></tr><tr><td>20. How do feel that Pharmville and the related clips helped your learning?</td><td>35</td></tr><tr><td>21. Space for any other comments about Pharmville that you would like to make.</td><td>17</td></tr></table>
ab801841984517d68ca83a263b8151b2c89db486eb60b5b1834464e424235dee.png
complex
<table><tr><td rowspan="2">Runs order</td><td colspan="2">Operating conditions</td><td rowspan="2">Response Dry cell mass (g/l)</td></tr><tr><td>A</td><td>B</td></tr><tr><td>1</td><td>1</td><td>1</td><td>13.66 &#177; 0.08</td></tr><tr><td>2</td><td>0</td><td>1</td><td>14.96 &#177; 0.06</td></tr><tr><td>3</td><td>0</td><td>0</td><td>15.28 &#177; 0.01</td></tr><tr><td>4</td><td>&#8722;1</td><td>1</td><td>15.44 &#177; 0.04</td></tr><tr><td>5</td><td>&#8722;1</td><td>0</td><td>16.04 &#177; 0.01</td></tr><tr><td>6</td><td>0</td><td>1</td><td>14.55 &#177; 0.13</td></tr><tr><td>7</td><td>&#8722;1</td><td>0</td><td>16.12 &#177; 0.06</td></tr><tr><td>8</td><td>1</td><td>&#8722;1</td><td>15.14 &#177; 0.05</td></tr><tr><td>9</td><td>&#8722;1</td><td>0</td><td>15.88 &#177; 0.05</td></tr><tr><td>10</td><td>0</td><td>0</td><td>14.69 &#177; 0.02</td></tr><tr><td>11</td><td>1</td><td>0</td><td>15.55 &#177; 0.02</td></tr><tr><td>12</td><td>&#8722;1</td><td>0</td><td>16.20 &#177; 0.03</td></tr><tr><td>13</td><td>1</td><td>&#8722;1</td><td>14.87 &#177; 0.05</td></tr><tr><td>14</td><td>&#8722;1</td><td>1</td><td>15.99 &#177; 0.07</td></tr><tr><td>15</td><td>0</td><td>&#8722;1</td><td>15.91 &#177; 0.06</td></tr><tr><td>16</td><td>&#8722;1</td><td>0</td><td>16.17 &#177; 0.07</td></tr></table>
2f9aa3bdcf898d7af7dbb841fa0ac941399b733e4d8cb053fc4ca866a8f43a13.png
simple
<table><tr><td>UHI Assessment TOOL</td><td>Geographical Cover</td><td>Scale of the Assessment</td><td>Type of Assessment</td><td>User Input Parameters</td><td>Tool Output</td></tr><tr><td>Decision Support System (DSS) UHI project</td><td>Bologna/Modena, Venice/Padua, Wien, Stuttgart, Lodz/Warsaw, Ljubljana, Budapest and Prague.</td><td>Supra-metropolitan</td><td>Phase 1: Mapping Urban Heat. Phase 2: Understanding regulations and policies related to UHI (greenery: street or roof, material reflectance...)</td><td>1/Location, 2/Scale (building or urban) 3/Typology of the intervention (building, facade, roofs, surface lots, urban structure and urban green) 4/Economic assessment 5/Skills.</td><td>1/climate change assessment (Change in annual mean temperature per decade, changes in annual near-surface temperature for 30 year periods and heat wave frequency), 2/a set of normative applicable to the selected area and skills, 3/a set of potential mitigation strategies.</td></tr><tr><td>CE Urban Heat Island Atlas UHI project</td><td>Central Europe region</td><td>Regional</td><td>Phase 1: Mapping Urban heat related parameters.</td><td>1/Location</td><td>1/Air temperature 2/Digital elevation models 3/Land surface temperature 4/Land cover regional scale (corine) 5/Urban land use.</td></tr><tr><td>STAR tools GRaBS project</td><td>North West region of England</td><td>Neighbourhood</td><td>Phase 4: Testing conceptual design</td><td>1/Location 2/Land cover proposal (% of buildings, major roads, other impervious surfaces, green and blue surfaces and bare soil or gravel surfaces) 3/Temperature scenario for 2050 (Baseline temperature, 2050&#8217;s 10% probability level, 50% probability level or 90% probability level).</td><td>1/Maximum surface temperature</td></tr><tr><td>London unified model (Londum)</td><td>City of London</td><td>City</td><td>Phase 1: Simluation map of the Urban Heat Island of the existing city. Phase 4: Simulation map of the Urban Heat Island of the projected city.</td><td>1/ Volume (Reflection, Shadowing, conduction of heat into the buildings, flux of heat into the atmosphere). Provided by the tool for the city of London.</td><td>1/Urban heat island intensity (air temperature at 1,5m height).</td></tr><tr><td>ADMS model</td><td>City of London</td><td>Neighbourhood</td><td>Phase 1: Simluation map of the Urban Heat Island of the existing city. Phase 4: Simulation map of the Urban Heat Island of the projected city.</td><td>1/Location 2/Surface cover (Albedo, evapotranspiration, thermal admittance).</td><td>2/Air temperature variations -due to land cover- at 2m height.</td></tr><tr><td>London site-specific air temperature prediction model (LSSAT)</td><td>City of London</td><td>Neighbourhood</td><td>Phase 1: Air temperature mapping at a particular time. Phase 4: Air temperature prediction based on intervention proposed.</td><td>1/Location</td><td>1/Hourly prediction of air temperature based on site specific transects (Global solar radiation, cloud cover, wind velocity and relative humidity).</td></tr><tr><td>EPA Mitigation Impact Screening Tool (MIST)</td><td>U.S.A. 230 cities</td><td>City</td><td>Phase 4: Testing the mitigation effect of the selected mitiation strategy.</td><td>1/Location 2/The latitude 3/the cooling degree day (CDD) 4/the heating degree day (HDD) 5/the population 6/the mean annual temperature 7/the typical peak (one hour) ozone 8/Mitigation strategy (albedo or vegetation modification).</td><td>Calculation of the effect of the mitigation strategy 1/Reduction of the mean city temperature 2/Cooling degree days 3/the heating degree day 4/the typical 1hr and 8hr max ozone 5/The energy consumption.</td></tr></table>
4445e34c2dde6c6417996c914fafdadc9a23942fa22bee0d84c136025fc98822.png
complex
<table><tr><td>Item</td><td>SE</td><td>LE</td><td>SEM</td><td><i>P</i> value</td></tr><tr><td colspan="5">Sow BW (kg)</td></tr><tr><td> At insemination</td><td>72.7</td><td>72.9</td><td>0.9</td><td>0.840</td></tr><tr><td> At day 90 of pregnancy</td><td>127.9</td><td>117.0</td><td>1.9</td><td>0.002</td></tr><tr><td>Litter size</td><td>12.0</td><td>11.8</td><td>0.9</td><td>0.856</td></tr><tr><td>Fetal weight (g)</td><td>574.4</td><td>507.7</td><td>17.9</td><td>0.039</td></tr><tr><td>CV, %</td><td>14.86</td><td>12.72</td><td>1.48</td><td>0.345</td></tr></table>
dfdf9aec20d517508f2e751422c57e798d281f8c9c6c17a36ed98e53df10cb3f.png
complex
<table><tr><td>Pharmacological agents</td><td>Neonatal rat spinal cord preparation</td><td>Decerebrate cat preparation</td><td>Acute spinal cat</td><td>Early chronic spinal cat</td><td>Late chronic spinal cat</td><td>Late chronic spinal rat</td></tr><tr><td>Edrophonium (EDRO)</td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor</td></tr><tr><td>Neostigmine (NEO)</td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor</td></tr><tr><td>EDRO + ACh</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + acetylocholine</td></tr><tr><td>EDRO + tubocurarine</td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + nicotinic antagonist</td></tr><tr><td>Clonidine</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>NA agonist</td></tr><tr><td>EDRO + clonidine</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor+ NA agonist</td></tr><tr><td>Clonidine (low dose)</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>NA agonist</td></tr><tr><td>Atropine</td><td rowspan="2"></td><td rowspan="2">&#8596;</td><td rowspan="2">&#8596;</td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>muscarinic antagonist</td></tr><tr><td>Atropine + clonidine (low dose)</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>muscarinic antagonist + NA agonist</td></tr><tr><td>Clonidine (low dose) + atropine</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>NA agonist + muscarinic antagonist</td></tr><tr><td>Carbachol</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8595;&#8595;</td><td rowspan="2"></td><td rowspan="2">&#8595;&#8595;</td></tr><tr><td>cholinergic agonist</td></tr><tr><td>Carbachol + atropine</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td></tr><tr><td>cholinergic agonist + muscarinic antagonist</td></tr><tr><td>Atropine + carbachol</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8595;&#8595;</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>muscarinic antagonist + cholinergic agonist</td></tr><tr><td>EDRO + atropine</td><td rowspan="2">&#8593;&#8595;&#8595;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + muscarinic antagonist</td></tr><tr><td>EDRO + telenzepine</td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + M<sub>1</sub> antagonist</td></tr><tr><td>EDRO + telenzepine (high dose)</td><td rowspan="2">&#8595;&#8595;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + M<sub>1</sub> antagonist</td></tr><tr><td>EDRO + methoctramine (METHOC)</td><td rowspan="2">&#8593;&#8595;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + M<sub>2</sub> antagonist</td></tr><tr><td>EDRO + METHOC (high dose)</td><td rowspan="2">&#8595;&#8595;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + M<sub>2</sub> antagonist</td></tr><tr><td>EDRO + 4-diphenylacetoxy-N-methylpiperidine metiodide (4-DAMP)</td><td rowspan="2">&#8595;&#8595;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td></tr><tr><td>AChE inhibitor + M<sub>3</sub> antagonist</td></tr><tr><td>MT-3</td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>M<sub>4</sub> antagonist</td></tr><tr><td>Mecamylamine</td><td rowspan="2"></td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>nicotinic antagonist</td></tr><tr><td>Mecamylamine + atropine</td><td rowspan="2"></td><td rowspan="2">&#8596;</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>nicotinic antagonist + muscarinic antagonist</td></tr><tr><td>Dihydro-&#946;-erythrpidine</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2">&#8593;&#8593;</td><td rowspan="2"></td></tr><tr><td>nicotinic antagonist</td></tr></table>
72472f5696f4038d9e964c1b24026b22442a24bea3c7412e4db364aae0b5aa88.png
simple
<table><tr><td>Samples with decreased expression (n)</td><td>Gene symbol</td><td>Mean log ratio</td><td>Range of log ratio</td><td>Samples with increased expression (n)</td><td>Mean log ratio</td><td>Range of log ratio</td></tr><tr><td>11</td><td>CD14</td><td>-2.99</td><td>-0.27/-5.38</td><td>0</td><td>-</td><td>-</td></tr><tr><td>10</td><td>TIA1</td><td>-0.68</td><td>-0.24/-1.05</td><td>1</td><td>-</td><td>0.77</td></tr><tr><td>10</td><td>YWHAH</td><td>-0.72</td><td>-0.27/-1.80</td><td>0</td><td>-</td><td>-</td></tr><tr><td>10</td><td>PPP3CA</td><td>-0.69</td><td>-0.34/-1.14</td><td>0</td><td>-</td><td>-</td></tr><tr><td>10</td><td>ITGB2</td><td>-2.87</td><td>-0.58/-5.11</td><td>0</td><td>-</td><td>-</td></tr><tr><td>9</td><td>PDGFRA</td><td>-1.32</td><td>-0.42/-3.30</td><td>2</td><td>2.62</td><td>1.21/4.03</td></tr><tr><td>9</td><td>RASA1</td><td>-0.93</td><td>-0.42/-1.17</td><td>0</td><td>-</td><td>-</td></tr><tr><td>8</td><td>LDHB</td><td>-0.60</td><td>-0.32/-1.25</td><td>2</td><td>1.11</td><td>0.64/1,58</td></tr><tr><td>8</td><td>CSF1R</td><td>-3.05</td><td>-0.63/-5.08</td><td>0</td><td>-</td><td>-</td></tr><tr><td>8</td><td>RARA</td><td>-0.95</td><td>-0.51/-1.23</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>ANXA4</td><td>-1.10</td><td>-0.64/-1.16</td><td>4</td><td>1.37</td><td>0.84/2.33</td></tr><tr><td>7</td><td>CTSB</td><td>-0.93</td><td>-0.23/-1.97</td><td>3</td><td>0.94</td><td>0.82/1.13</td></tr><tr><td>7</td><td>DAPK1</td><td>-1.35</td><td>-0.59/-2.07</td><td>2</td><td>1,40</td><td>1.19/1.60</td></tr><tr><td>7</td><td>CASP1</td><td>-1.69</td><td>-0.71/-2.90</td><td>2</td><td>1.44</td><td>0.97/1.90</td></tr><tr><td>7</td><td>PRF1</td><td>-1.68</td><td>-0.54/-3.68</td><td>2</td><td>0.79</td><td>0.67/0.91</td></tr><tr><td>7</td><td>EPHB4</td><td>-1.30</td><td>-0.68/-2.34</td><td>1</td><td>-</td><td>0.30</td></tr><tr><td>7</td><td>HCK</td><td>-1.79</td><td>-0.39/-3.65</td><td>1</td><td>-</td><td>1.08</td></tr><tr><td>7</td><td>ESD</td><td>-0.76</td><td>-0.44/-0.95</td><td>1</td><td>-</td><td>0.36</td></tr><tr><td>7</td><td>DHCR24</td><td>-1.97</td><td>-0.75/-4.34</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>PPP1CB</td><td>-0.99</td><td>-0.62/-1.56</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>MYO18A/TIAF1</td><td>-1.23</td><td>-0.67/-2.02</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>BIRC5</td><td>-2.95</td><td>-1.17/-4.91</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>PDGFRB</td><td>-1.28</td><td>-0.61/-2.26</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>ATG5</td><td>-1.39</td><td>-0.61/-3.19</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>DOCK1</td><td>-0.86</td><td>-0.40/-1.23</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>PTPN13</td><td>-1.97</td><td>-0.69/-3.17</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>BTK</td><td>-1.78</td><td>-0.39/-3.28</td><td>0</td><td>-</td><td>-</td></tr><tr><td>7</td><td>SYK</td><td>-4.26</td><td>-0.34/-8.06</td><td>0</td><td>-</td><td>-</td></tr></table>
7ba81582c24aadeb91891f7aaef4c73d5108a4e8b72f133e3cde637a8756d58d.png
simple
<table><tr><td>Patient</td><td>Age</td><td>Site</td><td>Stage</td><td>Primary date</td><td>Primary therapy*</td><td>Recurrence</td><td>Expiry</td></tr><tr><td>1</td><td>50</td><td>Retromolar trigone</td><td>IV</td><td>2009/05/30</td><td>S+CCRT</td><td></td><td></td></tr><tr><td>2</td><td>55</td><td>Oral tongue</td><td>IV</td><td>2010/10/24</td><td>S+CCRT</td><td></td><td></td></tr><tr><td>3</td><td>59</td><td>Buccal mucosa</td><td>IV</td><td>2011/05/04</td><td>S+CCRT</td><td></td><td></td></tr><tr><td>4</td><td>56</td><td>Buccal mucosa</td><td>IV</td><td>2010/05/31</td><td>S+CCRT</td><td>2010/08/09</td><td>2010/10/31</td></tr><tr><td>5</td><td>49</td><td>Buccal mucosa</td><td>IV</td><td>2010/07/27</td><td>S+CCRT</td><td>2010/11/24</td><td>2011/06/07</td></tr><tr><td>6</td><td>48</td><td>Buccal mucosa</td><td>III</td><td>2009/10/06</td><td>S+C/T</td><td>2009/12/29</td><td>2010/02/11</td></tr></table>
fc3299270282cb5f3774d5fa7f6966937e72512b4b20e69a2baa837f38054905.png
complex
<table><tr><td></td><td colspan="2">Acid fast bacilli</td><td>Total</td></tr><tr><td></td><td>negative for AFB</td><td>positive for AFB</td><td></td></tr><tr><td>Giant cells</td><td></td><td></td><td></td></tr><tr><td> Not present</td><td>50</td><td>25</td><td>75</td></tr><tr><td> Present</td><td>6</td><td>19</td><td>25</td></tr><tr><td>Total</td><td>56</td><td>44</td><td>100</td></tr></table>
bb216bed9e7d1f0d8c98e4853b62f93535044ee30e87d123baa46d362861cd61.png
simple
<table><tr><td>Parameters</td><td>&#8804;5 (<i>n</i> = 92)</td><td>6&#8211;15 (<i>n</i> = 26)</td><td>&#8805;16 (<i>n</i> = 18)</td><td><i>P</i> value</td></tr><tr><td>TAC, g/dL</td><td>2.37 &#177; 0.57</td><td>2.55 &#177; 0.43</td><td>2.71 &#177; 39</td><td>0.025</td></tr><tr><td>MDA, <i>&#956;</i>mol/L</td><td>3.74 &#177; 1.11</td><td>3.82 &#177; 1.18</td><td>3.50 &#177; 0.88</td><td>0.60</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>24.46 &#177; 3.80</td><td>26.06 &#177; 3.34</td><td>25.61 &#177; 2.88</td><td>0.09</td></tr></table>
161cbac47ac7f617014a1cef53e78739f70a72b602ab45cdac36cdf6baf473f6.png
simple
<table><tr><td>Parameter</td><td>P-value</td></tr><tr><td>Region</td><td>0.027</td></tr><tr><td>Age</td><td>0.103</td></tr><tr><td>Gender</td><td>0.168</td></tr><tr><td>Histology</td><td>0.906</td></tr><tr><td>Stage</td><td>0.901</td></tr><tr><td>Smoking status</td><td>0.668</td></tr><tr><td>Diabetes mellitus</td><td>0.142</td></tr></table>
0e6eada3e9b98021118d71adeacf1cfae78abef80c3eaf01a32b83c01e001308.png
complex
<table><tr><td></td><td>&#946;-coefficient</td><td>OR</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td colspan="5">Measurements at sea level (after variable selection)</td></tr><tr><td>age</td><td>0.075</td><td>1.08</td><td>0.99&#8211;1.18</td><td>0.092</td></tr><tr><td>BUN</td><td>&#8722;0.259</td><td>0.77</td><td>0.60&#8211;0.99</td><td>0.040*</td></tr><tr><td colspan="5">Measurements at 3700 m (after variable selection)</td></tr><tr><td>age</td><td>0.090</td><td>1.09</td><td>0.98&#8211;1.23</td><td>0.110</td></tr><tr><td>SpO<sub>2</sub></td><td>&#8722;0.191</td><td>0.84</td><td>0.76&#8211;0.93</td><td>0.001**</td></tr><tr><td>HR</td><td>0.029</td><td>1.03</td><td>1.00&#8211;1.07</td><td>0.042*</td></tr><tr><td>SBP</td><td>&#8722;0.019</td><td>0.98</td><td>0.95&#8211;1.01</td><td>0.091</td></tr><tr><td>BUN</td><td>&#8722;0.452</td><td>0.64</td><td>0.46&#8211;0.88</td><td>0.007**</td></tr></table>
7565c7f6961ec760e151806e32f9c86f2d2495b3041be4b9ea4b7228d7501ef7.png
simple
<table><tr><td></td><td>OR</td><td>95% CI</td><td><i>P</i>-value</td></tr><tr><td><i>Ser/Ser</i> vs. <i>Asn/Asn</i></td><td>5.68</td><td>4.83&#8211;6.70</td><td>&lt; 0.0001</td></tr><tr><td><i>Ser/Ser</i> vs. <i>Asn/Ser</i></td><td>4.93</td><td>4.28&#8211;5.68</td><td>&lt; 0.0001</td></tr><tr><td><i>Ser/Ser</i> vs. <i>Asn/Asn</i> + <i>Asn/Ser</i></td><td>5.21</td><td>4.65&#8211;5.85</td><td>&lt; 0.0001</td></tr></table>
50334f82dfe4e125176077c21f85b5c2ac4a5ce5fa066230c1b56c9760f7d852.png
complex
<table><tr><td></td><td colspan="2">Pneumonia (n=5709)</td></tr><tr><td></td><td>Without rickets</td><td>With rickets</td></tr><tr><td></td><td>n=5600</td><td>n=109</td></tr><tr><td>Deaths n (%)</td><td>345 (6.16)</td><td>9 (8.26)</td></tr><tr><td><i>Odds-ratio</i></td><td colspan="2"><i>1.37 (p-value = 0.32)</i></td></tr><tr><td></td><td colspan="2">Severe malnutrition (n=727)</td></tr><tr><td></td><td>Without rickets</td><td>With rickets</td></tr><tr><td></td><td>n=680</td><td>n=47</td></tr><tr><td>Deaths n (%)</td><td>88 (12.94)</td><td>2 (4.26)</td></tr><tr><td><i>Odds-ratio</i></td><td colspan="2"><i>0.30 (p-value = 0.11)</i></td></tr><tr><td></td><td colspan="2">Malnutrition (Severe, moderate, mild) (n=1150)</td></tr><tr><td></td><td>Without rickets</td><td>With rickets</td></tr><tr><td></td><td>n=1079</td><td>n=71</td></tr><tr><td>Deaths n (%)</td><td>118 (10.94)</td><td>3 (4.23)</td></tr><tr><td><i>Odds-ratio</i></td><td colspan="2"><i>0.36 (p-value = 0.11)</i></td></tr><tr><td></td><td colspan="2">Dehydration (n=2233)</td></tr><tr><td></td><td>Without rickets</td><td>With rickets</td></tr><tr><td></td><td>n=2180</td><td>n=53</td></tr><tr><td>Deaths n (%)</td><td>230 (10.55)</td><td>4 (7.55)</td></tr><tr><td><i>Odds-ratio</i></td><td colspan="2"><i>0.69 (p-value = 0.65)</i></td></tr><tr><td></td><td colspan="2">Diarrhea, n=2805</td></tr><tr><td></td><td>Without Rickets</td><td>With Rickets</td></tr><tr><td></td><td>n=2772</td><td>n=33</td></tr><tr><td>Deaths n (%)</td><td>172 (6.2)</td><td>2 (6.06)</td></tr><tr><td><i>Odds-ratio</i></td><td colspan="2"><i>0.97 (p-value=1.00)</i></td></tr></table>
d856948bd4a18d91c2b128894fd29a54b57a83691ad31cface15bbaaa2b96b34.png
simple
<table><tr><td>State</td><td>NE level</td><td>I<sub>h</sub></td><td>Apical function</td></tr><tr><td>Asleep</td><td>Low</td><td>High</td><td>Isolated from soma</td></tr><tr><td>Awake</td><td>Moderate</td><td>Moderate</td><td>Selective amplification</td></tr><tr><td>Attentive</td><td>High</td><td>Low</td><td>Inc. Selectivity &amp; Amplif.</td></tr><tr><td>High arousal</td><td>Maximum</td><td>Minimum</td><td>Selective drive e.g., Stereotypical impulses</td><td></td></tr><tr><td>Anesthetized Ketamine propofol Isoflurane</td><td>Low</td><td>Minimum</td><td>Non-selective slow waves</td></tr></table>
9bebc6c8cb5168fc18c705e333b8c9b5bfe811c0d8449be107e5b75abc10d973.png
complex
<table><tr><td></td><td></td><td></td><td colspan="5">Relative Normalised Expression</td></tr><tr><td>Receptor Class</td><td>Accession Number</td><td>Gene Name</td><td colspan="3">BMM</td><td colspan="2">TEPM</td></tr><tr><td></td><td></td><td></td><td>2 h</td><td>6 h</td><td>24 h</td><td>1 h</td><td>7 h</td></tr><tr><td colspan="8">Repressed by LPS in BMM and TEPM</td></tr><tr><td>Class A</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NM_009924</td><td>Cnr2</td><td>0.2</td><td>0.1</td><td>0.3</td><td>0.3</td><td>0.1</td></tr><tr><td></td><td>NM_009911</td><td>Cxcr4</td><td>0.3</td><td>0.1</td><td>7.1</td><td>0.7</td><td>0.1</td></tr><tr><td></td><td>NM_183031</td><td>Ebi2</td><td>0.2</td><td>0.1</td><td>0.1</td><td>0.4</td><td>0.2</td></tr><tr><td></td><td>NM_004230</td><td>Edg5</td><td>0.2</td><td>0.5</td><td>2.0</td><td>0.4</td><td>0.6</td></tr><tr><td></td><td>NM_022320</td><td>Gpr35</td><td>0.2</td><td>0.4</td><td>1.6</td><td>0.6</td><td>0.1</td></tr><tr><td></td><td>NM_030258</td><td>Gpr146</td><td>0.1</td><td>0.4</td><td>1.0</td><td>0.4</td><td>0.1</td></tr><tr><td></td><td>NM_008772</td><td>P2ry1</td><td>0.3</td><td>0.1</td><td>0.2</td><td>0.3</td><td>0.1</td></tr><tr><td></td><td>NM_175116</td><td>P2ry5</td><td>0.1</td><td>0.1</td><td>0.7</td><td>0.3</td><td>0.1</td></tr><tr><td></td><td>NM_013641</td><td>Ptger1</td><td>0.7</td><td>0.5</td><td>0.3</td><td>0.7</td><td>0.3</td></tr><tr><td></td><td>NM_008965</td><td>Ptger4</td><td>3.1</td><td>0.5</td><td>1.0</td><td>1.9</td><td>0.3</td></tr><tr><td colspan="8">Repressed by LPS in BMM</td></tr><tr><td>Class A</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NM_007420</td><td>Adrb2</td><td>0.3</td><td>0.1</td><td>0.1</td><td>1.9</td><td>0.8</td></tr><tr><td></td><td>NM_009779</td><td>C3ar1</td><td>0.7</td><td>0.5</td><td>0.3</td><td>0.8</td><td>0.6</td></tr><tr><td></td><td>NM_007577</td><td>C5r1</td><td>1.1</td><td>0.7</td><td>0.1</td><td>3.0</td><td>1.1</td></tr><tr><td></td><td>NM_009915</td><td>Ccr2</td><td>0.5</td><td>0.4</td><td>0.2</td><td>0.8</td><td>0.9</td></tr><tr><td></td><td>NM_009910</td><td>Cxcr3</td><td>0.7</td><td>0.1</td><td>0.1</td><td>1.6</td><td>0.9</td></tr><tr><td></td><td>NM_009987</td><td>Cx3cr1</td><td>0.5</td><td>0.1</td><td>0.1</td><td>1.0</td><td>0.7</td></tr><tr><td></td><td>NM_030720</td><td>Gpr84</td><td>8.3</td><td>10.0</td><td>0.2</td><td>7.7</td><td>50.0</td></tr><tr><td></td><td>NM_027571</td><td>P2ry12</td><td>0.5</td><td>0.1</td><td>0.2</td><td>1.0</td><td>1.0</td></tr><tr><td>Class B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NM_018782</td><td>Calcrl</td><td>1.0</td><td>2.6</td><td>0.2</td><td>0.6</td><td>7.1</td></tr><tr><td colspan="8">Repressed by LPS in TEPM</td></tr><tr><td>Class A</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NM_007719</td><td>Ccr7</td><td>1.0</td><td>5.0</td><td>1.9</td><td>0.4</td><td>2.9</td></tr><tr><td></td><td>NM_021381</td><td>Prokr1</td><td>0.8</td><td>33.3</td><td>7.1</td><td>0.3</td><td>0.1</td></tr><tr><td></td><td>NM_198168</td><td>Ppp2r5b</td><td>1.0</td><td>1.3</td><td>1.1</td><td>0.8</td><td>0.5</td></tr><tr><td></td><td>NM_008964</td><td>Ptger2</td><td>2.4</td><td>1.3</td><td>11.1</td><td>0.3</td><td>0.1</td></tr><tr><td>Class B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NM_080437</td><td>Celsr3</td><td>0.8</td><td>1.2</td><td>2.3</td><td>0.2</td><td>0.2</td></tr><tr><td></td><td>NM_173036</td><td>Gpr97</td><td>0.8</td><td>1.0</td><td>0.8</td><td>0.5</td><td>0.2</td></tr><tr><td></td><td>NM_016894</td><td>Ramp1</td><td>1.0</td><td>1.0</td><td>1.0</td><td>0.5</td><td>0.2</td></tr><tr><td>Class C</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NM_022420</td><td>Gprc5b</td><td>1.0</td><td>1.0</td><td>1.3</td><td>0.8</td><td>0.1</td></tr></table>
6b5397669cff38bf5f54dbdff8f0b5e180c5e4255de1eb970bcee7ba9e0f9907.png
complex
<table><tr><td colspan="5">Presence of IFG</td></tr><tr><td>Characteristics</td><td>Yes (%)</td><td>N (%)</td><td>COR</td><td>AOR</td></tr><tr><td colspan="5">Age</td></tr><tr><td>&lt; 25</td><td>7 (2.0)</td><td>336 (98.0)</td><td>1.0</td><td>1.0</td></tr><tr><td> 25&#8211;34</td><td>28 (7.7)</td><td>334 (92.3)</td><td>4.0 (1.7&#8211;9.3)</td><td>1.8 (0.7&#8211;4.8)</td></tr><tr><td> 35&#8211;44</td><td>39 (27.5)</td><td>103 (72.5)</td><td>18.2 (7.9&#8211;41.9)</td><td>3.1 (0.8&#8211;12.0)</td></tr><tr><td>&#8805; 45</td><td>46 (51.8)</td><td>43 (48.3)</td><td>51.4 (21.8&#8211;120.9)</td><td>4.9 (1.1&#8211;23.1)</td></tr><tr><td colspan="5">Police rank</td></tr><tr><td> Lower rank</td><td>47 (6.6)</td><td>663 (93.4)</td><td>1.0</td><td>1.0</td></tr><tr><td> Middle rank</td><td>23 (18.4)</td><td>102 (81.6)</td><td>3.2 (1.9&#8211;5.5)</td><td>0.5 (0.2&#8211;1.1)</td></tr><tr><td> Higher rank</td><td>50 (49.5)</td><td>51 (50.5)</td><td>13.8 (8.5&#8211;22.6)</td><td>0.9 (0.9&#8211;2.6)</td></tr><tr><td colspan="5">Years of service</td></tr><tr><td> 1&#8211;10</td><td>20 (7.0)</td><td>268 (93.0)</td><td>1.0</td><td>1.0</td></tr><tr><td> 11&#8211;20</td><td>27 (13.3)</td><td>254 (86.7)</td><td>4.3 (2.3&#8211;14.3)</td><td>2.4 (1.0&#8211;6.1)</td></tr><tr><td>&gt; 20</td><td>73 (47.1)</td><td>82 (52.9)</td><td>24.8 (14.4&#8211;42.9)</td><td>3.3 (0.9&#8211;11.9)</td></tr><tr><td colspan="5">Family history</td></tr><tr><td> Yes</td><td>31 (47.0)</td><td>35 (53.0)</td><td>5.8 ((2.3&#8211;7.8)</td><td>3.2 (1.4&#8211;7.5)</td></tr><tr><td> No</td><td>89 (11.5)</td><td>704 (88.5)</td><td>1.0</td><td>1.0</td></tr><tr><td colspan="5">Ever Smoked</td></tr><tr><td> Yes</td><td>20 (31.7)</td><td>43 (68.3)</td><td>3.6 (2.0&#8211;6.4)</td><td>1.0 (0.4&#8211;1.4)</td></tr><tr><td> No</td><td>100 (11.5)</td><td>773 (88.7)</td><td>1.0</td><td>1.0</td></tr><tr><td colspan="5">Chewing Khat</td></tr><tr><td> Yes</td><td>5 (41.7)</td><td>7 (58.3)</td><td>5.6 (1.8&#8211;18.0)</td><td>2.8 (0.6&#8211;17.8)</td></tr><tr><td> Yes, daily</td><td>21 (22.8)</td><td>71 (77.2)</td><td>2.3 (1.4&#8211;4.0)</td><td>2.5 (1.0&#8211;6.4)</td></tr><tr><td> No, at all</td><td>94 (11.3)</td><td>738 (88.7)</td><td>1.0</td><td>1.0</td></tr><tr><td colspan="5">Current alcohol consumption</td></tr><tr><td> Yes</td><td>91 (13.9)</td><td>565 (86.1)</td><td>1.5 (0.2&#8211;11.6)</td><td>0.8 (0.4&#8211;1.4)</td></tr><tr><td> No</td><td>1 (10.0)</td><td>9 (90.0)</td><td>1.0</td><td>1.0</td></tr><tr><td colspan="5">Physical activity</td></tr><tr><td> Vigorous</td><td>20 (4.8)</td><td>401 (95.2)</td><td>1.0</td><td>1.0</td></tr><tr><td> Moderate</td><td>18 (10.2)</td><td>159 (89.8)</td><td>2.3 (1.2&#8211;4.4)</td><td>1.5 (0.7&#8211;3.0)</td></tr><tr><td> Poor</td><td>82 (24.3)</td><td>256 (75.7)</td><td>6.4 (3.8&#8211;10.7)</td><td>1.6 (0.7&#8211;3.7)</td></tr><tr><td colspan="5">Hypertension</td></tr><tr><td> Yes</td><td>76 (45.5)</td><td>91 (54.5)</td><td>13.8 (8.9&#8211;21&#8211;2)</td><td>4.5 (2.6&#8211;7.8)</td></tr><tr><td> No</td><td>44 (5.7)</td><td>725 (94.3)</td><td>1.0</td><td>1.0</td></tr><tr><td colspan="5">BMI</td></tr><tr><td>&lt; 25</td><td>46 (6.1)</td><td>707 (93.90</td><td>1.0</td><td>1.0</td></tr><tr><td> 25&#8211;29.9</td><td>64 (38.1)</td><td>104 (61.9)</td><td>9.5 (6.2&#8211;14.6)</td><td>3.0 (1.7&#8211;5.4)</td></tr><tr><td>&#8805; 30</td><td>10 (66.7)</td><td>5 (33.3)</td><td>30.7 (10.1&#8211;93.7)</td><td>6.0 (1.2&#8211;30.2)</td></tr><tr><td colspan="5">WHR</td></tr><tr><td> Obese</td><td>54 (32.3)</td><td>113 (67.7)</td><td>5.1 (3.4&#8211;7.7)</td><td>4.5 (2.6&#8211;7.8)</td></tr><tr><td> Normal</td><td>66 (8.6)</td><td>703 (91.4)</td><td>1.0</td><td>1.0</td></tr></table>
40d9274345459fb00befd198c932e34d3714ce7d1a55994b74d8c1506402f12c.png
simple
<table><tr><td></td><td>V1</td><td>V2</td><td>V3</td><td>V4</td></tr><tr><td>V1</td><td>1.00 (69)</td><td>0.37 (69)**</td><td>0.07 (69)</td><td>0.08 (69)</td></tr><tr><td></td><td>1.00 (165)</td><td>0.35 (109)**</td><td>0.10 (96)</td><td>0.24 (89)*</td></tr><tr><td>V2</td><td></td><td>1.00 (69)</td><td>0.21 (69)</td><td>0.19 (69)</td></tr><tr><td></td><td></td><td>1.00 (120)</td><td>0.21 (113)*</td><td>0.21 (76)</td></tr><tr><td>V3</td><td></td><td></td><td>1.00 (69)</td><td>0.24 (69)*</td></tr><tr><td></td><td></td><td></td><td>1.00 (172)</td><td>0.28 (93)**</td></tr><tr><td>V4</td><td></td><td></td><td></td><td>1.00 (69)</td></tr><tr><td></td><td></td><td></td><td></td><td>1.00 (105)</td></tr></table>
ddd547cac72d797fa3c07fc9d41c9bf867349874f494746e07582981af2f8a61.png
simple
<table><tr><td></td><td>Mean</td><td>SD</td><td>Maximum</td><td>Minimum</td></tr><tr><td>Maximum level of low back pain in the past year</td><td>8.81</td><td>1.13</td><td>10</td><td>7</td></tr><tr><td>Number of days without pain in the past year</td><td>37.04</td><td>51.82</td><td>174</td><td>0</td></tr><tr><td>Number of days with low pain in the past year</td><td>149.37</td><td>86.12</td><td>303</td><td>0</td></tr><tr><td>Number of days with moderate pain in the past year</td><td>119.29</td><td>51.94</td><td>210</td><td>22</td></tr><tr><td>Number of days with high pain in the past year</td><td>57.04</td><td>68.72</td><td>262</td><td>0</td></tr></table>
4b44e2eeeb006a698ec59dfb9c62466d04ad6eaf27c194255702942c837ef6ed.png
complex
<table><tr><td rowspan="2">Clinical Factors</td><td colspan="3">No. of patients (%)</td><td rowspan="2">P value <sup>b</sup></td><td colspan="3">No. of patients (%)</td></tr><tr><td>Total</td><td>Low MTV <sup>a</sup></td><td>High MTV <sup>a</sup></td><td>Low TLG <sup>a</sup></td><td>High TLG <sup>a</sup></td><td>P value <sup>b</sup></td></tr><tr><td>Age</td><td></td><td></td><td></td><td>0.607</td><td></td><td></td><td>0.737</td></tr><tr><td> &#8804;60 y</td><td>53</td><td>28(61)</td><td>25(56)</td><td></td><td>26(57)</td><td>27(60)</td><td></td></tr><tr><td> &gt;60 y</td><td>28</td><td>18(39)</td><td>20(44)</td><td></td><td>20(43)</td><td>18(40)</td><td></td></tr><tr><td>NCCN-IPI score</td><td></td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> 0-3</td><td>52</td><td>37(80)</td><td>15(33)</td><td></td><td>35(76)</td><td>17(38)</td><td></td></tr><tr><td> 4-8</td><td>39</td><td>9(20)</td><td>30(67)</td><td></td><td>11(24)</td><td>28(62)</td><td></td></tr><tr><td>Ann Arbor Stage</td><td></td><td></td><td></td><td>0.003</td><td></td><td></td><td>0.037</td></tr><tr><td> I/II</td><td>34</td><td>24(52)</td><td>10(22)</td><td></td><td>22(48)</td><td>12(27)</td><td></td></tr><tr><td> III/IV</td><td>57</td><td>22(48)</td><td>35(48)</td><td></td><td>24(52)</td><td>33(73)</td><td></td></tr><tr><td>B symptoms</td><td></td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>0.008</td></tr><tr><td> No</td><td>41</td><td>29(63)</td><td>12(27)</td><td></td><td>27(59)</td><td>14(31)</td><td></td></tr><tr><td> Yes</td><td>50</td><td>17(37)</td><td>33(73)</td><td></td><td>19(41)</td><td>31(69)</td><td></td></tr><tr><td>Performance status</td><td></td><td></td><td></td><td>0.002</td><td></td><td></td><td>0.037</td></tr><tr><td> ECOG 0-1</td><td>71</td><td>42(91)</td><td>29(64)</td><td></td><td>40(87)</td><td>31(69)</td><td></td></tr><tr><td> ECOG &gt;1</td><td>20</td><td>4(9)</td><td>16(36)</td><td></td><td>6(13)</td><td>14(31)</td><td></td></tr><tr><td>No. of extranodal sites</td><td></td><td></td><td></td><td>0.072</td><td></td><td></td><td>0.17</td></tr><tr><td> 0-1</td><td>55</td><td>32(70)</td><td>23(51)</td><td></td><td>31(67)</td><td>24(53)</td><td></td></tr><tr><td> 2 or more</td><td>36</td><td>14(30)</td><td>22(49)</td><td></td><td>15(33)</td><td>21(47)</td><td></td></tr><tr><td>LDH level</td><td></td><td></td><td></td><td>0.002</td><td></td><td></td><td>0.002</td></tr><tr><td> normal</td><td>55</td><td>35(85)</td><td>20(44)</td><td></td><td>35(76)</td><td>20(44)</td><td></td></tr><tr><td> elevated</td><td>36</td><td>11(24)</td><td>25(56)</td><td></td><td>11(24)</td><td>25(56)</td><td></td></tr></table>
4d38196e43591fd25440c72362c9ca11cec5b82b5741d43b876e556da50121f1.png
simple
<table><tr><td>Country</td><td>2012</td><td>2013</td><td>2014</td><td>2015</td><td>2016</td><td>2017</td><td>2018</td></tr><tr><td>Angola</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>2 267 799</td><td>6 933 500</td><td>9 536 500</td><td>17 327 500</td><td>25 494 500</td><td>30 988 000</td><td>34 542 500</td></tr><tr><td>GAVI</td><td>4 669 500</td><td>11 969 500</td><td>13 225 500</td><td>13 387 000</td><td>2 565 500</td><td>1 567 000</td><td>0</td></tr><tr><td>Armenia</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>193 804</td><td>292 500</td><td>494 000</td><td>620 000</td><td>848 000</td><td>953 500</td><td>1 082 000</td></tr><tr><td>GAVI</td><td>563 500</td><td>444 500</td><td>1 037 500</td><td>742 500</td><td>262 500</td><td>166 500</td><td>0</td></tr><tr><td>Azerbaijan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>1 224 450</td><td>940 000</td><td>1 673 000</td><td>1 910 000</td><td>2 606 500</td><td>3 105 000</td><td>3 028 500</td></tr><tr><td>GAVI</td><td>387 000</td><td>3 607 500</td><td>2 389 000</td><td>1 827 500</td><td>413 500</td><td>0</td><td>0</td></tr><tr><td>Bhutan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>39 068</td><td>51 500</td><td>91 500</td><td>93 000</td><td>130 500</td><td>132 500</td><td>133 500</td></tr><tr><td>GAVI</td><td>98 000</td><td>105 000</td><td>74 000</td><td>38 500</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Bolivia</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>730 675</td><td>614 000</td><td>2 058 500</td><td>3 073 500</td><td>3 804 500</td><td>5 083 000</td><td>5 134 000</td></tr><tr><td>GAVI</td><td>1 192 500</td><td>1 683 500</td><td>3 400 000</td><td>2 610 000</td><td>881 000</td><td>0</td><td>0</td></tr><tr><td>Congo</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>563 712</td><td>1 506 000</td><td>2 382 000</td><td>2 986 000</td><td>4 034 500</td><td>4 349 500</td><td>4 513 500</td></tr><tr><td>GAVI</td><td>3 490 000</td><td>3 979 000</td><td>3 061 000</td><td>2 273 000</td><td>400 000</td><td>230 000</td><td>0</td></tr><tr><td>Georgia</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>239 941</td><td>299 000</td><td>571 500</td><td>824 000</td><td>1 229 000</td><td>1 448 500</td><td>1 710 000</td></tr><tr><td>GAVI</td><td>650 500</td><td>545 500</td><td>904 500</td><td>974 500</td><td>369 500</td><td>250 000</td><td>0</td></tr><tr><td>Guyana</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>36 447</td><td>87 500</td><td>133 000</td><td>240 500</td><td>288 500</td><td>378 000</td><td>365 000</td></tr><tr><td>GAVI</td><td>603 000</td><td>397 000</td><td>232 500</td><td>214 000</td><td>93 500</td><td>0</td><td>0</td></tr><tr><td>Honduras</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>1 088 385</td><td>1 467 500</td><td>2 042 000</td><td>2 708 500</td><td>3 572 000</td><td>3 578 500</td><td>3 365 000</td></tr><tr><td>GAVI</td><td>5 084 000</td><td>3 886 500</td><td>2 484 000</td><td>2 057 000</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Indonesia</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>&#8212;</td><td>2 088 500</td><td>11 787 500</td><td>20 765 500</td><td>27 420 500</td><td>32 638 000</td><td>32 314 500</td></tr><tr><td>GAVI</td><td>&#8212;</td><td>10 024 000</td><td>23 931 500</td><td>13 843 500</td><td>6 855 500</td><td>0</td><td>0</td></tr><tr><td>Kiribati</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>15 475</td><td>24 000</td><td>17 000</td><td>37 000</td><td>51 500</td><td>61 500</td><td>60 000</td></tr><tr><td>GAVI</td><td>15 500</td><td>89 500</td><td>36 500</td><td>38 500</td><td>9 500</td><td>0</td><td>0</td></tr><tr><td>Moldova</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>154 092</td><td>283 500</td><td>489 500</td><td>728 500</td><td>1 002 500</td><td>1 149 500</td><td>1 116 000</td></tr><tr><td>GAVI</td><td>482 000</td><td>762 500</td><td>816 000</td><td>642 500</td><td>136 000</td><td>0</td><td>0</td></tr><tr><td>Mongolia</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>129 985</td><td>266 500</td><td>424 000</td><td>489 500</td><td>658 000</td><td>668 000</td><td>676 000</td></tr><tr><td>GAVI</td><td>428 500</td><td>544 000</td><td>307 000</td><td>171 500</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Sri Lanka</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>943 752</td><td>646 500</td><td>1 928 500</td><td>1 796 500</td><td>1 823 500</td><td>1 906 000</td><td>1 860 500</td></tr><tr><td>GAVI</td><td>2 313 000</td><td>2 811 000</td><td>271 500</td><td>68 500</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Total</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Country</td><td>7 627 585</td><td>15 500 500</td><td>33 628 500</td><td>53 600 000</td><td>72 964 000</td><td>86 439 500</td><td>89 901 000</td></tr><tr><td>GAVI</td><td>19 977 000</td><td>40 849 000</td><td>52 170 500</td><td>38 888 500</td><td>11 986 500</td><td>2 213 500</td><td>0</td></tr></table>
96a035a64fa3b71b4969a2ca3a40014ca0ebb56eab686082d2e4276f75e230c2.png
simple
<table><tr><td>Pathogen</td><td>Number of patients</td><td>Gender (male/female) </td><td>Median age (min&#8211;max)</td><td>Mortality (%) (survivors/death)</td></tr><tr><td><i>S. pneumoniae </i></td><td>14</td><td>5/8<sup>1</sup></td><td>5.5 (0&#8211;40)</td><td>46% (7/6)<sup>1</sup></td></tr><tr><td><i>N. meningitidis </i></td><td>22</td><td>10/9<sup>2</sup></td><td>5.5 (1&#8211;60)</td><td>27% (16/6)</td></tr><tr><td><i>H. influenzae </i></td><td>9</td><td>7/2</td><td>2 (1&#8211;4)</td><td>0% (9/0)</td></tr></table>
bb5b5e2b780a56f6087e9af78ca43b9744d916a0fd7b16f58c30170d616ca862.png
simple
<table><tr><td>Author</td><td>Derivation sample</td><td>Validation sample</td><td>Predictors</td><td>Outcomes</td><td>Performance in the validation sample</td><td>Presentation of a simplified score</td></tr><tr><td>Pillai et al.</td><td>208 patients from India with severe TBI</td><td>26 patients from the same centre</td><td>1-oculocephalic reflex2-motor GCS3-midline shift</td><td>Death or vegetative state</td><td>Sensitivity (75%)Specificity (67%)PPV 50%</td><td>No</td></tr><tr><td>Signorini et al</td><td>372 patients from Scotland with moderate and severe TBI</td><td>520 patients from the same centre</td><td>1-GCS2-ISS3-pupils reactivity and 4-haematoma (CT scan)</td><td>Survival at 1 year</td><td>A.U.R.O.C (0.835)Error rate (15.2%)Brier score (0.1160)Hosmer-Lemeshow(p &lt; 0.001)</td><td>Nomogram</td></tr><tr><td>Signorini et al</td><td>110 patients from Scotland with moderate and severe TBI</td><td>140 patients from the same centre</td><td>1-GCS2-ISS3-pupils reactivity and 4-haematoma (CT scan)5-ICP measures</td><td>Survival at 1 year</td><td>Not reported</td><td>No</td></tr><tr><td>Hukkelhoven et al.</td><td>134 patients from Netherlands with moderate and severe TBI</td><td>180 patients from the same centre</td><td>1-age2-motor GCS3-pupils reactivity4-pupillary size5-hypotension6-ISS</td><td>Raised ICP</td><td>A.U.R.O.C. (0.50)Hosmer-Lemeshow(p = 0.18)</td><td>No</td></tr><tr><td>Hukkelhoven et al.</td><td>275 patients from Netherlands with moderate and severe TBI</td><td>250 patients from the same centre</td><td>1-age2-cause of injury3-pupils reactivity4-pupillary size5-hypotension6-ISS</td><td>Surgical removable lesions</td><td>A.U.R.O.C. (0.67)Hosmer-Lemeshow(p = 0.01)</td><td>No</td></tr><tr><td>Hukkelhoven et al.</td><td>2269 patients from 2 trials in high income countries with moderate and severe TBI</td><td>796 patients from Europe</td><td>1-age2-motorGCS3-pupils reactivity4-hypoxia5-hypotension6-CT classification7-subarachnoid haemorrhage</td><td>Death or disability at 6 months</td><td>A.U.R.O.C. (0.83)Hosmer-Lemeshow(p = 0.05)</td><td>Score chart</td></tr><tr><td>Hukkelhoven et al.</td><td>2269 patients from 2 trials in high income countries with moderate and severe TBI</td><td>796 patients from Europe and 746 from the United States</td><td>1-age2-motor GCS3-pupils reactivity4-hypoxia5-hypotension6-CT classification7-subarachnoid haemorrhage</td><td>Death at 6 months</td><td>A.U.R.O.C. (0.87/0.89)Hosmer-Lemeshow(p = 0.42/&lt;0.001)</td><td>Score chart</td></tr></table>
5418b4230b01ae77d9ff07987060b6ddc9acd71b0a4ae9aebf06a62fc78cc0a7.png
simple
<table><tr><td>Rank</td><td>Feature name</td><td>Mean SP</td><td>Mean ME</td><td>P-value</td><td>Rank</td><td>Feature name</td><td>Mean SP</td><td>Mean ME</td><td>P-value</td></tr><tr><td>1</td><td>Degree</td><td>36.6</td><td>86.9</td><td>2.8e-106</td><td>21</td><td>42</td><td>0.00631</td><td>0.0108</td><td>8.2e-45</td></tr><tr><td>2</td><td>57</td><td>0.00207</td><td>0.00584</td><td>2.5e-95</td><td>22</td><td>16</td><td>0.0657</td><td>0.0502</td><td>1.2e-44</td></tr><tr><td>3</td><td>43</td><td>0.00486</td><td>0.0104</td><td>9.8e-86</td><td>23</td><td>47</td><td>0.00333</td><td>0.00622</td><td>2.7e-44</td></tr><tr><td>4</td><td>45</td><td>0.006</td><td>0.0113</td><td>5.2e-82</td><td>24</td><td>10</td><td>0.00372</td><td>0.00619</td><td>1.5e-43</td></tr><tr><td>5</td><td>50</td><td>0.00407</td><td>0.00853</td><td>3.6e-81</td><td>25</td><td>36</td><td>0.00772</td><td>0.0125</td><td>1.3e-41</td></tr><tr><td>6</td><td>13</td><td>0.0895</td><td>0.0552</td><td>9.5e-79</td><td>26</td><td>65</td><td>0.00099</td><td>0.00263</td><td>7.6e-38</td></tr><tr><td>7</td><td>3</td><td>0.0556</td><td>0.0363</td><td>1.2e-76</td><td>27</td><td>32</td><td>0.0145</td><td>0.0206</td><td>1.4e-31</td></tr><tr><td>8</td><td>58</td><td>0.00211</td><td>0.00563</td><td>1.4e-76</td><td>28</td><td>66</td><td>0.00116</td><td>0.00263</td><td>5.9e-29</td></tr><tr><td>9</td><td>15</td><td>0.0871</td><td>0.0558</td><td>3.8e-76</td><td>29</td><td>34</td><td>0.00912</td><td>0.0136</td><td>1.7e-26</td></tr><tr><td>10</td><td>64</td><td>0.00076</td><td>0.00315</td><td>3.9e-74</td><td>30</td><td>38</td><td>0.00576</td><td>0.00866</td><td>3.4e-26</td></tr><tr><td>11</td><td>33</td><td>0.00999</td><td>0.0166</td><td>2.1e-66</td><td>31</td><td>55</td><td>0.00267</td><td>0.00481</td><td>2.3e-23</td></tr><tr><td>12</td><td>48</td><td>0.00309</td><td>0.00716</td><td>3.7e-66</td><td>32</td><td>23</td><td>0.0152</td><td>0.0197</td><td>1.1e-22</td></tr><tr><td>13</td><td>54</td><td>0.0033</td><td>0.00707</td><td>3.7e-65</td><td>33</td><td>61</td><td>0.00211</td><td>0.00397</td><td>6e-22</td></tr><tr><td>14</td><td>22</td><td>0.0491</td><td>0.0344</td><td>2.8e-63</td><td>34</td><td>40</td><td>0.00921</td><td>0.0133</td><td>9e-21</td></tr><tr><td>15</td><td>60</td><td>0.00176</td><td>0.00444</td><td>9.9e-61</td><td>35</td><td>59</td><td>0.00186</td><td>0.003</td><td>9.8e-21</td></tr><tr><td>16</td><td>56</td><td>0.00187</td><td>0.0048</td><td>7.1e-58</td><td>36</td><td>7</td><td>0.0117</td><td>0.0144</td><td>5.6e-20</td></tr><tr><td>17</td><td>6</td><td>0.00608</td><td>0.00917</td><td>9e-53</td><td>37</td><td>62</td><td>0.00172</td><td>0.0029</td><td>2.1e-19</td></tr><tr><td>18</td><td>44</td><td>0.00651</td><td>0.0107</td><td>2.4e-50</td><td>38</td><td>67</td><td>0.00076</td><td>0.00156</td><td>1.1e-17</td></tr><tr><td>19</td><td>1</td><td>0.0265</td><td>0.0199</td><td>3.4e-48</td><td>39</td><td>14</td><td>0.0474</td><td>0.039</td><td>2.4e-17</td></tr><tr><td>20</td><td>53</td><td>0.0044</td><td>0.00793</td><td>2.3e-46</td><td>40</td><td>46</td><td>0.00712</td><td>0.00968</td><td>2.2e-16</td></tr></table>
d79bbfdaf3c7c8c8dab23c2db5df81ca91924e4635105683022dbb7f21e1b34e.png
simple
<table><tr><td> </td><td>Mild TBI</td><td>Moderate TBI</td><td>Severe TBI</td><td>p-value</td></tr><tr><td>Number of patients</td><td>229</td><td>85</td><td>54</td><td>-</td></tr><tr><td>Age at time of injury (years)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean &#177; standard deviation</td><td>23.7 &#177; 16.6</td><td>29.0 &#177; 20.9</td><td>22.5 &#177; 16.4</td><td>0.038</td></tr><tr><td>Range (minimum - maximum)</td><td>1.0 - 66.0</td><td>1.0 - 76.0</td><td>1.0 - 60.0</td><td> </td></tr><tr><td>median</td><td>20.0</td><td>28.0</td><td>19.0</td><td> </td></tr><tr><td>Age at time of reexamination (years)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean &#177; standard deviation</td><td>44.2 &#177; 16.9</td><td>43.4 &#177; 20.08</td><td>26.5 &#177; 16.5</td><td>0.018</td></tr><tr><td>Range (minimum - maximum)</td><td>12.0 - 87.0</td><td>11.0 - 87.0</td><td>12.0 - 76.0</td><td> </td></tr><tr><td>median</td><td>41.0</td><td>42.0</td><td>34.5</td><td> </td></tr><tr><td>Time to reexamination (years)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean &#177; standard deviation</td><td>20.3 &#177; 6.5</td><td>14.2 &#177; 4.1</td><td>14.0 &#177; 3.9</td><td>&lt;0.001</td></tr><tr><td>Number of patients &lt;18 years</td><td>101</td><td>33</td><td>26</td><td>0.531</td></tr><tr><td>(%)</td><td>(44.1%)</td><td>(38.8%)</td><td>(48.1%)</td><td> </td></tr><tr><td>Gender distribution (&#9794;: &#9792;)</td><td>129: 100</td><td>57: 28</td><td>40: 14</td><td>0.026</td></tr><tr><td>Injury Severity (ISS)</td><td>-</td><td>14.8 &#177; 7.5</td><td>21.4 &#177; 7.1</td><td>&lt;0.001</td></tr><tr><td>New Injury Severity (NISS)</td><td>-</td><td>24.3 &#177; 12.3</td><td>36.3 &#177; 14.8</td><td>&lt;0.001</td></tr><tr><td>Marital status at follow-up</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>- Single</td><td>40.7%</td><td>42.2%</td><td>64.8%</td><td>0.010</td></tr><tr><td> - Married or cohabitant</td><td>51.0%</td><td>50.6%</td><td>24.1%</td><td> </td></tr><tr><td> - Divorced</td><td>8.3%</td><td>7.2%</td><td>11.1%</td><td> </td></tr><tr><td>Housing situation before TBI</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> - in rented accommodation</td><td>51.2%</td><td>46.8%</td><td>38.5%</td><td>0.249</td></tr><tr><td>Housing situation at follow-up</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> - in rented accommodation</td><td>50.2%</td><td>42.0%</td><td>38.5%</td><td>0.205</td></tr><tr><td> - confinement in bed</td><td>0.0%</td><td>0.0%</td><td>5.6%</td><td>&lt;0.001</td></tr></table>
80b1d592b442dc42dd3f5b72343857a7d59664c062171d14ba891d9d7dd83bca.png
simple
<table><tr><td>Variable</td><td>Case (n=127)</td><td>Control (127)</td></tr><tr><td> </td><td>Number (%)</td><td>Number (%)</td></tr><tr><td>Ethnicity</td><td> </td><td> </td></tr><tr><td>Oromo</td><td>122(96.1)</td><td>123(96.9)</td></tr><tr><td>Others</td><td>5(3.9)</td><td>4(3.1)</td></tr><tr><td>Religion</td><td> </td><td> </td></tr><tr><td>Muslim</td><td>124(97.6)</td><td>123(96.9)</td></tr><tr><td>Christian</td><td>3(2.4)</td><td>4(3.1)</td></tr><tr><td>Education status of mother</td><td> </td><td> </td></tr><tr><td>Illiterate</td><td>115(90.6)</td><td>102(80.3)</td></tr><tr><td>Literate</td><td>12(9.4)</td><td>25(19.7)</td></tr><tr><td>Occupation of mother</td><td> </td><td> </td></tr><tr><td>Housewife</td><td>92(72.4)</td><td>95(74.8)</td></tr><tr><td>Farmer</td><td>31(24.4)</td><td>30(23.6)</td></tr><tr><td>Merchant</td><td>4(3.1)</td><td>2(0.8)</td></tr><tr><td>Age of mothers (years)</td><td> </td><td> </td></tr><tr><td>&lt;20</td><td>5(3.9)</td><td>3(2.4)</td></tr><tr><td>20-34</td><td>85(66.9)</td><td>98(77.2)</td></tr><tr><td>&#8805;35</td><td>37(29.2)</td><td>26(20.4)</td></tr><tr><td>Marital status</td><td> </td><td> </td></tr><tr><td>Married</td><td>121(95.3)</td><td>126(99.2)</td></tr><tr><td>Widowed</td><td>6(4.7)</td><td>1(0.8)</td></tr><tr><td>Sex of infants</td><td> </td><td> </td></tr><tr><td>Male</td><td>74(58.3)</td><td>73(57.5)</td></tr><tr><td>Female</td><td>53(41.7)</td><td>54(42.5)</td></tr></table>
d7f040fbd3b5c11441c93635d70fe654b291636d6cf8fc8311daefa8726fda3c.png
simple
<table><tr><td>Variables</td><td>Cupping<i>n</i> = 30</td><td>Resting<i>n</i> = 30</td><td><i>P</i></td></tr><tr><td>Gender (%)</td><td> </td><td> </td><td>0.640</td></tr><tr><td> Male</td><td>3 (10.0)</td><td>2 (6.7)</td><td> </td></tr><tr><td> Female</td><td>27 (90.0)</td><td>28 (93.3)</td><td> </td></tr><tr><td>Age (mean &#177; SD)</td><td>43.6 &#177; 8.0</td><td>42.5 &#177; 7.4</td><td>0.486</td></tr></table>
63eff125664ac9e982bbda705cde8c6ce1cdbd9a799e5fca97fe917be81d84dd.png
simple
<table><tr><td>Method</td><td>MDR</td><td>AntEpiSeeker</td><td>BOOST</td><td>MegaSNPHunter</td><td>KNN-MDR</td></tr><tr><td>Power</td><td>N/A</td><td>0.65</td><td>0.67</td><td>0.80</td><td>0.74</td></tr><tr><td>Corrected power</td><td>N/A</td><td>0.15</td><td>0.28</td><td>0.12</td><td>0.63</td></tr></table>
8bdfbaa0789f10cf1d4d468f3eb694ad8f26d84d5357b949927abdc313bd1e18.png
complex
<table><tr><td>Patient</td><td colspan="4">HAX-1</td><td>ER</td></tr><tr><td></td><td colspan="2">Normal</td><td colspan="2">Tumor</td><td>Tumor</td></tr><tr><td></td><td>Cytoplasm</td><td>Nucleus</td><td>Cytoplasm</td><td>Nucleus</td><td>Nucleus</td></tr><tr><td>1</td><td>0</td><td>-</td><td>2</td><td>-</td><td>+</td></tr><tr><td>2</td><td>0/1</td><td>-</td><td>1</td><td>-</td><td>-</td></tr><tr><td>3</td><td>1</td><td>-</td><td>1</td><td>-</td><td>-</td></tr><tr><td>4</td><td>0</td><td>-</td><td>0</td><td>-</td><td>-</td></tr><tr><td>5</td><td>0</td><td>-</td><td>1</td><td>-</td><td>-</td></tr><tr><td>6</td><td>0</td><td>-</td><td>1</td><td>-</td><td>-</td></tr><tr><td>7</td><td>1</td><td>-</td><td>0</td><td>+</td><td>+</td></tr><tr><td>8</td><td>0</td><td>-</td><td>2</td><td>+</td><td>+</td></tr><tr><td>9</td><td>0</td><td>-</td><td>1</td><td>-</td><td>-</td></tr><tr><td>10</td><td>2</td><td>-</td><td>2</td><td>-</td><td>+</td></tr><tr><td>11</td><td>1</td><td>-</td><td>1/2</td><td>-</td><td>+</td></tr><tr><td>12</td><td>0</td><td>-</td><td>2</td><td>+</td><td>+</td></tr><tr><td>13</td><td>0</td><td>-</td><td>2</td><td>-</td><td>-</td></tr><tr><td>14</td><td>0</td><td>-</td><td>2</td><td>+</td><td>+</td></tr><tr><td>15</td><td>0</td><td>-</td><td>3</td><td>-</td><td>-</td></tr></table>
1a0c56ad2f3f0df193b17cd684516c8d3c04cfda90ed85fe03c550c494fbb12c.png
complex
<table><tr><td rowspan="2">Ricketts analysis</td><td colspan="3">Pretreatment (16 years, 4 months)</td><td colspan="3">Posttreatment (19 years, 8 months)</td></tr><tr><td>Norm</td><td>Value</td><td>Deviation</td><td>Norm</td><td>Value</td><td>Deviation</td></tr><tr><td colspan="7">Cranial relations</td></tr><tr><td> Facial axis (&#176;)</td><td>90 &#177; 3.5</td><td>88.4</td><td rowspan="4">vertical growth type</td><td>90 &#177; 3.5</td><td>89.0</td><td rowspan="4">dolichofacial face type</td></tr><tr><td> Mandibular plane (&#176;)</td><td>23.6 &#177; 4</td><td>34.0</td><td>29.6 &#177; 4</td><td>29.9</td></tr><tr><td> Mandibular arc (&#176;)</td><td>26 &#177; 4</td><td>30.1</td><td>27.7 &#177; 4</td><td>26.4</td></tr><tr><td> Lower facial height (&#176;)</td><td>45 &#177; 4</td><td>54.1</td><td>45 &#177; 4</td><td>58.1</td></tr><tr><td> Maxillary depth (&#176;)</td><td>90 &#177; 3</td><td>87.4</td><td>maxilla ortho- to retrognathic</td><td>90 &#177; 3</td><td>89.7</td><td>maxilla orthognathic</td></tr><tr><td> SN-Palatal plane (&#176;)</td><td>7.3 &#177; 3</td><td>&#8722;3.3</td><td>anterior rotation of maxilla</td><td>7.3 &#177; 3</td><td>&#8722;1.2</td><td>less anterior rotation of maxilla</td></tr><tr><td> Facial (angle) depth (&#176;)</td><td>89.4 &#177; 3</td><td>84.6</td><td>mandible prognathic</td><td>90.6 &#177; 3</td><td>85.7</td><td>mandible prognathic</td></tr><tr><td> Facial taper</td><td>68 &#177; 3</td><td>61.4</td><td>posterior rotation of mandible</td><td>68 &#177; 3</td><td>64.4</td><td>less posterior rotation of mandible</td></tr><tr><td> Convexity of point A (mm)</td><td>&#8722;0.4 &#177; 2</td><td>2.6</td><td>slight skeletal class III</td><td>&#8722;1.6 &#177; 2</td><td>3.8</td><td>skeletal class III</td></tr><tr><td colspan="7">Denture Relations</td></tr><tr><td> Upper incisor to A-Pog (mm)</td><td>3.5 &#177; 2</td><td>10.7</td><td>distinctly protruded</td><td>3.5 &#177; 2</td><td>9.6</td><td>slightly less protruded</td></tr><tr><td> Upper incisor to FH (&#176;)</td><td>111 &#177; 4</td><td>105.5</td><td>slightly retroinclined</td><td>111 &#177; 4</td><td>107.4</td><td>normally inclined</td></tr><tr><td> Upper molar to PtV(mm)</td><td>19.3 &#177; 1</td><td>15.2</td><td>upper dental arch retruded</td><td>22.7 &#177; 1</td><td>18.3</td><td>upper dental arch retruded</td></tr><tr><td> Lower incisor to A-Pog (mm)</td><td>1 &#177; 2</td><td>6.5</td><td>distinctly protruded</td><td>1 &#177; 2</td><td>7.1</td><td>distinctly protruded</td></tr><tr><td> Lower incisor inclination (&#176;)</td><td>22 &#177; 4</td><td>24.5</td><td>normally inclined</td><td>22 &#177; 4</td><td>23.4</td><td>normally inclined</td></tr><tr><td> Interincisal angle (&#176;)</td><td>130 &#177; 6</td><td>132.4</td><td>normal</td><td>130 &#177; 6</td><td>131.8</td><td>normal</td></tr><tr><td> Molar relation (mm)</td><td>&#8722;3.0 &#177; 2</td><td>&#8722;2.6</td><td>Angle class I</td><td>&#8722;3.0 &#177; 2</td><td>&#8722;1.1</td><td>Angle class I</td></tr><tr><td> Incisor Overjet (mm)</td><td>2.5 &#177; 1</td><td>4.6</td><td>increased</td><td>2.5 &#177; 1</td><td>2.5</td><td>normal</td></tr><tr><td> Incisor Overbite (mm)</td><td>2.5 &#177; 1</td><td>3.2</td><td>increased</td><td>2.5 &#177; 1</td><td>2.2</td><td>normal</td></tr><tr><td colspan="7">Esthetic Relations</td></tr><tr><td> Lower lip &#8211; E-Plane(mm)</td><td>&#8722;2 &#177; 2</td><td>&#8722;3.9</td><td>lower lip slightly retruded</td><td>&lt; -2 &#177; 2</td><td>&#8722;4.3</td><td>lower lip slightly retruded</td></tr></table>
7b3d1e4ee81d516256fbc5c510f52b918cb88d8b3010367af94e87310afa7fee.png
complex
<table><tr><td>Author</td><td>Year, Country</td><td rowspan="2">Investigation period</td><td rowspan="2">No. of colic cases</td><td colspan="2">Distribution of cases</td><td colspan="4">Cases euthanized or dead %</td><td colspan="3">Short-term survival rates (%)</td></tr><tr><td colspan="2"> </td><td>Medical %</td><td>Surgical %</td><td rowspan="2">Without any treatment</td><td rowspan="2">Medical cases</td><td colspan="2">Cases undergoing surgery</td><td colspan="3"> </td></tr><tr><td colspan="6"> </td><td>During surgery</td><td>After recovery</td><td>Overall</td><td>Medically treated cases</td><td>Surgically treated cases</td></tr><tr><td>[3]</td><td>1989, USA</td><td>1974-1984</td><td>320</td><td>41</td><td>59</td><td>16</td><td>6</td><td>31</td><td>25</td><td>59</td><td>94</td><td>44</td></tr><tr><td>[7]</td><td>2005, Germany</td><td>1990-1997</td><td>1431</td><td>80</td><td>20</td><td>*</td><td>7</td><td>35</td><td>16</td><td>84</td><td>93</td><td>49</td></tr><tr><td>[5]</td><td>2003, The Netherlands</td><td>1999-2000</td><td>649</td><td>64</td><td>36</td><td>8</td><td>15</td><td>26</td><td>21</td><td>69</td><td>85</td><td>54</td></tr><tr><td>[6]</td><td>2005, Canada</td><td>1992-2002</td><td>604</td><td>54</td><td>46</td><td>21</td><td>6</td><td>26</td><td>14</td><td>66</td><td>94</td><td>60</td></tr><tr><td>[8]</td><td>2009, Israel</td><td>2003-2006</td><td>208</td><td>30</td><td>70</td><td>6</td><td>8**</td><td colspan="2">34</td><td>71</td><td>92</td><td>66</td></tr><tr><td>[9]</td><td>2009, South Africa</td><td>1998-2007</td><td>929</td><td>60</td><td>40</td><td>3</td><td>7</td><td>21</td><td>13</td><td>79</td><td>93</td><td>66</td></tr><tr><td>UHLA***</td><td>2013, Denmark</td><td>2000-2009</td><td>1588</td><td>69</td><td>31</td><td>10</td><td>13</td><td>44</td><td>14</td><td>68</td><td>87</td><td>42</td></tr></table>
121a48c5bb2753a4b436324012f024bc01aeb69a511876b224f0b7dd0d17c04f.png
complex
<table><tr><td rowspan="2">Place, author's and years of Examination</td><td colspan="2">Prevalence of schistosomiasis</td></tr><tr><td><i>Schistosoma haematobium</i> %</td><td><i>Schistosoma mansoni</i> %</td></tr><tr><td colspan="3">This study</td></tr><tr><td>Before mass treatment 2002</td><td>13.6</td><td>36.3</td></tr><tr><td>After mass treatment 2008</td><td>18.6</td><td>31.0</td></tr><tr><td colspan="3">Mali (Clements et al.) (26)</td></tr><tr><td>Before mass treatment (1989)</td><td>25.7</td><td>7.4</td></tr><tr><td>After mass treatment (2006)</td><td>38.3</td><td>6.7</td></tr><tr><td colspan="3">Mali (Landoure A et al.) (27)</td></tr><tr><td>Before mass treatment (2004)</td><td>88.0</td><td>17.0</td></tr><tr><td>After mass treatment (2010)</td><td>61.0</td><td>12.0</td></tr><tr><td colspan="3">Tanzania (Poggensee G et al.) (28)</td></tr><tr><td>Before mass treatment 1996</td><td>36.7</td><td>22.9</td></tr><tr><td>After mass treatment 2002</td><td>33.6</td><td>00.7</td></tr></table>
850578d392ae27ee86f62c979e359584302852b5d7dc34db33bc45f3272638cc.png
complex
<table><tr><td rowspan="3">into</td><td colspan="5">from</td></tr><tr><td>AG-T</td><td>MEX</td><td>SA1</td><td>SA2</td><td>USA</td></tr><tr><td>AG-T</td><td>99 (96.4&#8211;100)</td><td>0.3 (0&#8211;1.6)</td><td>0.3 (0&#8211;1.7)</td><td>0.3 (0&#8211;1.6)</td><td>0.2 (0&#8211;1.7)</td></tr><tr><td>MEX</td><td>0 (0&#8211;0.2)</td><td>99 (98.5&#8211;100)</td><td>0 (0&#8211;0.3)</td><td>0.3 (0&#8211;1.1)</td><td>0.2 (0&#8211;0.6)</td></tr><tr><td>SA1</td><td>0 (0&#8211;0.4)</td><td>0.2 (0&#8211;0.9)</td><td>95.3 (93.0&#8211;97.4)</td><td>4.2 (2.2&#8211;6.4)</td><td>0 (0&#8211;0.9)</td></tr><tr><td>SA2</td><td>0 (0&#8211;0.4)</td><td>0.1 (0&#8211;0.6)</td><td>0.3 (0&#8211;1.5)</td><td>99.2 (97.7&#8211;100)</td><td>0.3 (0&#8211;1.1)</td></tr><tr><td>USA</td><td>0 (0&#8211;0.1)</td><td>0 (0&#8211;0.2)</td><td>0 (0&#8211;0.2)</td><td>0 (0&#8211;0.2)</td><td>99.9 (99.6&#8211;100)</td></tr></table>
97554ee2302cf487726a533e57a4527ec1e366629ec31d74f0ed50e16c8713c3.png
simple
<table><tr><td>Cigarettes: &#8216;surgeon general&#8217;s warning&#8217;</td><td>Smokeless tobacco: &#8216;warning&#8217;</td></tr><tr><td>Smoking causes lung cancer, heart disease, emphysema, and may complicate pregnancy</td><td>This product may cause mouth cancer</td></tr><tr><td>Quitting smoking now greatly reduces serious risks to your health</td><td>This product may cause gum disease and tooth loss</td></tr><tr><td>Smoking by pregnant women may result in fetal injury, premature birth, and low birth weight</td><td>Proposed: this product contains nicotine and is addictive</td></tr><tr><td>Cigarette smoke contains carbon monoxide</td><td>Compromise: this product is not a safe alternative to cigarettes</td></tr></table>
767f0d68a4436b33ef57ea5c42fc2a44d9e625c3375279d66e81fe3621564790.png
complex
<table><tr><td colspan="2">Variable</td><td>&gt;18.50</td><td>18.50&#8211;24.99</td><td>25.0&#8211;29.99</td><td>&#8805;30</td><td rowspan="2"><i>p</i> Value</td></tr><tr><td></td><td></td><td>(<i>n</i> = 141)</td><td>(<i>n</i> = 1164)</td><td>(<i>n</i> = 225)</td><td>(<i>n</i> = 72)</td></tr><tr><td colspan="2">Duration of stimulation (<i>d</i>)</td><td>10.35 &#177; 2.17</td><td>10.01 &#177; 2.55</td><td>10.09 &#177; 2.19</td><td>10.52 &#177; 1.72</td><td>0.53</td></tr><tr><td colspan="2">Total dose of gonadotrophin (IU)</td><td>2439 &#177; 1403</td><td>2658 &#177; 1406</td><td>2573 &#177; 1029</td><td>2788 &#177; 1222</td><td>0.58</td></tr><tr><td colspan="2">Ovarian stimulation protocol <i>n</i> (%)</td><td colspan="5"></td></tr><tr><td colspan="2">GnRH antagonist</td><td>101 (71.6%)</td><td>842 (72.3%)</td><td>180 (80.0%)</td><td>53 (73.6%)</td><td></td></tr><tr><td colspan="2">Long</td><td>32 (22.7%)</td><td>262 (22.5%)</td><td>37 (16.4%)</td><td>16 (22.2%)</td><td></td></tr><tr><td colspan="2">Others</td><td>8 (5.7%)</td><td>60 (5.2%)</td><td>8 (3.6%)</td><td>3 (4.2%)</td><td>0.41</td></tr><tr><td colspan="2">E2 on hCG day (pg/mL)</td><td>1823.07 &#177; 969.29</td><td>1716 &#177; 1092</td><td>1883 &#177; 1354</td><td>1571 &#177; 872</td><td>0.17</td></tr><tr><td colspan="2">Retrieved oocytes (<i>n</i>)</td><td>8.26 &#177; 5.87</td><td>8.17 &#177; 6.09</td><td>7.88 &#177; 5.83</td><td>6.22 &#177; 4.73</td><td>0.06</td></tr><tr><td colspan="2">MII (%)</td><td>74.56 &#177; 21.93</td><td>76.93 &#177; 24.75</td><td>73.15 &#177; 24.96</td><td>67.24 &#177; 30.55</td><td>0.005 <sup>a</sup></td></tr><tr><td colspan="2">Cycles without oocytes <i>n</i> (%)</td><td>12 (8.5%)</td><td>98 (8.4%)</td><td>20 (8.9%)</td><td>10 (13.9%)</td><td>0.46</td></tr><tr><td colspan="2">Used oocytes (<i>n</i>)</td><td>5.61 &#177; 3.94</td><td>5.99 &#177; 4.12</td><td>5.62 &#177; 4.29</td><td>4.19 &#177; 3.43</td><td>0.003 <sup>a</sup></td></tr><tr><td colspan="2">ICSI (%)</td><td>110/129 (85.3%)</td><td>902/1066 (84.6%)</td><td>181/205 (88.3%)</td><td>56/62 (90.3%)</td><td>0.37</td></tr><tr><td colspan="2">Fertilization rate (%)</td><td>68.05 &#177; 28.61</td><td>67.22 &#177; 27.12</td><td>66.34 &#177; 29.47</td><td>60.98 &#177; 28.49</td><td>0.35</td></tr><tr><td colspan="2">Embryo quality score</td><td>1.90 &#177; 0.66</td><td>2.03 &#177; 0.71</td><td>1.96 &#177; 0.73</td><td>1.92 &#177; 0.77</td><td>0.27</td></tr><tr><td colspan="2">Day of ET</td><td colspan="5"></td></tr><tr><td colspan="2">Day 3</td><td>52/84 (61.9)</td><td>486/763 (63.7)</td><td>91/140 (65.0)</td><td>39/50 (78.0)</td><td></td></tr><tr><td colspan="2">Day 5</td><td>32/84 (38.1)</td><td>277/763 (36.3)</td><td>49/140 (35.0)</td><td>11/50 (22.0)</td><td>0.22</td></tr><tr><td colspan="2">Embryos transferred (<i>n</i>)</td><td>1.69 &#177; 0.64</td><td>1.74 &#177; 0.62</td><td>1.73 &#177; 0.69</td><td>1.68 &#177; 0.59</td><td>0.81</td></tr><tr><td colspan="2">Blastulation rate (%)</td><td>53.57 &#177; 23.09</td><td>56.57 &#177; 22.46</td><td>53.07 &#177; 20.75</td><td>52.65 &#177; 29.47</td><td>0.46</td></tr></table>
22423437329823591e8a7e6e415ad67c9d6ce6f112b7958a3512eda569d61d0f.png
simple
<table><tr><td>Primer Name</td><td>Sequence</td><td>Gene</td></tr><tr><td>CSnmrAF</td><td>AGTAGGGTAGGCAGCATCCA</td><td>Check for PC-06 (NmrA)</td></tr><tr><td>CSnmrAR</td><td>GCGCACTATTTCTGAGCAGC</td><td>Check for PC-06</td></tr><tr><td>pen1</td><td>ATGTCCAGATCCCTAACCCAC</td><td>Screen for penP deletion</td></tr><tr><td>pen2</td><td>CATAATTGGGGTCACCTGATG</td><td>Screen for penP deletion</td></tr><tr><td>CSpenCF</td><td>CGTCGACAGAATCTCCAGCT</td><td>Check for penC</td></tr><tr><td>CSpenCR</td><td>TCATCCATCACACCGCGATT</td><td>Check for penC</td></tr><tr><td>CSjanCF</td><td>GGGGAAGGTAGCCATGCTTT</td><td>Check for janC</td></tr><tr><td>CSjanCR</td><td>TGCGGATATTACGAGGCGAC</td><td>Check for janC</td></tr><tr><td>jan1</td><td>CCAATGTTAGAGTCCCAACG</td><td>Screen for jan P deletion</td></tr><tr><td>jan2</td><td>GTCGTATACTCCCCGACATG</td><td>Screen for jan P deletion</td></tr><tr><td>CSP450F</td><td>ACGGTCACGGTCAAGTCTTC</td><td>Check for PJ-13 (P450)</td></tr><tr><td>CSP450R</td><td>CGTTACAGGGCCGGGTATTT</td><td>Check for PJ-13 (P450)</td></tr><tr><td>CSjanQF</td><td>TACAGGCCAGCTCTTCAACC</td><td>Check for janQ</td></tr><tr><td>CSjanQR</td><td>TCGGACATCTTTCGCACCAA</td><td>Check for janQ</td></tr><tr><td>CS janD intF</td><td>GGACTTACAAGGCTTTCGCA</td><td>Screen for janD deletion</td></tr><tr><td>CS janD intR</td><td>ACGCTTAAAGCCCAGAAACA</td><td>Screen for janD deletion</td></tr><tr><td>CSFADF</td><td>CTTCCTCGTGCCCTTGACAT</td><td>Check for janO (FAD)</td></tr><tr><td>CSFADR</td><td>GACCATGCTGTACCGAACGT</td><td>Check for janO (FAD)</td></tr></table>
e359a11f03731c303bfd1b1a5705b4833b9265383ca0a8a6098be53a3545ea16.png
simple
<table><tr><td>Translocation</td><td>Translocation partner</td><td>ATRA response</td></tr><tr><td>t(11;17) (q23;q21) [5]</td><td>PLZF (promyelocytic leukaemia zinc finger protein)</td><td>Resistant</td></tr><tr><td>t(5;17) (q35;q21) [6]</td><td>NPM (nucleophosmin)</td><td>Sensitive</td></tr><tr><td>t(11;17) (q13;q21) [7]</td><td>NUMA (nuclear mitotic apparatus)</td><td>Sensitive</td></tr><tr><td>der(17) [8]</td><td>STAT5b (signal transducer and activator of transcription)</td><td>Resistant</td></tr><tr><td>t(3;15) (q26;q13) (present case)</td><td></td><td>Sensitive</td></tr></table>
b45c1faf904228b5f1ed982f2eaed6f61865e4c346d75366154e1947276c5c3b.png
simple
<table><tr><td>N = 1094</td><td>Total</td><td>Males (n = 506)</td><td>Females (n = 588)</td><td>&#967;<sup>2</sup></td></tr><tr><td>Age, mean (SD)</td><td>53.1(11.4)</td><td>53.8(11.6)</td><td>52.5(11.1)</td><td></td></tr><tr><td>Marital status (% married /living together)</td><td>54.6</td><td>61.1</td><td>49.0</td><td><i>p</i> &lt; 0.05</td></tr><tr><td>Level of education (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>High</td><td>41.7</td><td>41.1</td><td>41.9</td><td><i>p &gt;</i>0.05</td></tr><tr><td>Middle</td><td>27.1</td><td>28.4</td><td>26.0</td><td></td></tr><tr><td>Low</td><td>26.5</td><td>25.2</td><td>27.5</td><td></td></tr><tr><td>Not applicable</td><td>4.7</td><td>5.0</td><td>4.6</td><td></td></tr><tr><td>Frequency of exercise</td><td></td><td></td><td></td><td></td></tr><tr><td>Do not exercise/hardly</td><td>10.6</td><td>12.7</td><td>8.7</td><td><i>p &gt;</i>0.05</td></tr><tr><td>Once per week</td><td>10.2</td><td>10.3</td><td>10.1</td><td></td></tr><tr><td>Twice or more per week</td><td>79.2</td><td>76.9</td><td>81.2</td><td></td></tr><tr><td>Smoking (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>76.1</td><td>74.4</td><td>77.5</td><td><i>p &gt;</i>0.05</td></tr><tr><td>Yes</td><td>23.9</td><td>25.6</td><td>22.5</td><td></td></tr><tr><td>Obesity (BMI &#8805; 30 kg/m<sup>2</sup>) (%)</td><td>16.9</td><td>15.2</td><td>18.4</td><td><i>p &gt;</i>0.05</td></tr><tr><td>MDD-S<sup>#</sup> (%)</td><td>12.5</td><td>10.0</td><td>14.7</td><td><i>p</i> &lt; 0.05</td></tr><tr><td>MDD-R<sup>#</sup> (%)</td><td>8.2</td><td>5.4</td><td>10.6</td><td><i>p</i> &lt; 0.05</td></tr></table>
824ce2445897b04865caef8d4d0d66df939d5a86b1828bdc714cde6072f933f8.png
simple
<table><tr><td>1. Was an 'a priori' design provided?The research question and inclusion criteria should be established before the conduct of the review.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>2. Was there duplicate study selection and data extraction?There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>3. Was a comprehensive literature search performed?At least two electronic sources should be searched. The report must include years and databases used (e.g. Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>5. Was a list of studies (included and excluded) provided?A list of included and excluded studies should be provided.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>6. Were the characteristics of the included studies provided?In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>7. Was the scientific quality of the included studies assessed and documented?'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>8. Was the scientific quality of the included studies used appropriately in formulating conclusions?The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>9. Were the methods used to combine the findings of studies appropriate?For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi-squared test for homogeneity, I<sup>2</sup>). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?).</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>10. Was the likelihood of publication bias assessed?An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test).</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr><tr><td>11. Was the conflict of interest stated?Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.</td><td>&#9633; Yes&#9633; No&#9633; Can't answer&#9633; Not applicable</td></tr></table>
9228996ee9988f0e57a17b6bd6e775b60bb6c59bc8fe77ded1d7342a96ca1c43.png
simple
<table><tr><td>Nutrient</td><td>Amount (DM)</td></tr><tr><td>Crude protein</td><td>76.9%</td></tr><tr><td>Crude fat</td><td>1.9%</td></tr><tr><td>Ca</td><td>12.31%</td></tr><tr><td>P</td><td>1.03%</td></tr><tr><td>Na</td><td>4.09%</td></tr><tr><td>K</td><td>0.3%</td></tr><tr><td>Mg</td><td>2.08%</td></tr><tr><td>S</td><td>0.24%</td></tr><tr><td>Mn</td><td>615 ppm</td></tr><tr><td>Zn</td><td>924 ppm</td></tr><tr><td>Cu</td><td>308 ppm</td></tr><tr><td>Co</td><td>26 ppm</td></tr><tr><td>I</td><td>87 ppm</td></tr><tr><td>Se</td><td>6&#8211;8 ppm</td></tr><tr><td>Vitamin A</td><td>90,200 IU/kg</td></tr><tr><td>Vitamin D</td><td>9020 IU/kg</td></tr><tr><td>Vitamin E</td><td>226 IU/kg</td></tr><tr><td>Rumensin&#174; 0.68 g/kg</td><td>616 g/t</td></tr><tr><td>Tylan &#174; 0.14 g/kg</td><td>123 g/t</td></tr></table>
8bae349887d3020bde49b47bb98d37d5864128511bef791cda4d05c48859cf75.png
simple
<table><tr><td>#</td><td>m/z</td><td>z</td><td>m</td><td>Sequence proposal</td><td>Alignment</td><td>Protein homologue</td></tr><tr><td>1</td><td>1185.6</td><td>3</td><td>3553.8</td><td>SNVLYGPDTPTLSQSLGNS</td><td>Query: NVLYGPDTPTLSQS</td><td>CEACAM8</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NVLYGPD PT+S S</td><td>P31997</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sbjct: NVLYGPDAPTISPS</td><td>H. sapiens</td></tr><tr><td>2</td><td>693.3</td><td>3</td><td>2076.9</td><td>BXXTVESVPPNAAEGKDALLR</td><td>Query: TVESVPPNAAEGKDALL</td><td>CEACAM8</td></tr><tr><td></td><td>1039</td><td>2</td><td></td><td></td><td>T+E VP NAAEGK+ LL</td><td>P31997</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sbjct: TIEAVPSNAAEGKEVLL</td><td>H. sapiens</td></tr><tr><td>3</td><td>553.2</td><td>2</td><td>1104.4</td><td>BVTTPGPAYSGR</td><td>Query: TPGPAYSGR</td><td>CEACAM8</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>TPGPAYS R</td><td>P31997</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sbjct: TPGPAYSNR</td><td>H. sapiens</td></tr><tr><td>4</td><td>656.8</td><td>4</td><td>2623.2</td><td>B [VL]LPGDTASLTWFK [W/GE/AD/SV]TVLPXXK</td><td>Query: WFKGETV</td><td>CEACAM8</td></tr><tr><td></td><td>875.4</td><td>3</td><td></td><td></td><td>W+KGETV</td><td>P31997</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sbjct: WYKGETV</td><td>H. sapiens</td></tr><tr><td>5</td><td>539.2</td><td>2</td><td>1076.4</td><td>BLLLYVLDTK</td><td>Query: BLLLYVLDT</td><td>Q9NOP7</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>+++ YV+ T</td><td>CEA protein</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sbjct: RIIGYVIAT</td><td>P. hamadryas</td></tr><tr><td>6</td><td>425.2</td><td>2</td><td>848.4</td><td>BFETALLR</td><td>No match</td><td></td></tr><tr><td>7</td><td>386.2</td><td>2</td><td>770.4</td><td>BTVPDSPR</td><td>No match</td><td></td></tr></table>
fef84bac2c52dbafadeb88e27d7220609590a0b4ed53ffb62f5e10ef5fc1c430.png
simple
<table><tr><td></td><td>Nutritional factors</td><td>Chick -starter diet</td><td>Chick-Grower diet</td></tr><tr><td>1.</td><td>ME<sup>*</sup> Kcal/ kg</td><td>2915</td><td>2915</td></tr><tr><td>2.</td><td>Crude protein %</td><td>17.50</td><td>15.00</td></tr><tr><td>3.</td><td>Fat %</td><td>3-4</td><td>3-4</td></tr><tr><td>4.</td><td>Fibre %</td><td>3-4</td><td>3-4</td></tr><tr><td>5.</td><td>Lysine %</td><td>0.70</td><td>0.75</td></tr><tr><td>6.</td><td>Methionine %</td><td>0.40</td><td>0.35</td></tr><tr><td>7.</td><td>Calcium %</td><td>1.00</td><td>1.00</td></tr><tr><td>8.</td><td>Total Phosphorus %</td><td>0.70</td><td>0.60</td></tr><tr><td>9.</td><td>Vitamin A (I.U.)</td><td>4550</td><td>4450</td></tr><tr><td>10.</td><td>Vitamin D (I.U.)</td><td>1600</td><td>1600</td></tr><tr><td>11.</td><td>Vitamin E (I.U.)</td><td>15.0</td><td>15.0</td></tr><tr><td>12.</td><td>Vitamin K (mg)</td><td>1.00</td><td>1.00</td></tr><tr><td>13.</td><td>Choline (mg)</td><td>45.0</td><td>45.0</td></tr><tr><td>14.</td><td>Linoleic acid %</td><td>1.00</td><td>1.00</td></tr></table>
a62ebbbf80a86ae56a12c0c742a2443163e760262a6e0a2dc3a88514da62e418.png
complex
<table><tr><td rowspan="2"></td><td colspan="4">Pharmacist</td><td colspan="4">PMV</td></tr><tr><td colspan="2">Any FP training</td><td colspan="2">No FP training</td><td colspan="2">Any FP training</td><td colspan="2">No FP training</td></tr><tr><td>Minimum age</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td> Male condom</td><td>172</td><td>79.7</td><td>238</td><td>74.0</td><td>213</td><td>75.6*</td><td>261</td><td>66.7</td></tr><tr><td> Pill</td><td>148</td><td>89.2***</td><td>170</td><td>75.3</td><td>153</td><td>85.0*</td><td>160</td><td>75.0</td></tr><tr><td> EC</td><td>127</td><td>89.8**</td><td>165</td><td>77.6</td><td>89</td><td>82.0*</td><td>94</td><td>69.2</td></tr><tr><td> Injectable</td><td>130</td><td>88.5</td><td>159</td><td>80.5</td><td>na</td><td>na</td><td>na</td><td>na</td></tr><tr><td colspan="9">Minimum parity</td></tr><tr><td> Male condom</td><td>172</td><td>2.9</td><td>238</td><td>2.9</td><td>213</td><td>7.5</td><td>261</td><td>4.2</td></tr><tr><td> Pill</td><td>148</td><td>29.1</td><td>170</td><td>28.8</td><td>153</td><td>42.5</td><td>160</td><td>44.4</td></tr><tr><td> EC</td><td>127</td><td>11.8</td><td>165</td><td>12.7</td><td>89</td><td>25.8</td><td>94</td><td>14.9</td></tr><tr><td> Injectable</td><td>130</td><td>22.3</td><td>159</td><td>21.4</td><td>na</td><td>na</td><td>na</td><td>na</td></tr><tr><td colspan="9">Marital status</td></tr><tr><td> Male condom</td><td>172</td><td>7.6</td><td>238</td><td>10.9</td><td>213</td><td>6.6</td><td>261</td><td>7.7</td></tr><tr><td> Pill</td><td>148</td><td>43.9</td><td>170</td><td>39.4</td><td>153</td><td>61.4</td><td>160</td><td>53.8</td></tr><tr><td> EC</td><td>127</td><td>24.4</td><td>165</td><td>27.9</td><td>89</td><td>31.5*</td><td>94</td><td>16.0</td></tr><tr><td> Injectable</td><td>130</td><td>41.5</td><td>159</td><td>48.4</td><td>na</td><td>na</td><td>na</td><td>na</td></tr><tr><td colspan="9">Bias score</td></tr><tr><td> Male condom</td><td>172</td><td>0.9</td><td>238</td><td>0.9</td><td>213</td><td>0.9*</td><td>261</td><td>0.8</td></tr><tr><td> Pill</td><td>148</td><td>1.6</td><td>170</td><td>1.4</td><td>153</td><td>1.9</td><td>160</td><td>1.7</td></tr><tr><td> EC</td><td>127</td><td>1.3</td><td>165</td><td>1.2</td><td>89</td><td>1.4**</td><td>94</td><td>1.0</td></tr><tr><td> Injectable</td><td>130</td><td>1.5</td><td>159</td><td>1.5</td><td>na</td><td>na</td><td>na</td><td>na</td></tr><tr><td>Total<sup>a</sup></td><td></td><td>3.8</td><td></td><td>3.5</td><td></td><td>4.2</td><td></td><td>3.5</td></tr></table>
6cef1e235238f86f47185f304670af9a0f69e592154ad90a74551a6baaa17afb.png
simple
<table><tr><td>Genotypes/alleles</td><td>Patients (47)</td><td>Controls (76)</td></tr><tr><td>ID</td><td>26 (55.3%)</td><td>34 (44.7%)</td></tr><tr><td>DD</td><td>14 (29.8%)</td><td>30 (39.5%)</td></tr><tr><td>II</td><td>7 (14.9%)</td><td>12 (15.8%)</td></tr><tr><td>AC</td><td>20 (42.6%)</td><td>31 (40.8%)</td></tr><tr><td>AA</td><td>25 (53.2%)</td><td>40 (52.6%)</td></tr><tr><td>CC</td><td>2 (4.2%)</td><td>5 (6.6%)</td></tr><tr><td>MT</td><td>23 (48.9%)</td><td>40 (52.6%)</td></tr><tr><td>MM</td><td>17 (36.2%)</td><td>24 (31.6%)</td></tr><tr><td>TT</td><td>7 (14.9%)</td><td>12 (15.8%)</td></tr><tr><td>D allele presence</td><td>40 (85.1%)</td><td>64 (84.2%)</td></tr><tr><td>I allele presence</td><td>33 (70.2%)</td><td>46 (60.5%)</td></tr><tr><td>A allele presence</td><td>45 (95.7%)</td><td>71 (93.4%)</td></tr><tr><td>C allele presence</td><td>22 (46.8%)</td><td>36 (47.3%)</td></tr><tr><td>M allele presence</td><td>40 (85.1%)</td><td>64 (84.2%)</td></tr><tr><td>T allele presence</td><td>30 (63.8%)</td><td>52 (68.4%)</td></tr></table>
d232dd30e0c0055c935df65b0abf19b2826965777005aacd7f17d2dffd67b4b7.png
simple
<table><tr><td>Assumptions</td><td>Justification</td></tr><tr><td>66.45% of standard care monitoring occurs in primary care with practice nurses</td><td>Based on previous TAR (manufacturers submission for TA256)70</td></tr><tr><td>60% of the cohort have atrial fibrillation, 40% have an artificial heart valve</td><td>In line with the observed proportions of patients with these conditions in self-monitoring trials68</td></tr><tr><td>Average age of the cohort is 65 years, and 55% are male</td><td>In line with the observed mean age of included patients with these conditions in self-monitoring trials68</td></tr><tr><td>50% of self-monitoring people self-test, 50% self-manage</td><td>Self- assumption</td></tr><tr><td>The increase in the number of tests performed per year with self-monitoring is 23</td><td>In line with the observed frequency of self-testing in self-monitoring trials68</td></tr><tr><td>Relative treatment effects are estimated and applied separately for self-testing and self-management</td><td>Derived from the observed event rates in cohorts of people being managed under current standard models of care. Relative risks of these events resulting from improved/reduced INR control, conferred by self-monitoring, were derived from the meta-analysis of RCTs of self-monitoring versus standard practice. (see section on clinical effectiveness results)</td></tr><tr><td>15% of participants do not commence self-monitoring following training</td><td>Based on the RCT literature43 and the expert advisory committee consultation</td></tr><tr><td>10% of participants discontinue self-monitoring within a year of commencing</td><td>Based on consideration of the views of the expert advisory committee (&#8764;5%) and a rate of 14% reported in the largest UK-based trial.43</td></tr><tr><td>Self-monitoring device costs are annuitized over 5 years to account for the potential for loss and accidental damage</td><td>It was assumed that the NHS would pay for devices and loan them out to patients. As such they were annuitized over their expected useful life, to provide an equivalent annual/quarterly cost of use</td></tr><tr><td>75% of devices are reused by another patient when a patient discontinues self-monitoring</td><td>In line with a previous UK-based economic evaluation71</td></tr></table>
7a50a78e5e4b92568f44aafd16772f792890b3cb0c95b33a502ceabe8fb2fa87.png
simple
<table><tr><td></td><td>HR (95% CI)</td><td>P</td></tr><tr><td>ABDC treatment</td><td>3.63 (1.57-8.34)</td><td>0.003</td></tr><tr><td><i>Candida</i> spp. load until day 5</td><td>1.19 (0.70-2.02)</td><td>0.51</td></tr><tr><td><i>Candida</i> spp. load after day 5</td><td>0.67 (0.31-1.47)</td><td>0.32</td></tr><tr><td>Duration of colonization until day 5</td><td>0.96 (0.90-1.02)</td><td>0.13</td></tr><tr><td>Duration of colonization after day 5</td><td>0.92 (0.88-0.96)</td><td>&lt;0.001</td></tr><tr><td>CPIS day 7</td><td>0.91 (0.76-1.10)</td><td>0.32</td></tr><tr><td>LIS day 7</td><td>0.60 (0.40-0.91)</td><td>0.02</td></tr></table>
e1a84eeca240c0e03c38572b1bae87a73b423515aef0b807304b77cf457ecc14.png
complex
<table><tr><td>Clinical Features</td><td colspan="2">Colombia</td><td colspan="2">Mexico</td><td colspan="2">Latinos USA (NLAAS)</td><td colspan="2">USA(NCS-R)</td></tr><tr><td></td><td>n<sup>&#165;</sup></td><td>%(95%CI)*</td><td>n<sup>&#165;</sup></td><td>%(95%CI)*</td><td>n<sup>&#165;</sup></td><td>%(95%CI)*</td><td>n<sup>&#165;</sup></td><td>%(95%CI)*</td></tr><tr><td>Recurrent hazard-laden smoking</td><td>9</td><td>3 (1, 5)</td><td>7</td><td>3 (&lt;1, 5)</td><td>15</td><td>6 (3, 9)</td><td>59</td><td>3 (2, 4)</td></tr><tr><td>Social problems</td><td>13</td><td>5 (2, 7)</td><td>8</td><td>3 (&lt;1, 5)</td><td>5</td><td>2 (&lt;1, 3)</td><td>27</td><td>1 (1, 2)</td></tr><tr><td>Continued smoking despite experiencing these problems<sup>&#8225;</sup></td><td>9</td><td>4 (1, 6)</td><td>6</td><td>2 (&lt;1, 4)</td><td>4</td><td>2 (&lt;1, 3)</td><td>22</td><td>1 (1, 2)</td></tr><tr><td>Work problems</td><td>8</td><td>2 (&lt;1, 4)</td><td>6</td><td>2 (&lt;1, 4)</td><td>5</td><td>1 (&lt;1, 3)</td><td>24</td><td>1 (&lt;1, 2)</td></tr><tr><td>Legal problems</td><td>6</td><td>2 (&lt;1, 4)</td><td>3</td><td>1 (&lt;1, 2)</td><td colspan="2">Not available**</td><td>5</td><td>Not estimated</td></tr></table>
f13af735eda9f71f2bc73698d080922a8446fb56d8efea35dd4c6ffd56d057a5.png
complex
<table><tr><td rowspan="2">Persistent Organic Pollutants</td><td colspan="3">&#8710; cMetS Score</td><td colspan="3">Relative Change of Glucose (%)</td><td colspan="3">Relative Change of HDL&#8722;c (%)</td><td colspan="3">Relative Change of TG (%)</td><td colspan="3">Relative Change of SBP (%)</td><td colspan="3">Relative Change of DBP (%)</td></tr><tr><td><i>&#946;</i></td><td colspan="2">95% CI</td><td><i>&#946;</i></td><td colspan="2">95% CI</td><td><i>&#946;</i></td><td colspan="2">95% CI</td><td><i>&#946;</i></td><td colspan="2">95% CI</td><td><i>&#946;</i></td><td colspan="2">95% CI</td><td><i>&#946;</i></td><td colspan="2">95% CI</td></tr><tr><td>PCB 52</td><td>0.64 <sup>a</sup></td><td>0.21</td><td>1.07</td><td>1.91</td><td>&#8722;0.46</td><td>4.29</td><td>&#8722;0.21</td><td>&#8722;2.74</td><td>2.33</td><td>2.66</td><td>0.05</td><td>5.26</td><td>0.45</td><td>&#8722;1.42</td><td>2.32</td><td>2.05</td><td>&#8722;0.55</td><td>4.65</td></tr><tr><td>PCB 101</td><td>0.40</td><td>&#8722;0.03</td><td>0.82</td><td>&#8722;0.13</td><td>&#8722;2.46</td><td>2.19</td><td>0.09</td><td>&#8722;2.36</td><td>2.54</td><td>1.52</td><td>&#8722;1.03</td><td>4.07</td><td>0.09</td><td>&#8722;1.72</td><td>1.90</td><td>0.86</td><td>&#8722;1.68</td><td>3.40</td></tr><tr><td>PCB 118</td><td>0.56</td><td>&#8722;0.08</td><td>1.20</td><td>1.06</td><td>&#8722;2.45</td><td>4.56</td><td>0.20</td><td>&#8722;3.50</td><td>3.91</td><td>2.01</td><td>&#8722;1.84</td><td>5.86</td><td>0.15</td><td>&#8722;2.58</td><td>2.89</td><td>2.93</td><td>&#8722;0.87</td><td>6.74</td></tr><tr><td>PCB 138</td><td>0.31</td><td>&#8722;0.17</td><td>0.80</td><td>&#8722;0.50</td><td>&#8722;3.13</td><td>2.12</td><td>&#8722;0.08</td><td>&#8722;2.85</td><td>2.70</td><td>0.59</td><td>&#8722;2.30</td><td>3.48</td><td>0.71</td><td>&#8722;1.32</td><td>2.75</td><td>3.01 <sup>a</sup></td><td>0.20</td><td>5.82</td></tr><tr><td>PCB 153</td><td>0.14</td><td>&#8722;0.23</td><td>0.50</td><td>0.21</td><td>&#8722;1.76</td><td>2.18</td><td>0.86</td><td>&#8722;1.21</td><td>2.93</td><td>0.14</td><td>&#8722;2.03</td><td>2.31</td><td>0.95</td><td>&#8722;0.57</td><td>2.48</td><td>2.33 <sup>a</sup></td><td>0.21</td><td>4.45</td></tr><tr><td>PCB 156</td><td>0.22</td><td>&#8722;0.31</td><td>0.76</td><td>&#8722;1.77</td><td>&#8722;4.64</td><td>1.11</td><td>&#8722;1.90</td><td>&#8722;4.93</td><td>1.14</td><td>0.63</td><td>&#8722;2.55</td><td>3.82</td><td>1.43</td><td>&#8722;0.80</td><td>3.67</td><td>2.76</td><td>0.35</td><td>5.88</td></tr><tr><td>PCB 180</td><td>0.25</td><td>&#8722;0.14</td><td>0.63</td><td>1.03</td><td>&#8722;1.04</td><td>3.10</td><td>&#8722;0.52</td><td>&#8722;2.71</td><td>1.67</td><td>1.35</td><td>&#8722;0.93</td><td>3.63</td><td>1.36</td><td>&#8722;0.25</td><td>2.97</td><td>2.05</td><td>&#8722;0.20</td><td>4.30</td></tr><tr><td>&#931;PCB</td><td>0.60</td><td>&#8722;0.04</td><td>1.24</td><td>&#8722;0.58</td><td>&#8722;4.02</td><td>2.85</td><td>&#8722;0.84</td><td>&#8722;4.55</td><td>2.87</td><td>3.66</td><td>&#8722;0.15</td><td>7.47</td><td>1.22</td><td>&#8722;1.49</td><td>3.93</td><td>4.84 <sup>a</sup></td><td>1.11</td><td>8.57</td></tr><tr><td>Marker PCB</td><td>0.51</td><td>&#8722;0.11</td><td>1.12</td><td>&#8722;0.81</td><td>&#8722;4.10</td><td>2.49</td><td>&#8722;0.34</td><td>&#8722;3.91</td><td>3.22</td><td>3.71 <sup>a</sup></td><td>0.05</td><td>7.36</td><td>1.54</td><td>&#8722;1.06</td><td>4.15</td><td>4.44 <sup>a</sup></td><td>0.85</td><td>8.03</td></tr><tr><td>Dioxin-like PCB</td><td>0.09</td><td>&#8722;0.50</td><td>0.68</td><td>&#8722;2.24</td><td>&#8722;5.39</td><td>0.91</td><td>&#8722;0.49</td><td>&#8722;3.91</td><td>2.93</td><td>0.72</td><td>&#8722;2.81</td><td>4.25</td><td>0.72</td><td>&#8722;1.78</td><td>3.23</td><td>3.01</td><td>&#8722;0.46</td><td>6.48</td></tr><tr><td>HCB</td><td>0.13</td><td>&#8722;0.10</td><td>0.36</td><td>&#8722;1.22</td><td>&#8722;2.46</td><td>0.01</td><td>0.49</td><td>&#8722;0.83</td><td>1.81</td><td>1.09</td><td>&#8722;0.27</td><td>2.46</td><td>0.18</td><td>&#8722;0.80</td><td>1.15</td><td>0.49</td><td>&#8722;0.88</td><td>1.85</td></tr><tr><td><i>trans</i>-Nonachlor</td><td>&#8722;0.09</td><td>&#8722;0.61</td><td>0.43</td><td>&#8722;0.84</td><td>&#8722;3.65</td><td>1.96</td><td>1.25</td><td>&#8722;1.71</td><td>4.20</td><td>0.19</td><td>&#8722;2.90</td><td>3.28</td><td>&#8722;0.26</td><td>&#8722;2.43</td><td>1.91</td><td>1.83</td><td>&#8722;1.20</td><td>4.86</td></tr><tr><td>&#946;-HCH</td><td>&#8722;0.13</td><td>&#8722;0.45</td><td>0.19</td><td>0.65</td><td>&#8722;1.10</td><td>2.39</td><td>1.91 <sup>a</sup></td><td>0.09</td><td>3.74</td><td>&#8722;1.13</td><td>&#8722;3.05</td><td>0.79</td><td>0.20</td><td>&#8722;1.16</td><td>1.57</td><td>1.05</td><td>&#8722;0.86</td><td>2.95</td></tr><tr><td><i>p,p&#8217;</i>-DDT</td><td>0.03</td><td>&#8722;0.58</td><td>0.64</td><td>1.28</td><td>&#8722;1.99</td><td>4.56</td><td>2.11</td><td>&#8722;1.34</td><td>5.56</td><td>&#8722;0.31</td><td>&#8722;3.93</td><td>3.30</td><td>&#8722;0.15</td><td>&#8722;2.72</td><td>2.41</td><td>1.70</td><td>&#8722;1.89</td><td>5.28</td></tr><tr><td><i>p,p&#8217;</i>-DDE</td><td>&#8722;0.01</td><td>&#8722;0.40</td><td>0.37</td><td>0.94</td><td>&#8722;1.14</td><td>3.01</td><td>2.03</td><td>&#8722;0.15</td><td>4.20</td><td>&#8722;0.88</td><td>&#8722;3.17</td><td>1.41</td><td>0.30</td><td>&#8722;1.31</td><td>1.92</td><td>1.61</td><td>&#8722;0.64</td><td>3.87</td></tr></table>
874c9fdccc9f38e476d230b0990c9748938b15b2b1c356fa0bff1651b90bd43b.png
simple
<table><tr><td></td><td>ECW</td><td>ECS</td><td>ECT</td><td>NW</td></tr><tr><td>ECW</td><td>1</td><td></td><td></td><td>0.33</td></tr><tr><td>ECS</td><td>1</td><td>1</td><td></td><td>0.33</td></tr><tr><td>ECT</td><td>1</td><td>1</td><td>1</td><td>0.33</td></tr></table>
ccaca0382305d1ea31554e96a0466f89a472886d7e5dcdc05c1af29712c1d661.png
complex
<table><tr><td rowspan="2">Crude plant extracts</td><td colspan="3">LC<sub>50</sub></td></tr><tr><td>6 hrs</td><td>12 hrs</td><td>24 hrs</td></tr><tr><td>HE I</td><td>&#8212;</td><td>3943</td><td>3880</td></tr><tr><td>CE I</td><td>2836</td><td>183</td><td>2</td></tr><tr><td>ME I</td><td>2840</td><td>183</td><td>16</td></tr><tr><td>CE II</td><td>2836</td><td>542</td><td>79</td></tr><tr><td>BE II</td><td>2840</td><td>545</td><td>194</td></tr></table>
ad3ba86dd73fb166a26bba30129dac18f0fff0944e19edc8765fe8a7ebeba9a9.png
simple
<table><tr><td>groups</td><td>Rhizoma Coptidis</td><td>Radix Scutellariae</td><td>Cortex Phellodendri</td><td>Fructus Gardeniae</td></tr><tr><td>F1</td><td>3</td><td>2</td><td>2</td><td>3</td></tr><tr><td>F2</td><td>6</td><td>2</td><td>2</td><td>3</td></tr><tr><td>F3</td><td>3</td><td>4</td><td>4</td><td>6</td></tr><tr><td>F4</td><td>3</td><td>4</td><td>2</td><td>12</td></tr><tr><td>F5</td><td>3</td><td>2</td><td>8</td><td>6</td></tr><tr><td>F6</td><td>3</td><td>8</td><td>4</td><td>3</td></tr><tr><td>F7</td><td>12</td><td>4</td><td>8</td><td>3</td></tr><tr><td>F8</td><td>6</td><td>1</td><td>2</td><td>6</td></tr><tr><td>F9</td><td>6</td><td>4</td><td>1</td><td>3</td></tr></table>
03db7a532f64a38cde3be448fb75ad85c9089c83301787ba901f0d4b08e2bd1b.png
complex
<table><tr><td>Reagent</td><td>AS</td><td>DRG</td><td>LB</td><td>KOH</td><td>NP/PEG</td><td> </td></tr><tr><td>Metabolites</td><td>Terpenes and steroids</td><td>Alkaloids</td><td>Triterpenes and steroids</td><td>Coumarins and anthraquinones</td><td>Flavonoids andphenolic acids</td><td>Saponins</td></tr><tr><td colspan="7"><i>L. origanoides</i> leaves</td></tr><tr><td>HEFL</td><td>++</td><td>&#8722;</td><td>+</td><td>+</td><td>+</td><td>&#8722;</td></tr><tr><td>DIFL</td><td>+</td><td>&#8722;</td><td>+</td><td>+</td><td>+</td><td>&#8722;</td></tr><tr><td>EAFL</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td><td>++</td><td>+</td></tr><tr><td>AQFL</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td><td>+</td><td>+</td></tr><tr><td colspan="7"><i>L. origanoides</i> stems</td></tr><tr><td>HEFS</td><td>++</td><td>&#8722;</td><td>+</td><td>+</td><td>&#8722;</td><td>&#8722;</td></tr><tr><td>DIFS</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>EAFS</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td><td>++</td><td>+</td></tr><tr><td>AQFS</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td><td>+</td><td>+</td></tr></table>
1b3efcb2847f18f0d6083c0dfcc527edfe3e9ed91515fe534a3764057efbbcdb.png
simple
<table><tr><td>Variable</td><td>Patients with vascular events (<i>n</i> = 7)</td><td>Patients without vascular events(<i>n</i> = 83)</td></tr><tr><td>Age (years), median (IQR) </td><td>47 (31&#8211;62)</td><td>50 (40&#8211;62)</td></tr><tr><td>Males, <i>n</i> (%)</td><td>4 (57.1%)</td><td>43 (51.8%)</td></tr><tr><td>Personal history VTE, <i>n</i> (%)</td><td>1 (14.3%)</td><td>6 (7.2%)</td></tr><tr><td>Family history VTE, <i>n</i> (%)</td><td>1 (14.3%)</td><td>7 (8.4%)</td></tr><tr><td>Unprovoked SVT, <i>n</i> (%)</td><td>2 (28.6%)</td><td>31 (37.4%)</td></tr><tr><td>Liver cirrhosis, <i>n</i> (%)</td><td>3 (42.9%)</td><td>11 (13.3%)</td></tr><tr><td>Solid cancer, <i>n</i> (%)</td><td>0 (0%)</td><td>6 (7.2%)</td></tr><tr><td>Myeloproliferative neoplasm, <i>n</i> (%)</td><td>1 (14.3%)</td><td>6 (7.2%)</td></tr><tr><td>Recent abdominal surgery, <i>n</i> (%)</td><td>0 (0%)</td><td>10 (12.1%)</td></tr><tr><td>Hormonal therapy, <i>n</i> (%)<sup>*</sup></td><td>1 (33.3%)</td><td>10 (25.0%)</td></tr><tr><td>Inflammatory bowel disease, <i>n</i> (%)</td><td>0 (0%)</td><td>5 (6.0%)</td></tr><tr><td>JAK2 V617F mutation, <i>n</i> (%)<sup>**</sup></td><td>1 (20.0%)</td><td>2 (5.4%)</td></tr><tr><td>Factor V Leiden or prothrombin G20210A mutation, <i>n</i> (%)<sup>**</sup></td><td>1 (20.0%)</td><td>8 (16.0%)</td></tr><tr><td>Previous VKA treatment duration (months), median (IQR)</td><td>9.9 (3.2&#8211;12.9)</td><td>12.7 (7.2&#8211;24.0)</td></tr><tr><td>Time within therapeutic range (%), median (IQR)</td><td>68 (67&#8211;80)</td><td>62 (56&#8211;75)</td></tr><tr><td>Antiplatelet therapy during follow-up, <i>n</i> (%)</td><td>2 (28.6%)</td><td>12 (14.5%)</td></tr></table>
e63ca7f5e25f1c0de5e2618ef9d2ea015ec57cf6d2ad9f2a90d4836b117deb57.png
simple
<table><tr><td>Tests</td><td>Patient&#8217;s data</td><td>Units</td><td>Reference ranges</td></tr><tr><td>Cortisol dynamic</td><td>1 (confirmed twice)</td><td>nmol/L</td><td> </td></tr><tr><td>ACTH</td><td>46.2</td><td>pg/mL</td><td>&lt;46.0</td></tr><tr><td>Na<sup>+</sup></td><td>134</td><td>mmol/L</td><td>136 to 145</td></tr><tr><td>K<sup>+</sup></td><td>4.1</td><td>mmol/L</td><td>3.3 to 4.8</td></tr><tr><td>Cl<sup>-</sup></td><td>112</td><td>mmol/L</td><td>98 to 108</td></tr><tr><td>Urea</td><td>52</td><td>mg/dL</td><td>12 to 40</td></tr><tr><td>Creatinine</td><td>2.4</td><td>mg/dL</td><td>0.7 to 1.2</td></tr><tr><td>Ca<sup>2+</sup></td><td>9.3</td><td>mg/dL</td><td>8.9 to 10.2</td></tr><tr><td>Random glucose</td><td>119</td><td>mg/dL</td><td> </td></tr><tr><td>Magnesium</td><td>2.49</td><td>mg/dL</td><td>1.7 to 2.55</td></tr><tr><td>ALT</td><td>5</td><td>g/dL</td><td>0 to 41</td></tr><tr><td>AST</td><td>24</td><td>U/L</td><td>0 to 40</td></tr><tr><td>Alkaline phosphatase</td><td>53</td><td>U/L</td><td>40 to 129</td></tr><tr><td>Albumin</td><td>3.4</td><td>g/dL</td><td>3.4 to 4.8</td></tr><tr><td>Total bilirubin</td><td>0.3</td><td>mg/dL</td><td>0 to 1.0</td></tr><tr><td>Tissue transglutaminase</td><td>2.7</td><td>U/mL</td><td>&lt;15</td></tr><tr><td>T4</td><td>10.6</td><td>pmol/L</td><td>11.5 to 22.7</td></tr><tr><td>T3</td><td>2.7</td><td>pmol/L</td><td>3.5 to 6.5</td></tr><tr><td>TSH</td><td>10.61</td><td>&#956;IU/mL</td><td>0.55 to 4.78</td></tr><tr><td>ATG</td><td>82.5</td><td>IU/mL</td><td>&lt;100</td></tr><tr><td>ATPO</td><td>670.7 (+ve)</td><td>IU/mL</td><td>&lt;50</td></tr><tr><td>Anti-adrenal antibodies</td><td>Negative</td><td> </td><td>&lt;1:10</td></tr><tr><td>Blood culture</td><td>Negative</td><td> </td><td> </td></tr><tr><td>Urine culture</td><td>Negative</td><td> </td><td> </td></tr><tr><td>Stool culture</td><td>Negative</td><td> </td><td> </td></tr></table>
b59396da109b84414cdc11b2617a875e1d5103d3520f4ebd50ea2e6997b61fab.png
complex
<table><tr><td>Variable</td><td>Company</td><td colspan="2">Prestudy period(<i>n </i>= 166/133)<sup>c</sup></td><td colspan="2">Study period(<i>n </i>= 174/144)<sup>c</sup></td><td>Age-adjusted HR(95% CI)</td><td>HR adjusted model<sup>d</sup>(95% CI)</td></tr><tr><td></td><td></td><td>Number</td><td>Incidence</td><td>Number</td><td>Incidence</td><td></td><td></td></tr><tr><td>Acute injuries, all</td><td>Int</td><td>83</td><td>3.37</td><td>60</td><td>2.47</td><td>0.77 (0.42 to 1.39)</td><td>0.79 (0.41 to 1.51)</td></tr><tr><td></td><td>Ctrl</td><td>58</td><td>3.63</td><td>63</td><td>3.21</td><td></td><td></td></tr><tr><td> Lower extremity</td><td>Int</td><td>53</td><td>2.15</td><td>32</td><td>1.32</td><td>0.84 (0.40 to 1.78)</td><td>0.86 (0.38 to 1.92)</td></tr><tr><td></td><td>Ctrl</td><td>39</td><td>2.44</td><td>38</td><td>1.94</td><td></td><td></td></tr><tr><td> Knee</td><td>Int</td><td>22</td><td>0.89</td><td>20</td><td>0.82</td><td>1.05 (0.37 to 2.99)</td><td>1.48 (0.46 to 4.81)</td></tr><tr><td></td><td>Ctrl</td><td>13</td><td>0.81</td><td>14</td><td>0.71</td><td></td><td></td></tr><tr><td> Ankle</td><td>Int</td><td>20</td><td>0.81</td><td>5</td><td>0.21</td><td>0.23 (0.06 to 0.85)</td><td>0.17 (0.04 to 0.68)</td></tr><tr><td></td><td>Ctrl</td><td>9</td><td>0.56</td><td>17</td><td>0.87</td><td></td><td></td></tr><tr><td> Upper extremity</td><td>Int</td><td>14</td><td>0.57</td><td>14</td><td>0.58</td><td>1.04 (0.30 to 3.62)</td><td>0.93 (0.24 to 3.56)</td></tr><tr><td></td><td>Ctrl</td><td>10</td><td>0.63</td><td>8</td><td>0.41</td><td></td><td></td></tr><tr><td>Total number of off-duty days<sup>e</sup></td><td>Int</td><td>303</td><td>12.3</td><td>203</td><td>8.4</td><td>0.69 (0.26 to 1.82)</td><td>0.64 (0.23 to 1.79)<sup>f</sup></td></tr><tr><td></td><td>Ctrl</td><td>198</td><td>12.4</td><td>217</td><td>11.1</td><td></td><td></td></tr><tr><td>Discharged from military service<sup>g</sup></td><td>Int</td><td>17</td><td>0.69</td><td>13</td><td>0.54</td><td>0.68 (0.24 to 1.97)</td><td>0.72 (0.24 to 2.12)<sup>f</sup></td></tr><tr><td></td><td>Ctrl</td><td>11</td><td>0.69</td><td>15</td><td>0.76</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4">Follow-up days</td><td></td><td></td></tr><tr><td></td><td>Int</td><td colspan="2">24,599</td><td colspan="2">24,292</td><td></td><td></td></tr><tr><td></td><td>Ctrl</td><td colspan="2">15,963</td><td colspan="2">19,628</td><td></td><td></td></tr></table>
43f38cde6f7b099ae382887d03ec6189df7f07a19f4f882c384771f97862a0a3.png
simple
<table><tr><td>Food item</td><td>Adjusted OR* (95 % CI)</td><td><i>P</i> value</td></tr><tr><td>Cold appetizer&#8212;pork liver</td><td>3.23 (1.26&#8211;8.30)</td><td>0.01</td></tr><tr><td>Lamb chops, carrots, radish wrapped in lotus leaves</td><td>3.98 (1.74&#8211;9.11)</td><td>0.001</td></tr></table>
b85507071d7a15968fdee2830051383ea20db16a067a0586c5e17257864027c7.png
simple
<table><tr><td>Diet</td><td>Echolocation Call Type</td><td>Bat Species</td></tr><tr><td>Fruits</td><td>Broadband clicks of short duration</td><td>Egyptian fruit bat</td></tr><tr><td>Moths, beetles, flies and other insects</td><td>Narrowband with dominant fundamental harmonic</td><td>Eastern red bat</td></tr><tr><td>Flying insects and small fruits</td><td>Multiharmonic narrowband, faintly audible to humans</td><td>Black-bearded tomb bat</td></tr><tr><td>Aquatic insects like midges, crane flies and black flies</td><td>Short, broadband, with dominant fundamental harmonic</td><td>Daubenton&#8217;s bat</td></tr><tr><td>Large insects, spiders and small vertebrates</td><td>Short, multiharmonic broadband</td><td>Greater false vampire bat</td></tr><tr><td>Moths</td><td>Long, multiharmonic broadband</td><td>Madagascar sucker-footed bat</td></tr><tr><td>Butterfly, moths and beetles</td><td>Constant frequency (CF) &amp; Frequency Modulated (FM)</td><td>Greater horseshoe bat</td></tr><tr><td>Beetles, moths, flies, wasps, and flying ants </td><td>Downswept FM narrowband</td><td>Big brown bat</td></tr><tr><td>Beetles, moths, flies, and small insects</td><td>FM broadband</td><td>Townsend&#8217;s big-eared bat</td></tr></table>
a476dbcd2fe3bf5da04ce8b93d6e1329b22278c986965d2d4e60612637712907.png
simple
<table><tr><td></td><td>Control</td><td>Mild</td><td>Moderate to severe</td></tr><tr><td></td><td> (<i>n</i> = 6)</td><td> (<i>n</i> = 10)</td><td>(<i>n</i> = 10) </td></tr><tr><td>PMN (%)</td><td>10.6 &#177; 1.7</td><td>3.8 &#177; 1.7</td><td>18.6 &#177; 11.3</td></tr><tr><td>Lymph (%)</td><td>2.5 &#177; 0.5</td><td>2.3 &#177; 0.8</td><td>3.4 &#177; 1.5</td></tr><tr><td>Macrophage (%)</td><td>85 &#177; 21</td><td>93.8 &#177; 2.3</td><td>68 &#177; 21</td></tr></table>
4c900a040042bca3d61a6eb615d4dafb2e0152feae1021ad1d696bd2c32b13ed.png
complex
<table><tr><td rowspan="2">Variables</td><td>Univariate</td><td colspan="3">Multivariate</td></tr><tr><td><i>P</i> value</td><td><i>P</i> value</td><td colspan="2">OR (95% CI)</td></tr><tr><td colspan="5">Control group</td></tr><tr><td> Age, y</td><td>0.041</td><td>0.125</td><td></td><td></td></tr><tr><td> Female sex</td><td>0.463</td><td></td><td></td><td></td></tr><tr><td> AF duration, months</td><td>0.008</td><td>0.016</td><td colspan="2">1.013 (1.002&#8211;1.023)</td></tr><tr><td> NYHA class</td><td>0.094</td><td>0.130</td><td></td><td></td></tr><tr><td> Diabetes</td><td>0.127</td><td>0.394</td><td></td><td></td></tr><tr><td> Hypertension</td><td>0.250</td><td></td><td></td><td></td></tr><tr><td> LAD, mm</td><td>0.114</td><td>0.246</td><td></td><td></td></tr><tr><td colspan="5">Long duration group</td></tr><tr><td> Age, y</td><td>0.594</td><td></td><td></td><td></td></tr><tr><td> Female sex</td><td>0.424</td><td></td><td></td><td></td></tr><tr><td> AF duration, months</td><td>0.064</td><td>0.049</td><td colspan="2">1.007 (1.001&#8211;1.013)</td></tr><tr><td> NYHA class</td><td>0.397</td><td></td><td></td><td></td></tr><tr><td> Diabetes</td><td>0.205</td><td>0.084</td><td></td><td></td></tr><tr><td> Hypertension</td><td>0.044</td><td>0.008</td><td colspan="2">1.062 (1.016&#8211;1.110)</td></tr><tr><td> LAD, mm</td><td>0.310</td><td></td><td></td><td></td></tr></table>
d1920694b47348191a7946fca8f461723a238aa980a6e7b7f37fc7a620ccadb7.png
simple
<table><tr><td>No.</td><td>Name</td><td>Country</td><td>Year</td><td>Accession Number</td></tr><tr><td>1</td><td>CH-1a</td><td>China</td><td>1996</td><td>AY032626</td></tr><tr><td>2</td><td>BJ-4</td><td>China</td><td>2000</td><td>AF331831</td></tr><tr><td>3</td><td>HB-1(sh)/2002</td><td>China</td><td>2002</td><td>AY150312</td></tr><tr><td>4</td><td>JXA1</td><td>China</td><td>2006</td><td>EF112445</td></tr><tr><td>5</td><td>HUB2</td><td>China</td><td>2006</td><td>EF112446</td></tr><tr><td>6</td><td>HuN4</td><td>China</td><td>2007</td><td>EF635006</td></tr><tr><td>7</td><td>SY0608</td><td>China</td><td>2007</td><td>EU144079</td></tr><tr><td>8</td><td>CH-1R</td><td>China</td><td>2008</td><td>EU807840</td></tr><tr><td>9</td><td>HB-1</td><td>China</td><td>2008</td><td>EU360130</td></tr><tr><td>10</td><td>WUH4</td><td>China</td><td>2011</td><td>JQ326271</td></tr><tr><td>11</td><td>QYYZ</td><td>China</td><td>2011</td><td>JQ308798</td></tr><tr><td>12</td><td>SD16</td><td>China</td><td>2012</td><td>JX087437</td></tr><tr><td>13</td><td>JXA1-R</td><td>China</td><td>2012</td><td>JQ804986</td></tr><tr><td>14</td><td>HEB-2013</td><td>China</td><td>2013</td><td>KJ591659</td></tr><tr><td>15</td><td>HB-XL</td><td>China</td><td>2013</td><td>KP162169</td></tr><tr><td>16</td><td>LMY</td><td>South Korea</td><td>2002</td><td>DQ473474</td></tr><tr><td>17</td><td>VR-2332</td><td>USA</td><td>1992</td><td>AY150564</td></tr><tr><td>18</td><td>EuroPRRSV</td><td>USA</td><td>1999</td><td>AY366525</td></tr><tr><td>19</td><td>RespPRRS MLV</td><td>USA</td><td>1994</td><td>AF066183</td></tr><tr><td>20</td><td>Lelystad virus</td><td>Europe</td><td>1991</td><td>M96262</td></tr></table>
80c1d10f7bff34c91d5a13cfc2fc1ae3917cdbb9b2290e9da43e52c6e6224429.png
simple
<table><tr><td>No</td><td>SSR</td><td>Africa</td><td>Asia</td><td>Central America</td><td>South America</td></tr><tr><td>1</td><td>Jc01 A</td><td>0.09</td><td>0.02</td><td>0.39</td><td>0.15</td></tr><tr><td>2</td><td>Jc01 B</td><td>0.10</td><td>0.00</td><td>0.19</td><td>0.15</td></tr><tr><td>3</td><td>Jc01 C</td><td>0.12</td><td>0.02</td><td>0.33</td><td>0.15</td></tr><tr><td>4</td><td>Jc03 A</td><td>0.00</td><td>0.00</td><td>0.46</td><td>0.00</td></tr><tr><td>5</td><td>Jc05 A</td><td>0.00</td><td>0.00</td><td>0.42</td><td>0.00</td></tr><tr><td>6</td><td>Jc07 B</td><td>0.00</td><td>0.08</td><td>0.65</td><td>0.00</td></tr><tr><td>7</td><td>Jc08 A</td><td>0.00</td><td>0.00</td><td>0.26</td><td>0.00</td></tr><tr><td>8</td><td>Jc09 A</td><td>0.05</td><td>0.00</td><td>0.63</td><td>0.15</td></tr><tr><td>9</td><td>Jc10 A</td><td>0.00</td><td>0.00</td><td>0.06</td><td>0.00</td></tr><tr><td>10</td><td>Jc10 B</td><td>0.00</td><td>0.00</td><td>0.35</td><td>0.00</td></tr><tr><td>11</td><td>Jc13 A</td><td>0.09</td><td>0.00</td><td>0.56</td><td>0.15</td></tr><tr><td>12</td><td>Jc14 B</td><td>0.00</td><td>0.08</td><td>0.65</td><td>0.00</td></tr><tr><td>13</td><td>Jc17 A</td><td>0.37</td><td>0.38</td><td>0.37</td><td>0.37</td></tr><tr><td>14</td><td>Jc28 A</td><td>0.00</td><td>0.00</td><td>0.54</td><td>0.00</td></tr></table>
42573da45aebd25d467962b73a5371ed60fb6d960540d3240ee2e6e79a7e8193.png
simple
<table><tr><td></td><td>Sensitivity (95% CI)</td><td>Specificity (95% CI)</td><td>Positive predictive value (95% CI)</td><td>Negative predictive value (95% CI)</td></tr><tr><td>GBS&gt;0</td><td>100 (87.7&#8211;100)</td><td>0 (0&#8211;2.9)</td><td>18.3 (12.5&#8211;25.4)</td><td>-</td></tr><tr><td>PRS &gt;0</td><td>100 (87.7&#8211;100)</td><td>12 (6.9&#8211;19)</td><td>20.3 (13.9&#8211;28)</td><td>100 (78.2&#8211;100)</td></tr><tr><td>CRS &gt;2</td><td>96.4 (81.7&#8211;99.9)</td><td>20 (13.4&#8211;28.1)</td><td>21.3 (14.5&#8211;29.4)</td><td>96.2 (80.4&#8211;99.9)</td></tr><tr><td>CSMCPI &#8805;5</td><td>53.6 (33.9&#8211;72.5)</td><td>60.8 (51.7&#8211;69.4)</td><td>23.4 (13.8&#8211;35.7)</td><td>85.4 (76.3&#8211;92)</td></tr></table>
43c6dcc0f7c6c2f91bfa850c1de87927620a7028cb4f63898d511a08e2caafef.png
simple
<table><tr><td>Dataset</td><td>DB size</td><td>Prior</td><td>Posterior</td><td>MetAssign</td><td>mzMatch</td><td>CAMERA</td></tr><tr><td>std1.NEG</td><td>100</td><td>0.93</td><td>0.93</td><td>0.90</td><td>0.68</td><td>0.17</td></tr><tr><td></td><td>600</td><td>0.71</td><td>0.74</td><td>0.81</td><td>0.56</td><td>0.16</td></tr><tr><td></td><td>1000</td><td>0.57</td><td>0.63</td><td>0.76</td><td>0.49</td><td>0.16</td></tr><tr><td>std1.POS</td><td>100</td><td>0.80</td><td>0.79</td><td>0.73</td><td>0.53</td><td>0.15</td></tr><tr><td></td><td>600</td><td>0.42</td><td>0.48</td><td>0.55</td><td>0.34</td><td>0.13</td></tr><tr><td></td><td>1000</td><td>0.29</td><td>0.38</td><td>0.50</td><td>0.27</td><td>0.13</td></tr><tr><td>std2.NEG</td><td>100</td><td>0.90</td><td>0.88</td><td>0.83</td><td>0.61</td><td>0.11</td></tr><tr><td></td><td>600</td><td>0.64</td><td>0.67</td><td>0.70</td><td>0.47</td><td>0.11</td></tr><tr><td></td><td>1000</td><td>0.52</td><td>0.58</td><td>0.65</td><td>0.40</td><td>0.11</td></tr><tr><td>std2.POS</td><td>100</td><td>0.85</td><td>0.85</td><td>0.83</td><td>0.66</td><td>0.10</td></tr><tr><td></td><td>600</td><td>0.35</td><td>0.44</td><td>0.52</td><td>0.32</td><td>0.09</td></tr><tr><td></td><td>1000</td><td>0.24</td><td>0.34</td><td>0.44</td><td>0.24</td><td>0.08</td></tr><tr><td>std3.NEG</td><td>100</td><td>0.66</td><td>0.67</td><td>0.69</td><td>0.39</td><td>0.15</td></tr><tr><td></td><td>600</td><td>0.29</td><td>0.35</td><td>0.40</td><td>0.21</td><td>0.13</td></tr><tr><td></td><td>1000</td><td>0.22</td><td>0.29</td><td>0.34</td><td>0.15</td><td>0.13</td></tr><tr><td>std3.POS</td><td>100</td><td>0.51</td><td>0.53</td><td>0.54</td><td>0.47</td><td>0.18</td></tr><tr><td></td><td>600</td><td>0.11</td><td>0.17</td><td>0.21</td><td>0.11</td><td>0.16</td></tr><tr><td></td><td>1000</td><td>0.06</td><td>0.12</td><td>0.17</td><td>0.06</td><td>0.15</td></tr></table>
6f8fe3d11f88e74aeac87ccea29a8f48ee4db7b2d7b9e5ece5fedf80dfc95e34.png
simple
<table><tr><td>Parameter</td><td>MEAN</td><td>STD</td><td>MIN</td><td>MAX</td></tr><tr><td>ACCX [g]</td><td>0.09</td><td>0.20</td><td>&#8722;0.95</td><td>0.59</td></tr><tr><td>ACCY [g]</td><td>0.88</td><td>0.17</td><td>0.27</td><td>1.99</td></tr><tr><td>ACCZ [g]</td><td>0.11</td><td>0.43</td><td>&#8722;1.13</td><td>1.02</td></tr></table>
1ede15a6416caa9604aad64ca45fd0e4f1599999ecaae3fae157f5d8be195be0.png
complex
<table><tr><td>Characteristic</td><td>Control (<i>n</i> = 62)</td><td>Template-developed (<i>n</i> = 68)</td><td>Bespoke user-tested (<i>n</i> = 63)</td><td>Total (<i>n</i> = 193)</td></tr><tr><td colspan="5">Gender, <i>n</i> (%)</td></tr><tr><td> Male</td><td>24 (38.7)</td><td>32 (47.8)</td><td>27 (43.6)</td><td>83 (43.5)</td></tr><tr><td colspan="5">Age</td></tr><tr><td> Mean (SD)</td><td>78.3 (5.8)</td><td>78.6 (6.6)</td><td>77.5 (7.8)</td><td>78.1 (6.8)</td></tr><tr><td colspan="5">Fallen in previous 6 months? <i>n</i> (%)</td></tr><tr><td> Yes</td><td>23 (37.1)</td><td>29 (43.3)</td><td>27 (42.9)</td><td>79 (41.2)</td></tr><tr><td> No</td><td>39 (62.9)</td><td>36 (53.7)</td><td>36 (57.1)</td><td>111 (57.8)</td></tr><tr><td> Don&#8217;t know</td><td>0 (0.0)</td><td>2 (3.0)</td><td>0 (0.0)</td><td>2 (1.0)</td></tr><tr><td colspan="5">If fallen in previous 6 months, how many times?</td></tr><tr><td> Median (min,max)</td><td>1 (1, 5)</td><td>1 (1, 20)</td><td>1 (1, 6)</td><td>1 (1, 20)</td></tr><tr><td colspan="5">Worried about having a fall during the previous 4 weeks</td></tr><tr><td> All of the time</td><td>4 (6.5)</td><td>3 (4.5)</td><td>4 (6.4)</td><td>11 (5.7)</td></tr><tr><td> Most of the time</td><td>1 (1.6)</td><td>4 (6.0)</td><td>2 (3.2)</td><td>7 (3.7)</td></tr><tr><td> A good bit of the time</td><td>6 (9.7)</td><td>3 (4.5)</td><td>4 (6.4)</td><td>13 (6.8)</td></tr><tr><td> Some of the time</td><td>19 (30.7)</td><td>13 (19.4)</td><td>9 (14.3)</td><td>41 (21.4)</td></tr><tr><td> A little of the time</td><td>23 (37.1)</td><td>27 (40.3)</td><td>29 (46.0)</td><td>79 (41.2)</td></tr><tr><td> None of the time</td><td>9 (14.5)</td><td>17 (25.4)</td><td>15 (23.8)</td><td>41 (21.4)</td></tr><tr><td colspan="5">Short Falls Efficacy Scale &#8211; International (FES-I)<sup>a</sup></td></tr><tr><td> Mean (SD)</td><td>13.1 (5.0)</td><td>11.7 (4.3)</td><td>12.1 (4.5)</td><td>12.3 (4.7)</td></tr><tr><td colspan="5">Frenchay Activities Index (FAI)<sup>a</sup></td></tr><tr><td> Mean (SD)</td><td>47.2 (6.7)</td><td>46.5 (7.2)</td><td>46.4 (7.1)</td><td>46.6 (7.0)</td></tr></table>
37b20271374a5ff3eb9195ffecf3a61f295c316e58feba8eabf1745a3518e9a3.png
simple
<table><tr><td> </td><td>Non-vertex n/N, (%) N = 369</td><td>Vertex n/N, (%) 1,055</td><td>Crude odds ratio (95% CI)</td><td>Adjusted odds ratio<sup>a </sup>(95% CI)</td></tr><tr><td>Maternal death</td><td>0/369 (0.0)</td><td>1/1055 (0.1)</td><td>*</td><td>*</td></tr><tr><td>ICU admission</td><td>17/369 (4.6)</td><td>18/1055 (1.7)</td><td>2.78 (1.42 &#8211; 5.45)</td><td>1.30 (0.88 &#8211; 1.94)</td></tr><tr><td>Blood transfusion</td><td>22/369 (6.0)</td><td>35/1055 (3.4)</td><td>1.84 (1.07 &#8211; 3.18)</td><td>1.23 (0.67 &#8211; 2.25)</td></tr><tr><td>Hysterectomy</td><td>0 / 369 (0.0)</td><td>0/1055 (0.0)</td><td>*</td><td>*</td></tr><tr><td>3<sup>rd</sup>/4<sup>th</sup> degree perineal laceration</td><td>5/369 (1.4)</td><td>20/1055 (1.9)</td><td>0.71 (0.27 &#8211; 1.91)</td><td>*</td></tr></table>
c4a353a7a5c0642afb9e6f1cb1a581c9583e0f43072e908e09293a1e7a9cbd47.png
complex
<table><tr><td rowspan="3">Gene Expression</td><td colspan="2">Normal-Weight Control (<i>n</i> = 10)</td><td colspan="2">Morbidly Obese (<i>n</i> = 30)</td></tr><tr><td>VAT</td><td>SAT</td><td>VAT</td><td>SAT</td></tr><tr><td>Mean &#177; SD</td><td>Mean &#177; SD</td><td>Mean &#177; SD</td><td>Mean &#177; SD</td></tr><tr><td>IL-6</td><td>2.38 &#177; 1.52</td><td>17. 07 &#177; 11.66</td><td>61.09 &#177; 14.13 *</td><td>86.40 &#177; 28.71 *</td></tr><tr><td>Adiponectin</td><td>0.77 &#177; 0.32</td><td>0.58 &#177; 0.30</td><td>0.53 &#177; 0.27</td><td>0.29 &#177; 0.17 *</td></tr><tr><td>Lipocalin-2</td><td>0.006 &#177; 0.003</td><td>0.029 &#177; 0.02</td><td>0.02 &#177; 0.01</td><td>0.064 &#177; 0.03</td></tr><tr><td>TNF&#945;</td><td>0.039 &#177; 0.02</td><td>0.076 &#177; 0.06</td><td>0.26 &#177; 0.20 *</td><td>0.043 &#177; 0.02</td></tr><tr><td>Resistin</td><td>0.008 &#177; 0.004</td><td>0.016 &#177; 0.005</td><td>0.030 &#177; 0.02 *</td><td>0.030 &#177; 0.02</td></tr></table>
9ee3eec58a5a2792d5a55945219ca8d095d12f3dff6121147f351ed807a9f08e.png
complex
<table><tr><td rowspan="2">Sample</td><td colspan="3">Chemical Composition (in wt %) </td></tr><tr><td>Ni</td><td>Ti</td><td>Al</td></tr><tr><td>NiTi46</td><td>54.0</td><td>46.0</td><td>-</td></tr><tr><td>NiTiAl1</td><td>53.5</td><td>45.5</td><td>1.0</td></tr><tr><td>NiTiAl3</td><td>52.4</td><td>44.6</td><td>3.0</td></tr><tr><td>NiTiAl5</td><td>51.3</td><td>43.7</td><td>5.0</td></tr><tr><td>NiTiAl7</td><td>50.2</td><td>42.8</td><td>7.0</td></tr></table>
29bcd47a4b33f53603a0462cca290e2769cb6e29f05c8f2f85b866be4a983675.png
complex
<table><tr><td>Surgical procedure classification (three-character ICD 10 code)</td><td>Number of hospital discharges</td><td>Number of adverse events (%)</td><td colspan="5">Degree of disability (no. of patients)</td></tr><tr><td></td><td></td><td></td><td>Sick leave &#8804; 3 months</td><td>1-15%</td><td>16-30%</td><td>&gt; 30%</td><td>Death</td></tr><tr><td>Primary prosthetic replacement of hip joint (NFB**)</td><td>50,733</td><td>304 (0.6)</td><td>18</td><td>259</td><td>22</td><td>4</td><td>1</td></tr><tr><td>Primary prosthetic replacement of knee joint (NGB**)</td><td>23,600</td><td>187 (0.8)</td><td>12</td><td>163</td><td>9</td><td>2</td><td>1</td></tr><tr><td>Decompression of spinal cord and nerve roots (ABC**)</td><td>17,507</td><td>168 (1.0)</td><td>12</td><td>120</td><td>12</td><td>22</td><td>2</td></tr><tr><td>Fracture surgery of femur (NFJ**)</td><td>68,123</td><td>105 (0.2)</td><td>9</td><td>80</td><td>14</td><td>1</td><td>1</td></tr><tr><td>Fracture surgery of ankle and foot femur (NHJ**)</td><td>22,490</td><td>103 (0.5)</td><td>8</td><td>92</td><td>2</td><td>2</td><td>0</td></tr><tr><td>Fracture surgery of knee and lower leg (NGJ**)</td><td>12,594</td><td>92 (0.7)</td><td>5</td><td>84</td><td>3</td><td>0</td><td>0</td></tr></table>
22b0c46cce177b1f355c9ccbd443ad58073bd725a6ba202e7d1c3425c8f8a0ac.png
simple
<table><tr><td>Variable</td><td>Odds ratio</td><td>Lower 95 % CI</td><td>Upper 95 % CI</td><td>P value</td></tr><tr><td>Body Area (n = 194, m = 18)</td><td></td><td></td><td></td><td></td></tr><tr><td>Girth</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td>Back</td><td>2.56</td><td>1.61</td><td>4.07</td><td>&lt;0.0001</td></tr><tr><td>Tail</td><td>0.44</td><td>0.26</td><td>0.74</td><td>0.002</td></tr><tr><td>Contact Material (n = 163, m = 18)</td><td></td><td></td><td></td><td></td></tr><tr><td>Bark</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td>Carpet</td><td>0.52</td><td>0.15</td><td>1.79</td><td>0.301</td></tr><tr><td>Blanket</td><td>0.78</td><td>0.30</td><td>2.02</td><td>0.612</td></tr><tr><td>Rice Sack</td><td>2.10</td><td>0.74</td><td>5.96</td><td>0.164</td></tr><tr><td>Saddle Weight (n = 191, m = 18)</td><td></td><td></td><td></td><td></td></tr><tr><td>Light (&lt;10 kg)</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td>Heavy (&gt;10 kg)</td><td>0.65</td><td>0.21</td><td>2.03</td><td>0.458</td></tr><tr><td>Break** (n = 194 , m = 18)</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>0.54</td><td>0.18</td><td>1.67</td><td>0.286</td></tr><tr><td>Age (n = 133, m = 17)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>1.03</td><td>1.002</td><td>1.05</td><td>0.034</td></tr><tr><td>Working Hours/Day (n = 194, m = 18)</td><td></td><td></td><td></td><td></td></tr><tr><td>Working Hours/Day</td><td>3.79</td><td>1.41</td><td>10.18</td><td>0.008</td></tr><tr><td>Working Hours/Day Squared</td><td>0.90</td><td>0.83</td><td>0.97</td><td>0.009</td></tr></table>
75ff3692c584e4ab9323233d47e8124f2f2c00e7039658a7570d9d4dea94ad88.png
simple
<table><tr><td>Simulation Parameters</td><td>Value</td></tr><tr><td>map dimension</td><td>2 km &#215; 1.5 km</td></tr><tr><td>Simulation time</td><td>1000 sec</td></tr><tr><td>Vehicle speed</td><td>0&#8211;15 m/s</td></tr><tr><td>Velocity threshold</td><td>7 m/s</td></tr><tr><td>MAC/PHY</td><td>IEEE 802.11p</td></tr><tr><td>Vehicle density</td><td>100&#8211;500</td></tr><tr><td>Route generator</td><td>SUMO</td></tr></table>
fb9e41fa0698366be1a7d74cbc5b11a6dca775a07ef6d850a0b61d07309463da.png
complex
<table><tr><td rowspan="2"></td><td>HFNO group</td><td>Venturi mask group</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>(n = 52)</td><td>(n = 48)</td></tr><tr><td colspan="4">Primary endpoint</td></tr><tr><td> Number (%) of patients requiring mechanical ventilation</td><td>8 (15 %)</td><td>4 (8 %)</td><td rowspan="3">0.36</td></tr><tr><td>Noninvasive mechanical ventilation</td><td>6<sup>a</sup></td><td>3<sup>a</sup></td></tr><tr><td>Invasive mechanical ventilation</td><td>4</td><td>2</td></tr><tr><td colspan="4">Secondary endpoints, median [25th&#8211;75th percentile]</td></tr><tr><td> Discomfort VAS score<sup>b</sup> at 120 min</td><td>3 [1&#8211;5]</td><td>3 [0&#8211;5]</td><td>0.88</td></tr><tr><td> Dyspnea VAS score<sup>b</sup> at 120 min</td><td>3 [2 &#8211; 6]</td><td>3 [1&#8211;6]</td><td>0.87</td></tr><tr><td> Thirst VAS score<sup>b</sup> at 120 min</td><td>6 [3&#8211;8]</td><td>6 [5 &#8211; 9]</td><td>0.40</td></tr><tr><td> Respiratory rate at 120 min, breaths/min</td><td>25 [22&#8211;29]</td><td>25 [21&#8211;31]</td><td></td></tr><tr><td> Heart rate at 120 min, beats/min</td><td>98 [90&#8211;110]</td><td>99 [83&#8211;112]</td><td>0.43</td></tr></table>
4fe8a6a9235fc5eb54a553cf8403ff6674dd0a0e0dc2df2859bc1d6c6599fa1e.png
simple
<table><tr><td>Gene-set ID</td><td>Gene-set Description</td><td>Gene N#</td></tr><tr><td>hi015</td><td>Predicted haploinsufficiency (most inclusive)</td><td>8862</td></tr><tr><td>hi035</td><td>Predicted haploinsufficiency</td><td>4136</td></tr><tr><td>hi055</td><td>Predicted haploinsufficiency (most stringent)</td><td>2214</td></tr><tr><td>ExpsNov_BrainFeAd_sp</td><td>Specific expression in human adult or fetal brain (Novartis Tissue Atlas)</td><td>1285</td></tr><tr><td>Synapse_GrantFull</td><td>Post-synaptic density components</td><td>1407</td></tr><tr><td>FMR1_Targets_Darnell</td><td>FMR1 targets (Darnell et al)</td><td>840</td></tr><tr><td>FMR1_Targets_Ascano</td><td>FMR1 targets (Ascano et al)</td><td>927</td></tr><tr><td>thrEXPR_log2rpkm</td><td>Expressed in brain (BrainSpan)</td><td>13802</td></tr><tr><td>thr4.86_log2rpkm</td><td>Expressed in brain, very high (BrainSpan)</td><td>4595</td></tr><tr><td>thr3.32_log2rpkm</td><td>Expressed in brain, high/medium (BrainSpan)</td><td>4604</td></tr><tr><td>thr0.84_log2rpkm</td><td>Expressed in brain, medium/low (BrainSpan)</td><td>4603</td></tr><tr><td>thr.MIN_log2rpkm</td><td>Not expressed in brain (BrainSpan)</td><td>4600</td></tr><tr><td>PhHs_NervSys_ADX</td><td>Human nervous system phenotype (HPO), autosomal dominant or X-linked</td><td>620</td></tr><tr><td>PhHs_NervSys_All</td><td>Human nervous system phenotype (HPO)</td><td>784</td></tr><tr><td>PhHs_MindFun_ADX</td><td>Higher mental function phenotype (HPO), autosomal dominant or X-linked</td><td>395</td></tr><tr><td>PhHs_MindFun_All</td><td>Higher mental function phenotype (HPO)</td><td>687</td></tr><tr><td>MmHs_Neuro_All</td><td>Mouse neuro phenotype (MGI/MPO)</td><td>3479</td></tr><tr><td>MmHs_Extend_All</td><td>Mouse developmental phenotype (MGI/MPO)</td><td>4314</td></tr><tr><td>NeuroF_large</td><td>Neurobiological function, inclusive</td><td>2601</td></tr><tr><td>NeuroF_small</td><td>Neurobiological function, stringent</td><td>1088</td></tr><tr><td>Total</td><td>Total gene count</td><td>18203</td></tr></table>
0de74ca5e38138650b78a7035d5b62308ac0f1d381aca860e377769994e00d3e.png
complex
<table><tr><td> </td><td colspan="2">P1</td><td colspan="2">N1</td><td colspan="2">P2</td></tr><tr><td> </td><td>Latency (ms)</td><td>Amplitude (microvolts)</td><td>Latency (ms)</td><td>Amplitude (microvolts)</td><td>Latency (ms)</td><td>Amplitude (microvolts)</td></tr><tr><td>Older nonmusicians</td><td>65 (8)</td><td>2.02 (1.1)</td><td>104 (10)</td><td>&#8722;0.02 (0.95)</td><td>171 (15)</td><td>2.0 (1.4)</td></tr><tr><td>Older musicians</td><td>61 (8)</td><td>2.24 (0.8)</td><td>109 (12)</td><td>0.27 (1.1)</td><td>174 (15)</td><td>1.69 (1.0)</td></tr><tr><td>Younger musicians</td><td>74 (10)</td><td>1.84 (0.75)</td><td>105 (11)</td><td>0.21 (0.88)</td><td>147 (10)</td><td>2.21 (1.1)</td></tr><tr><td>Younger nonmusicians</td><td>74 (10)</td><td>2.00 (0.76)</td><td>103 (11)</td><td>0.199 (1.2)</td><td>146 (11)</td><td>2.43 (0.81)</td></tr></table>
fd1385eb0dd1f7ee5485c2ff5217eb847aa68b1105df388fe9b2ee1cf410dab1.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Time Period 1: April 6-May 5</td><td colspan="2">Time period 2: Aug 4- Sept 2</td><td colspan="2">Time period 3: Oct 3-Nov 1</td><td>Total</td></tr><tr><td>Cluster 1</td><td>Outside cluster 1</td><td>Cluster 2</td><td>Outside cluster 2</td><td>Cluster 3</td><td>Outside cluster 3</td><td>All cases 2010</td></tr><tr><td>Number of Cases</td><td>62</td><td>36</td><td>58</td><td>54</td><td>17</td><td>49</td><td>1,134</td></tr><tr><td>% Male</td><td>42%</td><td>44%</td><td>40%</td><td>54%</td><td>53%</td><td>49%</td><td>52%</td></tr><tr><td>Age in months (median, IQR)</td><td>13 (7,32)</td><td>24 (12,55)</td><td>9 (6, 57)</td><td>9 (6, 33)</td><td>12 (7,64)</td><td>13 (7,43)</td><td>12 (7,29)</td></tr><tr><td>HIV infection status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Infected</td><td>2 (3%)</td><td>0 (0%)</td><td>1 (2%)</td><td>6 (11%)</td><td>3 (18%)</td><td>3 (6%)</td><td>41 (4%)</td></tr><tr><td>Exposed</td><td>4 (7%)</td><td>3 (8%)</td><td>10 (18%)</td><td>6 (11%)</td><td>2 (12%)</td><td>5 (10%)</td><td>100 (9%)</td></tr><tr><td>Not infected</td><td>51 (84%)</td><td>33 (92%)</td><td>39 (70%)</td><td>38 (72%)</td><td>11 (65%)</td><td>33 (67%)</td><td>905 (80%)</td></tr><tr><td>Unknown</td><td>4 (7%)</td><td>0 (0%)</td><td>6 (11%)</td><td>3 (6%)</td><td>1 (6%)</td><td>8 (16%)</td><td>80 (7%)</td></tr><tr><td>Measles vaccination status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Vaccinated</td><td>16 (26%)</td><td>8 (22%)</td><td>10 (18%)</td><td>8 (15%)</td><td>2 (12%)</td><td>8 (16%)</td><td>221 (20%)</td></tr><tr><td>Not Vaccinated</td><td>36 (58%)</td><td>21 (58%)</td><td>31 (54%)</td><td>31 (59%)</td><td>8 (47%)</td><td>25 (51%)</td><td>618 (55%)</td></tr><tr><td>Unknown</td><td>10 (16%)</td><td>7 (19%)</td><td>16 (28%)</td><td>14 (26%)</td><td>7 (41%)</td><td>16 (33%)</td><td>286 (25%)</td></tr></table>
0e31c0b56e3b12898521d00f8852fd4517bbc305e954114f5ce82d5a4b150bd0.png
complex
<table><tr><td rowspan="2">Performance objectives</td><td colspan="2">Determinants</td></tr><tr><td>Information/knowledge</td><td>Self-efficacy/skills</td></tr><tr><td>To own LLINs</td><td>Explain the benefits of LLINs ownership</td><td>Demonstrate how a net should be used</td></tr><tr><td>To fight bedbugs</td><td>Explain the importance of fighting bedbugs as hindrances of LLINs use</td><td>Demonstrate how the technique should be done using hot water and local laundry powder soap (OMO)</td></tr><tr><td>To use LLINs every night</td><td>Explain the importance of using LLINs every night</td><td>Use of LLINs in spite of warm weather or weather changes</td></tr><tr><td>To allow IRS at household level</td><td>Describe IRS benefits</td><td>Allow IRS in master roomAllow IRS in storage rooms</td></tr><tr><td>To cover households water collection instruments</td><td>Explain how water collection instruments can be a source of mosquito breeding.</td><td>Cover water collection instruments every time</td></tr><tr><td>To clear mosquito breeding sites surrounding homesteads</td><td>Explain the importance of clearing water pits and bushes surrounding the homesteads</td><td>Perform regular cleaning activities at household level</td></tr><tr><td>To own a health insurance</td><td>Describe the importance of a health insurance in prompt health care-seeking</td><td>Participate in solidarity groups to enable regular contribution</td></tr><tr><td>To provide education on malaria symptoms</td><td>Describe common malaria symptoms</td><td>Identify common malaria symptoms</td></tr><tr><td>To promote early fever/malaria care-seeking (within 24 h)</td><td>Describe the importance of early care-seeking</td><td>Take a decision of seeking care promptly</td></tr><tr><td>To raise community awareness on the importance of diagnostic test before treatment</td><td>Describe the importance of a lab confirmed treatment for proper care and prevention of treatment resistance</td><td>Seek care at health facility (health centre/hospital)</td></tr><tr><td>To raise community awareness on the importance of malaria medication compliance</td><td>Describe the importance of treatment compliance to prevent disease relapse and treatment resistance</td><td>Adhere to the advice/treatment provided</td></tr><tr><td>To ensure proper training before implementation of larval source control</td><td>To provide knowledge on mosquito reproduction, malaria preventive measures and larval source control using biological substances</td><td>Attend onsite practical training</td></tr><tr><td>To adhere to the implementation plan</td><td>Discuss how larval source control will be implementedTo explain the use of reporting formats</td><td>Participate in actual implementation of larval source control</td></tr></table>
869965179101c4df6535aaa53208747fa1c9bee1675dbfe8b02ba7a9094996a9.png
complex
<table><tr><td>NA added (&#956;mol L<sup>-1</sup>)</td><td>NA found (&#956;mol&#183;L<sup>-1</sup>)</td><td>RSD (%)</td><td>Recovery (%)</td><td>Mean (%)</td></tr><tr><td>10.00</td><td>9.832</td><td>3.4</td><td>98.3</td><td rowspan="5">101.8</td></tr><tr><td>40.00</td><td>41.03</td><td>2.1</td><td>102.6</td></tr><tr><td>50.00</td><td>52.23</td><td>2.7</td><td>104.5</td></tr><tr><td>70.00</td><td>69.42</td><td>1.9</td><td>99.2</td></tr><tr><td>90.00</td><td>93.78</td><td>2.9</td><td>104.2</td></tr></table>
5bf350a3d13455376126b3e5a8ec562a6f82d28b32364d0a98e4874133dfea20.png
simple
<table><tr><td>Company</td><td>Founded</td><td>Guidance and usage</td></tr><tr><td>EDAP TMS</td><td>1979</td><td>US</td></tr><tr><td>SonaCare Medical (previously US-HIFU, International HIFU and Focus Surgery)</td><td>1997</td><td>US</td></tr><tr><td>Chongqing HAIFU</td><td>1999</td><td>Both</td></tr><tr><td>China Medical</td><td>1999</td><td>US</td></tr><tr><td>Insightec</td><td>1999</td><td>MR</td></tr><tr><td>Image Guided Therapy</td><td>2001</td><td>MR&#8212;animals</td></tr><tr><td>Shanghai A&amp;S</td><td>2001</td><td>Both</td></tr><tr><td>Mirabilis</td><td>2004</td><td>US</td></tr><tr><td>Theraclion</td><td>2004</td><td>US</td></tr><tr><td>Medsonic</td><td>2005</td><td>MR</td></tr><tr><td>Philips Healthcare</td><td>2005</td><td>MR</td></tr><tr><td>Supersonic Imagine</td><td>2005</td><td>Both</td></tr><tr><td>Profound</td><td>2008</td><td>MR</td></tr><tr><td>EyeTechCare</td><td>2008</td><td>Visual</td></tr><tr><td>Alpinion</td><td>2008</td><td>US</td></tr><tr><td>International Cardio Corporation</td><td>2009</td><td>US</td></tr><tr><td>Kona Medical</td><td>2009</td><td>US</td></tr><tr><td>Histosonic</td><td>2009</td><td>US</td></tr><tr><td>FUS instruments</td><td>2009</td><td>MR&#8212;animals</td></tr><tr><td>Acublate</td><td>2010</td><td>Both</td></tr></table>
fc7e988d8438931ce7331cc1ed4a975eecaf52fc2efb1b537277fd356016ff79.png
complex
<table><tr><td>Complex</td><td>H-bond/vdW contact AH..B/A..B</td><td><i>E</i><sup>(2)</sup>, kcal/mol</td><td><i>C</i>str, A&#778;/mDyn</td></tr><tr><td>1</td><td>C1H...O2</td><td>0.36</td><td>39.549</td></tr><tr><td>2</td><td>C1H...N3</td><td>1.00</td><td>22.928</td></tr><tr><td rowspan="2">3</td><td>C1H...O2</td><td>0.76</td><td>37.566</td></tr><tr><td>C1H...N3</td><td>0.03</td><td>33.407</td></tr><tr><td>8</td><td>C1H...N3</td><td>3.53</td><td>11.200</td></tr><tr><td rowspan="3">9</td><td>C6H...O2</td><td>3.27</td><td>16.085</td></tr><tr><td>C5H..N3</td><td>0.55</td><td>66.521</td></tr><tr><td>C1H...O2</td><td>1.00</td><td>27.809</td></tr><tr><td rowspan="3">10</td><td>C1H...O2</td><td>0.29</td><td>126.112</td></tr><tr><td>C1H...N3</td><td>0.74</td><td>43.476</td></tr><tr><td>C6H...O2</td><td>3.98</td><td>11.659</td></tr></table>
f7e40af5645bff915387a079978776c0cd885380168cd352a7d1cbe1b97b7581.png
complex
<table><tr><td rowspan="2">Nomenclature</td><td rowspan="2">rs</td><td rowspan="2">Nucleotide changes</td><td rowspan="2">Effect</td><td rowspan="2">n</td><td colspan="3">Genotype frequencies, %</td><td colspan="2">Allele frequencies, %</td></tr><tr><td>wt</td><td>ht</td><td>vt</td><td>p</td><td>q</td></tr><tr><td> <i>CYP2C8*2</i> </td><td>rs11572103</td><td>T805A</td><td>I269F</td><td>383</td><td>99.22</td><td>0.78</td><td>0.00</td><td>99.61</td><td>0.39</td></tr><tr><td> <i>CYP2C8*3</i> </td><td>rs11572080+ rs10509681</td><td>G416A+ A1196G</td><td>R139K + K399R</td><td>390</td><td>83.85</td><td>15.64</td><td>0.51</td><td>91.67</td><td>8.33</td></tr><tr><td> <i>CYP2C9*2</i> </td><td>rs1799853</td><td>C430T</td><td>R144C</td><td>391</td><td>79.54</td><td>20.20</td><td>0.26</td><td>89.64</td><td>10.36</td></tr><tr><td> <i>CYP2C9*3</i> </td><td>rs1057910</td><td>A1075C</td><td>I359L</td><td>394</td><td>81.22</td><td>17.77</td><td>1.02</td><td>90.10</td><td>9.90</td></tr><tr><td> <i>CYP2C19*2</i> </td><td>rs4244285</td><td>G681A</td><td>Splicing defect</td><td>393</td><td>58.52</td><td>39.19</td><td>2.29</td><td>78.12</td><td>21.88</td></tr><tr><td> <i>CYP2C19*3</i> </td><td>rs4986893</td><td>G636A</td><td>W212X</td><td>388</td><td>97.94</td><td>2.06</td><td>0.00</td><td>98.97</td><td>1.03</td></tr><tr><td> <i>CYP3A4*1B</i> </td><td>rs2740574</td><td>A-392 G</td><td>5'NTO change</td><td>389</td><td>94.86</td><td>5.14</td><td>0.00</td><td>97.43</td><td>2.57</td></tr><tr><td> <i>CYP3A4*2</i> </td><td>rs55785340</td><td>T664C</td><td>S222P</td><td>391</td><td>100.00</td><td>0.00</td><td>0.00</td><td>100.00</td><td>0.00</td></tr><tr><td> <i>CYP3A5*3</i> </td><td>rs776746</td><td>A6986G</td><td>R487C</td><td>392</td><td>0.26</td><td>11.99</td><td>87.76</td><td>6.25</td><td>93.75</td></tr><tr><td> <i>CYP2B6*5</i> </td><td>rs3211371</td><td>C1459T</td><td>Splicing defect</td><td>390</td><td>85.64</td><td>12.56</td><td>1.79</td><td>91.92</td><td>8.08</td></tr></table>
f408a15449d143d9e355c8df3e1511bf3c2b1a37c5f0e8656fc06d43a2fc2e36.png
complex
<table><tr><td rowspan="2"> </td><td>Patients with anti-C1q autoantibodies</td><td>Patients without anti-C1q autoantibodies</td><td rowspan="2">r value(<i>P </i>value)</td><td>Patients with levels of C1q above 40.97 &#956;g/ml</td><td>Patients with levels of C1q under 40.97 &#956;g/ml</td><td rowspan="2">r value(<i>P </i>value)</td></tr><tr><td>Median(range)</td><td>Median(range)</td><td>Median(range)</td><td>Median(range)</td></tr><tr><td colspan="7">Histopathological data</td></tr><tr><td>Activity Indices score</td><td>9(0,19)</td><td>7(0,16)</td><td>0.238(&lt;0.001)</td><td>4(0,19)</td><td>9(0,19)</td><td>&#8722;0.327(&lt;0.001)</td></tr><tr><td>Endocapillary hypercellularity</td><td>3(0,3)</td><td>2(0,3)</td><td>0.249(&lt;0.001)</td><td>3(0,3)</td><td>1(0,3)</td><td>&#8722;0.337(&lt;0.001)</td></tr><tr><td>Cellular crescents</td><td>2(0,6)</td><td>0(0,6)</td><td>0.167(0.013)</td><td>2(0,6)</td><td>0(0,6)</td><td>&#8722;0.182(0.007)</td></tr><tr><td>Karyorrhexis/fibrinoid necrosis</td><td>2(0,6)</td><td>0(0,4)</td><td>0.175(0.009)</td><td>2(0,6)</td><td>0(0,2)</td><td>&#8722;0.310(&lt;0.001)</td></tr><tr><td>Subendothelial hyaline deposits</td><td>1(0,3)</td><td>1(0,3)</td><td>0.171(0.012)</td><td>1(0,3)</td><td>0(0,3)</td><td>&#8722;0.312(&lt;0.001)</td></tr><tr><td>Interstitial inflammation</td><td>1(0,3)</td><td>1(0,3)</td><td>NS</td><td>1(0,3)</td><td>1(0,3)</td><td>NS</td></tr><tr><td>Leukocyte infiltration</td><td>1(0,3)</td><td>1(0,3)</td><td>0.159(0.019)</td><td>1(0,3)</td><td>1(0,3)</td><td>&#8722;0.246(&lt;0.001)</td></tr><tr><td>Chronicity Indices score</td><td>2(0,9)</td><td>2(0,10)</td><td>NS</td><td>2(0,10)</td><td>2(0,9)</td><td>NS</td></tr><tr><td>Glomerular sclerosis</td><td>0(0,3)</td><td>0(0,3)</td><td>NS</td><td>0(0,3)</td><td>0(0,3)</td><td>0.146(0.031)</td></tr><tr><td>Fibrous crescents</td><td>0(0,3)</td><td>0(0,3)</td><td>NS</td><td>0(0,3)</td><td>0(0,2)</td><td>NS</td></tr><tr><td>Tubular atrophy</td><td>1(0,3)</td><td>1(0,3)</td><td>NS</td><td>1(0,3)</td><td>1(0,3)</td><td>NS</td></tr><tr><td>Interstitial fibrosis</td><td>1(0,3)</td><td>1(0,3)</td><td>NS</td><td>1(0,3)</td><td>1(0,3)</td><td>NS</td></tr></table>
04992532a98aa9e7feb033aab87b06c83ab830231403ebbf714cf20dc5a3b3e0.png
complex
<table><tr><td rowspan="2">Treatment type</td><td colspan="3">IC<sub>50</sub> values (&#956;M)</td></tr><tr><td>on HepG2 cells</td><td>on A549 cells</td><td>on B16 cells</td></tr><tr><td>Duopafei<sup>&#174;</sup></td><td>0.96 &#177; 0.05</td><td>0.74 &#177; 0.02</td><td>0.72 &#177; 0.10</td></tr><tr><td>DTX-micelles</td><td>0.34 &#177; 0.02**</td><td>0.44 &#177; 0.05*</td><td>0.49 &#177; 0.08**</td></tr><tr><td>Blank micelles</td><td>12.84 &#177; 0.12</td><td>29.62 &#177; 1.02</td><td>13.79 &#177; 0.24</td></tr></table>
8a697dff010fe315dc419e0d20b4227428f45bb5ff84e6aed5a5ef1ff6719904.png
complex
<table><tr><td></td><td colspan="3">Tusablea</td></tr><tr><td>Algorithm</td><td>Eight</td><td>Eleven</td><td>Twelve</td></tr><tr><td>Random Tweak</td><td>1.99</td><td>8.47</td><td>10.17</td></tr><tr><td>CCDb</td><td>159.46</td><td>511.10</td><td>527.77</td></tr><tr><td>Wriggling</td><td>5.67</td><td>28.50</td><td>22.50</td></tr><tr><td>PLOP-build</td><td>3.39</td><td>35.00</td><td>71.67</td></tr><tr><td>Direct Tweak</td><td>34.00</td><td>73.44</td><td>75.65</td></tr><tr><td>LOOPYbb</td><td>22.86</td><td>62.21</td><td>59.15</td></tr></table>
a8b094e408ada60383d16bf6364d2a9496f64356687501f04bfe3de70c78bcaa.png
complex
<table><tr><td rowspan="2">Characteristic</td><td>Round 1</td><td>Round 2</td></tr><tr><td>n-size</td><td>n-size</td></tr><tr><td>Response rate</td><td>46</td><td>22</td></tr><tr><td colspan="3">Subjects</td></tr><tr><td>Male / Female</td><td>30/8</td><td>15/6</td></tr><tr><td colspan="3">Location</td></tr><tr><td>Europe</td><td>18</td><td>9</td></tr><tr><td>Oceania</td><td>8</td><td>5</td></tr><tr><td>United States</td><td>5</td><td>4</td></tr><tr><td>Caribbean</td><td>2</td><td>1</td></tr><tr><td>Canada</td><td>1</td><td>-</td></tr><tr><td>Africa</td><td>1</td><td>1</td></tr><tr><td>South America</td><td>1</td><td>1</td></tr><tr><td>India</td><td>1</td><td>-</td></tr><tr><td>South East Asia</td><td>1</td><td>-</td></tr><tr><td colspan="3">Discipline</td></tr><tr><td>Public health(incl.epidemiology)</td><td>21</td><td>11</td></tr><tr><td>Law (public health/social justice)</td><td>4</td><td>3</td></tr><tr><td>Geography</td><td>3</td><td>2</td></tr><tr><td>Agriculture</td><td>2</td><td>2</td></tr><tr><td>Transport</td><td>2</td><td>1</td></tr><tr><td>Policy</td><td>1</td><td>1</td></tr><tr><td>Nutrition</td><td>1</td><td>1</td></tr><tr><td>Environmental health</td><td>1</td><td>-</td></tr><tr><td>Planning (urban)</td><td>2</td><td>-</td></tr><tr><td>Economics</td><td>1</td><td>-</td></tr><tr><td>Sector</td><td></td><td></td></tr><tr><td>Academia</td><td>22</td><td>10</td></tr><tr><td>Not-for profit organisation</td><td>3</td><td>3</td></tr><tr><td>Government</td><td>12</td><td>7</td></tr><tr><td>Industry</td><td>1</td><td>1</td></tr></table>
568049ed0d65229a57481ee075240e730ab71dabda8a9f05ac4026e46883c143.png
complex
<table><tr><td>Age &#8211; group</td><td>Number</td><td>(%)</td></tr><tr><td>20 - 29</td><td>7</td><td>12.5%</td></tr><tr><td>30 - 39</td><td>10</td><td>17.9%</td></tr><tr><td>40 - 49</td><td>12</td><td>21.4%</td></tr><tr><td>50 - 59</td><td>17</td><td>30.4%</td></tr><tr><td>&#8805; 60</td><td>10</td><td>17.9%</td></tr><tr><td>Total</td><td>56</td><td>100%</td></tr><tr><td><i>Mean &#177; SD</i> = 44.96 &#177; 13.80</td><td colspan="2"><i>Range =</i> (21,80)</td></tr><tr><td>SEX</td><td>Number</td><td>%age</td></tr><tr><td>Female</td><td>50</td><td>89.3%</td></tr><tr><td>Male</td><td>6</td><td>10.7%</td></tr></table>
b4576eedfb69a95f7a1835e59a796205593f4e6eb6df9ed3adc7aa7a07667060.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Whole cohort</td><td colspan="2">HSES</td><td colspan="2">LSES</td><td rowspan="2"><i>p</i> value*</td></tr><tr><td><i>N</i></td><td>Mean (SD)</td><td><i>N</i></td><td>Mean (SD)</td><td><i>N</i></td><td>Mean (SD)</td></tr><tr><td>Age (years)</td><td>1343</td><td>8.0 (2.4)</td><td>673</td><td>8.0 (2.3)</td><td>670</td><td>8.1 (2.5)</td><td>0.4</td></tr><tr><td>Birth weight (kg)</td><td>960</td><td>3.3 (0.6)</td><td>482</td><td>3.2 (0.6)</td><td>478</td><td>3.3 (0.6)</td><td>0.2</td></tr><tr><td>Maternal age (years)</td><td>1131</td><td>35.0 (6.0)</td><td>610</td><td>35.1 (6.1)</td><td>521</td><td>35.0 (5.9)</td><td>0.8</td></tr><tr><td>Maternal weight (kg)</td><td>1081</td><td>72.1 (12.1)</td><td>556</td><td>72.5 (12.4)</td><td>482</td><td>71.6 (11.9)</td><td>0.2</td></tr><tr><td>Maternal height (cm)</td><td>1038</td><td>163.1 (8.2)</td><td>581</td><td>163.5 (8.5)</td><td>500</td><td>162.6 (7.9)</td><td>0.1</td></tr><tr><td>Maternal BMI (kg/m<sup>2</sup>)</td><td>993</td><td>27.3 (5.0)</td><td>539</td><td>27.3 (5.1)</td><td>454</td><td>27.3 (4.9)</td><td>0.99</td></tr><tr><td>Child weight (kg)</td><td>1343</td><td>25.3 (7.9)</td><td>673</td><td>26.4 (8.4)</td><td>670</td><td>24.2 (7.2)</td><td>&lt;0.001</td></tr><tr><td>Child height (cm)</td><td>1343</td><td>124.6 (14.6)</td><td>673</td><td>126.2 (14.7)</td><td>670</td><td>123.0 (14.3)</td><td>&lt;0.001</td></tr><tr><td>Child BMI (kg/m<sup>2</sup>)</td><td>1343</td><td>15.9 (2.2)</td><td>673</td><td>16.2 (2.4)</td><td>670</td><td>15.7 (1.9)</td><td>&lt;0.001</td></tr><tr><td>BMI children &lt; 6 years</td><td>222</td><td>15.5 (2.0)</td><td>104</td><td>15.7 (2.2)</td><td>118</td><td>15.4 (1.9)</td><td>0.35</td></tr><tr><td>BMI children 6&#8211;10 years</td><td>896</td><td>15.7 (2.1)</td><td>466</td><td>16.0 (2.3)</td><td>430</td><td>15.5 (1.7)</td><td>&lt;0.001</td></tr><tr><td>BMI children &gt;10 years</td><td>225</td><td>17.1 (2.4)</td><td>103</td><td>17.7 (2.6)</td><td>122</td><td>16.7 (2.1)</td><td>0.002</td></tr></table>
70f845bddfff049f4ceeb4ab19ad96b7bce864cc98792cbea93f913b6dfb813a.png
simple
<table><tr><td></td><td>Crohn's disease</td><td>Healthy controls</td></tr><tr><td>Number (Male/Female)</td><td>16 (7/9)</td><td>16 (9/7)</td></tr><tr><td>Median [range] age (years)</td><td>42 [22-66]</td><td>33 [22-62]</td></tr><tr><td>Disease location</td><td>L1: 2</td><td>-</td></tr><tr><td></td><td>L2: 6</td><td>-</td></tr><tr><td></td><td>L3: 8</td><td>-</td></tr><tr><td>Previous bowel resection</td><td>6</td><td></td></tr></table>
dfd3cf20c0e51b642c89a67ce390e4516b06aeb0ef9486b4e1981362ad2c46ac.png
complex
<table><tr><td> </td><td colspan="6"><i>S. aureus </i>isolate</td></tr><tr><td>Antibiotic</td><td>#1</td><td>#2*</td><td>#6</td><td>#18</td><td>#19</td><td>#20</td></tr><tr><td>Cefazolin</td><td>0.11</td><td>0.55</td><td>0.08</td><td>0.13</td><td>0.12</td><td>0.36</td></tr><tr><td>Cefoxitin</td><td>0.11</td><td>0.64</td><td>0.09</td><td>0.12</td><td>0.12</td><td>0.30</td></tr><tr><td>Cefepime</td><td>0.68</td><td>0.44</td><td>0.80</td><td>0.58</td><td>0.47</td><td>0.66</td></tr></table>
ca8971ef303735cf5733f7f59eec9bac0c8c18af09f85a1d698a308de1463faf.png
simple
<table><tr><td><i>Mz</i><sub>max</sub></td><td><i>SS</i></td><td><i>DF</i></td><td><i>RMC</i></td><td><i>F</i>-Ratio</td><td><i>P</i>-Value</td><td>Contribution (%)</td></tr><tr><td><i>N</i></td><td>0.5677</td><td>2</td><td>0.2838</td><td>7.75</td><td>0.0010</td><td>4.86</td></tr><tr><td><i>F</i></td><td>0.4028</td><td>2</td><td>0.2014</td><td>5.50</td><td>0.0063</td><td>3.45</td></tr><tr><td><i>B</i></td><td>5.0963</td><td>2</td><td>2.5481</td><td>69.59</td><td>&lt;0.0001</td><td>43.67</td></tr><tr><td><i>N&#8211;F</i></td><td>1.3567</td><td>4</td><td>0.3392</td><td>9.26</td><td>&lt;0.0001</td><td>11.63</td></tr><tr><td><i>N&#8211;B</i></td><td>1.6521</td><td>4</td><td>0.4130</td><td>11.28</td><td>&lt;0.0001</td><td>14.16</td></tr><tr><td><i>F&#8211;B</i></td><td>0.3234</td><td>4</td><td>0.0808</td><td>2.21</td><td>0.0784</td><td>2.77</td></tr><tr><td>Error</td><td>2.2702</td><td>62</td><td>0.0366</td><td>&#8211;</td><td>&#8211;</td><td>19.45</td></tr><tr><td>Corrected Total</td><td>11.6692</td><td>80</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr></table>
6f3d3b8721b0cb3a6ae7af66a95110b711c099f24935028207cda9b91c85333a.png
simple
<table><tr><td>Background characteristics</td><td>Percent</td><td>Selected independent variables</td><td>Percent</td></tr><tr><td>Maternal age (years)</td><td>27.3 &#177; 5.5*</td><td>Mode of delivery</td><td> </td></tr><tr><td>15&#8211;24</td><td>38.0</td><td>Vaginal delivery</td><td>37.4</td></tr><tr><td>25&#8211;29</td><td>34.3</td><td>Vaginal delivery + episiotomy</td><td>41.3</td></tr><tr><td>30&#8211;34</td><td>16.8</td><td>C-section</td><td>21.3</td></tr><tr><td>35&#8211;51</td><td>11.0</td><td>Brought infant formula to delivery room</td><td>21.3</td></tr><tr><td>Maternal education</td><td> </td><td>Experienced breastfeeding problems</td><td>10.6</td></tr><tr><td>Primary school or less</td><td>11.4</td><td>Received breastfeeding support from a family member</td><td> </td></tr><tr><td>Secondary school</td><td>48.2</td><td>During pregnancy</td><td>31.8</td></tr><tr><td>High school</td><td>24.5</td><td>During first 3 days after delivery</td><td>31.9</td></tr><tr><td>College or higher</td><td>15.9</td><td>Received breastfeeding support from a health care provider</td><td> </td></tr><tr><td>Female child</td><td>48.0</td><td>During pregnancy</td><td>44.1</td></tr><tr><td>Rural area of residence</td><td>83.3</td><td>During first 3 days after delivery</td><td>31.6</td></tr><tr><td>SES in quartiles</td><td>25.0</td><td>Exposure to infant feeding messages on TV in past 30 days</td><td> </td></tr><tr><td> </td><td> </td><td>Saw only breastfeeding information</td><td>2.6</td></tr><tr><td> </td><td> </td><td>Saw only infant formula advertising</td><td>36.5</td></tr><tr><td> </td><td> </td><td>Saw both infant formula and breastfeeding advertising</td><td>43.3</td></tr><tr><td> </td><td> </td><td>Saw neither message</td><td>17.6</td></tr></table>
aa50aea81fa2d9c5b145fb83f4f364827221e18c1a46d868309a858c10f67f65.png
complex
<table><tr><td></td><td></td><td></td><td></td><td colspan="3">100,000<sup>a</sup></td><td></td></tr><tr><td>Expected molecules target</td><td>1,000,000</td><td>200,000</td><td>150,000</td><td>A</td><td>B</td><td>C</td><td>10,000</td></tr><tr><td>Observed molecules target<sup>b</sup></td><td>1,173,333</td><td>290,000</td><td>255,000</td><td>115,000</td><td>110,667</td><td>97,333</td><td>11,200</td></tr><tr><td>SD</td><td>161,658</td><td>35,000</td><td>91,788</td><td>5,000</td><td>9,292</td><td>3,055</td><td>2,081</td></tr><tr><td>CV</td><td>13.78%</td><td>12.07%</td><td>36%</td><td>4.35%</td><td>8.40%</td><td>3.14%</td><td>21.89%</td></tr></table>
7d2a1a96b3145c5122707695aac59f4f877c45f1e5d25c27e6f4d9f3a6565a75.png
complex
<table><tr><td colspan="2">Characteristics</td><td>Frequency</td><td>%</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>230</td><td>57.50</td></tr><tr><td>Female</td><td>170</td><td>42.50</td></tr><tr><td rowspan="3">Level of selfitis</td><td>Borderline</td><td>136</td><td>34.00</td></tr><tr><td>Acute</td><td>162</td><td>40.50</td></tr><tr><td>Chronic</td><td>102</td><td>25.50</td></tr><tr><td rowspan="4">Age</td><td>16 to 20 years</td><td>224</td><td>56.00</td></tr><tr><td>21 to 25 years</td><td>136</td><td>34.00</td></tr><tr><td>26 to 30 years</td><td>27</td><td>06.75</td></tr><tr><td>Above 30 years</td><td>13</td><td>03.25</td></tr><tr><td rowspan="3">Number of selfies taken per day</td><td>1 to 4 selfies</td><td>223</td><td>55.75</td></tr><tr><td>5 to 8 selfies</td><td>141</td><td>35.25</td></tr><tr><td>More than 8 selfies</td><td>36</td><td>09.00</td></tr><tr><td rowspan="3">Number of postings per day</td><td>None</td><td>136</td><td>34.00</td></tr><tr><td>At least one time to three times</td><td>162</td><td>40.50</td></tr><tr><td>More than three times</td><td>102</td><td>25.50</td></tr></table>
1f3f2c80feae4fcdf0d9d233a83c326364306a33d4c458a9ca8e8eaad485093d.png
complex
<table><tr><td></td><td>Baseline</td><td colspan="4">Outcomes</td></tr><tr><td>Measure</td><td></td><td>1 Month</td><td>3 Month</td><td>6 Month</td><td>12 Month</td></tr><tr><td>Demographic factors</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age, sex, race/ethnicity, educational attainment, employment status, martial/partner status, type of housing</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Smoking history</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Number of cigarettes per day, use of other tobacco products, use of electronic-cigarette, number of years smoking, prior quit attempt, smoker in household, home smoking policy</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Nicotine dependence (time to first cigarette)</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Previous cessation medication use</i></td><td><i>X</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Importance in ability to quit</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Confidence in ability to quit/stay quit</td><td><i>X</i></td><td>X</td><td><i>X</i></td><td><i>X</i></td><td></td></tr><tr><td>Tobacco abstinence status&#8211;self-report</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cigarette smoking status</td><td>X</td><td>X</td><td>X</td><td>X</td><td><i>X</i><sup>1</sup></td></tr><tr><td>Non-cigarette tobacco use status</td><td>X</td><td>X</td><td>X</td><td>X</td><td><i>X</i><sup>1</sup></td></tr><tr><td>Electronic-cigarette use</td><td>X</td><td>X</td><td>X</td><td>X</td><td><i>X</i><sup>1</sup></td></tr><tr><td>Tobacco abstinence status&#8211;biochemical validation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Saliva cotinine or expired aired CO</td><td></td><td></td><td></td><td>X</td><td></td></tr><tr><td>Quit attempt (&gt;24 hours)</td><td>X</td><td>X</td><td></td><td></td><td></td></tr><tr><td>Hospital admission or emergency room visit</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><td><i>Quality of life (EQ-5D)</i></td><td><i>X</i></td><td></td><td></td><td><i>X</i></td><td></td></tr><tr><td><i>Anxiety and depression symptoms (PHQ-4)</i></td><td><i>X</i></td><td><i>X</i></td><td><i>X</i></td><td><i>X</i></td><td></td></tr><tr><td>Alcohol use (AUDIT-C)</td><td>X</td><td></td><td></td><td><i>X</i></td><td></td></tr><tr><td><i>Other non-tobacco substance use</i></td><td><i>X</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Satisfaction with IVR</td><td></td><td>X</td><td><i>X</i></td><td></td><td></td></tr><tr><td><i>Satisfaction with Quit Coach</i></td><td></td><td><i>X</i></td><td><i>X</i></td><td></td><td></td></tr><tr><td>Smoking during index hospital stay</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>Smoking cessation medication used after discharge</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><td>Smoking cessation counseling used after discharge</td><td></td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><td><i>Other smoking cessation programs/resources used</i></td><td></td><td><i>X</i></td><td><i>X</i></td><td><i>X</i></td><td></td></tr></table>
47b7b003ae6617547a5fdcfafc8673d3025cbc8e33cea5b6bd61ef7862f58ee2.png
simple
<table><tr><td>Indicators Groups (IG)</td><td>Number of species per IG</td><td>Number of grid cells required to represent all species from each IG</td><td>Percentage of species represented by IG (%)</td><td>Land cost-effective by IG ($)</td></tr><tr><td>Brachycephalidae</td><td>35</td><td>9</td><td>63</td><td>30,929,850</td></tr><tr><td>Bufonidae</td><td>33</td><td>9</td><td>59</td><td>30,929,850</td></tr><tr><td>Cycloramphidae</td><td>41</td><td>11</td><td>69</td><td>37,803,150</td></tr><tr><td>Hylidae</td><td>184</td><td>26</td><td>69</td><td>89,352,900</td></tr><tr><td>Hylodidae</td><td>33</td><td>13</td><td>65</td><td>44,676,450</td></tr><tr><td>Leiuperidae</td><td>31</td><td>8</td><td>71</td><td>27,493,200</td></tr><tr><td>Leptodactylidae</td><td>30</td><td>11</td><td>65</td><td>37,803,150</td></tr><tr><td>Microhylidae</td><td>21</td><td>8</td><td>59</td><td>27,493,200</td></tr></table>
28921364d10545e9c13bcb54b58be6e321012129302a8d36c94ace71b486e0e9.png
complex
<table><tr><td rowspan="2">Locus</td><td rowspan="2">Fragment</td><td colspan="2">PCR product length (bp)</td><td colspan="2">Number of tandem repeats</td></tr><tr><td>Fragment analysis</td><td>Sequencing</td><td>Fragment analysis<sup>1</sup></td><td>Sequencing</td></tr><tr><td>Ms27</td><td>1</td><td>285</td><td>282</td><td>2.4</td><td>2.0</td></tr><tr><td> </td><td>2</td><td>290</td><td>288</td><td>3.3</td><td>3.0</td></tr><tr><td> </td><td>3</td><td>295</td><td>294</td><td>4.2</td><td>4.0</td></tr><tr><td>Ms28</td><td>1</td><td>189</td><td>190</td><td>2.8</td><td>3.0</td></tr><tr><td> </td><td>2</td><td>201</td><td>202</td><td>4.8</td><td>5.0</td></tr><tr><td> </td><td>3</td><td>207</td><td>208</td><td>5.8</td><td>6.0</td></tr><tr><td> </td><td>4</td><td>213</td><td>214</td><td>6.8</td><td>7.0</td></tr><tr><td>Ms34</td><td>1</td><td>107</td><td>112</td><td>1.2</td><td>2.0</td></tr><tr><td> </td><td>2</td><td>113</td><td>118</td><td>2.2</td><td>3.0</td></tr><tr><td> </td><td>3</td><td>124</td><td>130</td><td>4.1</td><td>5.0</td></tr><tr><td> </td><td>4</td><td>136</td><td>142</td><td>6.1</td><td>7.0</td></tr><tr><td> </td><td>5</td><td>143</td><td>148</td><td>7.1</td><td>8.0</td></tr><tr><td> </td><td>6</td><td>148</td><td>153</td><td>8.1</td><td>9.0</td></tr><tr><td>Ms20b</td><td>1</td><td>252</td><td>258</td><td>4.4</td><td>4.5</td></tr><tr><td> </td><td>2</td><td>269</td><td>273</td><td>4.9</td><td>5.0</td></tr><tr><td> </td><td>3</td><td>349</td><td>354</td><td>7.3</td><td>7.5</td></tr><tr><td>Ms24</td><td>1</td><td>165</td><td>163</td><td>9.3</td><td>9.0</td></tr><tr><td> </td><td>2</td><td>179</td><td>177</td><td>11.3</td><td>11.0</td></tr><tr><td> </td><td>3</td><td>192</td><td>191</td><td>13.1</td><td>13.0</td></tr><tr><td> </td><td>4</td><td>287</td><td>289</td><td>26.7</td><td>27.0</td></tr><tr><td>Ms31</td><td>1</td><td>130</td><td>136</td><td>2.1</td><td>3.0</td></tr><tr><td> </td><td>2</td><td>145</td><td>150</td><td>4.3</td><td>5.0</td></tr></table>
af373c4874f551b02588a5ba0213168f852519bcb82f32271ce8a120a20956e5.png
complex
<table><tr><td rowspan="2">Loci</td><td colspan="4">Male</td><td colspan="4">Female</td></tr><tr><td>NC (%)</td><td>AITD (%)</td><td><i>P</i> value</td><td>OR/95% CI</td><td>NC (%)</td><td>AITD (%)</td><td><i>P</i> value</td><td>OR/95% CI</td></tr><tr><td>rs2046068</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> AA</td><td>195 (68.66)</td><td>147 (63.09)</td><td>0.230</td><td></td><td>364 (64.20)</td><td>475 (64.02)</td><td>0.955</td><td></td></tr><tr><td> CC</td><td>7 (2.47)</td><td>11 (4.72)</td><td></td><td></td><td>24 (4.23)</td><td>34 (4.58)</td><td></td><td></td></tr><tr><td> AC</td><td>82 (28.87)</td><td>75 (32.19)</td><td></td><td></td><td>179 (31.57)</td><td>233 (31.40)</td><td></td><td></td></tr><tr><td> A</td><td>472 (83.10)</td><td>369 (79.18)</td><td>0.108</td><td>0.774/0.566&#8211;1.058</td><td>907 (79.98)</td><td>1183 (79.72)</td><td>0.867</td><td>0.984/0.811&#8211;1.193</td></tr><tr><td> C</td><td>96 (16.90)</td><td>97 (20.82)</td><td></td><td></td><td>227 (20.02)</td><td>301 (20.28)</td><td></td><td></td></tr><tr><td>rs2227478</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> TT</td><td>195 (68.66)</td><td>148 (63.52)</td><td>0.329</td><td></td><td>363 (64.02)</td><td>474 (63.88)</td><td>0.982</td><td></td></tr><tr><td> CC</td><td>8 (2.82)</td><td>11 (4.72)</td><td></td><td></td><td>24 (4.23)</td><td>33 (4.45)</td><td></td><td></td></tr><tr><td> TC</td><td>81 (28.52)</td><td>74 (31.76)</td><td></td><td></td><td>180 (31.75)</td><td>235 (31.67)</td><td></td><td></td></tr><tr><td> T</td><td>471 (82.92)</td><td>370 (79.40)</td><td>0.148</td><td>0.794/0.580&#8211;1.086</td><td>906 (79.89)</td><td>1183 (79.88)</td><td>0.901</td><td>0.989/0.816&#8211;1.199</td></tr><tr><td> C</td><td>97 (17.08)</td><td>96 (20.60)</td><td></td><td></td><td>228 (20.11)</td><td>301 (20.28)</td><td></td><td></td></tr><tr><td>rs2227485</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> CC</td><td>76 (26.76)</td><td>64 (27.47)</td><td>0.880</td><td></td><td>170 (29.98)</td><td>251 (33.83)</td><td>0.171</td><td></td></tr><tr><td> TT</td><td>70 (24.65)</td><td>53 (22.74)</td><td></td><td></td><td>126 (22.22)</td><td>174 (23.45)</td><td></td><td></td></tr><tr><td> CT</td><td>138 (48.59)</td><td>116 (49.79)</td><td></td><td></td><td>271 (47.80)</td><td>317 (42.72)</td><td></td><td></td></tr><tr><td> C</td><td>290 (51.06)</td><td>244 (52.36)</td><td>0.676</td><td>1.054/0.825&#8211;1.346</td><td>611 (53.88)</td><td>819 (55.19)</td><td>0.505</td><td>1.054/0.903&#8211;1.231</td></tr><tr><td> T</td><td>278 (48.94)</td><td>222 (47.64)</td><td></td><td></td><td>523 (46.12)</td><td>665 (44.81)</td><td></td><td></td></tr><tr><td>rs1179251</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> CC</td><td>119 (41.90)</td><td>104 (44.63)</td><td>0.449</td><td></td><td>235 (41.45)</td><td>323 (43.53)</td><td>0.048<sup>&#8727;</sup></td><td></td></tr><tr><td> GG</td><td>31 (10.92)</td><td>18 (7.73)</td><td></td><td></td><td>54 (9.52)</td><td>97 (13.07)</td><td></td><td></td></tr><tr><td> CG</td><td>134 (47.18)</td><td>111 (47.64)</td><td></td><td></td><td>278 (49.03)</td><td>322 (43.40)</td><td></td><td></td></tr><tr><td> C</td><td>372 (65.49)</td><td>319 (68.45)</td><td>0.314</td><td>1.143/0.881&#8211;1.484</td><td>748 (65.96)</td><td>968 (65.23)</td><td>0.696</td><td>0.968/0.823&#8211;1.139</td></tr><tr><td> G</td><td>196 (34.51)</td><td>147 (31.55)</td><td></td><td></td><td>386 (34.04)</td><td>516 (34.77)</td><td></td><td></td></tr><tr><td>rs11611206</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> GG</td><td>232 (81.69)</td><td>184 (78.97)</td><td>0.602</td><td></td><td>454 (80.07)</td><td>598 (80.59)</td><td>0.387</td><td></td></tr><tr><td> AA</td><td>1 (0.35)</td><td>2 (0.86)</td><td></td><td></td><td>3 (0.53)</td><td>9 (1.21)</td><td></td><td></td></tr><tr><td> GA</td><td>51 (17.96)</td><td>47 (20.17)</td><td></td><td></td><td>110 (19.40)</td><td>135 (18.20)</td><td></td><td></td></tr><tr><td> G</td><td>515 (90.67)</td><td>415 (89.06)</td><td>0.391</td><td>0.837/0.558&#8211;1.256</td><td>1018 (89.77)</td><td>1331 (89.69)</td><td>0.946</td><td>0.991/0.768&#8211;1.279</td></tr><tr><td> A</td><td>53 (9.33)</td><td>51 (10.94)</td><td></td><td></td><td>116 (10.23)</td><td>153 (10.31)</td><td></td><td></td></tr></table>
e50271e2fcc20a59bb5e8a28492141aa153f92abc5b7de5ab49ef323daad2b8b.png
simple
<table><tr><td>Biochemical category</td><td>Disease name</td><td>OMIM#</td><td>Gene(s)</td><td>Treatment</td><td>Effect</td><td>Level of evidence</td></tr><tr><td>Amino acids</td><td>PSAT deficiency</td><td>610992</td><td>PSAT1 (AR)</td><td>L-serine &amp; +/&#8722;glycine supplements</td><td>Primary/targeting underlying pathophysiology</td><td>4</td></tr><tr><td></td><td>PSPH deficiency (Serine deficiency)</td><td>614023</td><td>PSPH (AR)</td><td>L-serine &amp; +/&#8722;glycine supplements</td><td>Primary/targeting underlying pathophysiology</td><td>4</td></tr><tr><td>Creatine</td><td>Arginine:glycine amidinotransferase (AGAT) deficiency</td><td>612718</td><td><i>GATM (AR)</i></td><td>Creatine supplements</td><td>Primary/targeting underlying pathophysiology</td><td>4</td></tr><tr><td></td><td>Creatine transporter deficiency</td><td>300352</td><td><i>SLC6A8 (X-linked)</i></td><td>Creatine, glycine, arginine supplements</td><td>Primary/targeting underlying pathophysiology</td><td>4</td></tr><tr><td>Fatty acid oxidation</td><td>Carnitine palmitoyltransferase I deficiency</td><td>255120</td><td>CPT1A (AR)</td><td>Low-fat, high carbohydrate diet, avoid fasting, Medium Chain Triglyceride oil</td><td>Stablizilng/preventative treatment</td><td>4</td></tr><tr><td>Hyperhomocystinuria</td><td>Cobalamin deficiencies (<i>e.g.</i>, C, D, E, F, G)</td><td>251110, 277400, 277410, 236270, 277380</td><td>MMACHC, MMADHC, MTRR, LMBRD1, MTR (AR)</td><td>Hydroxy-/cyanocobalamin (+/&#8722; diet restriction, betaine, B12)</td><td>Stabilizing/preventative treatment</td><td>4</td></tr><tr><td>Lipid storage (Leukodystrophy)</td><td>Cerebrotendinous xanthomatosis (CTX)</td><td>213700</td><td>CYP27A1 (AR)</td><td>Chenodeoxycholic acid</td><td>Stabilizing/preventative treatment</td><td>4</td></tr><tr><td>Organic acids</td><td>HMG-CoA lyase deficiency</td><td>246450</td><td>HMGCL (AR)</td><td>Protein restriction, avoid fasting, emergency regimen</td><td>Stabilizing/preventative treatment</td><td>4-5</td></tr><tr><td></td><td>mHMG-CoA synthase deficiency</td><td>605911</td><td>HMGCS2 (AR)</td><td>Avoid fasting,emergency regimen, +/&#8722;dietary precursor restriction</td><td>Stabilizing/preventative treatment</td><td>5</td></tr><tr><td></td><td>SCOT deficiency</td><td>245050</td><td>OXCT1 (AR)</td><td>Avoid fasting, protein restriction, emergency regimen</td><td>Stabilizing/preventative treatment</td><td>5</td></tr><tr><td>Urea cycle</td><td>Carbamoyl phosphate synthetase (CPS) deficiency</td><td>237300</td><td><i>CPS1 (AR)</i></td><td>Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation)</td><td>Stabilizing/preventative treatment (primary/targeting underlying pathophysiology)</td><td>2b (4)</td></tr><tr><td></td><td>Citrullinemia type I (ASS deficiency)</td><td>215700</td><td><i>ASS1 (AR)</i></td><td>Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation)</td><td>Stabilizing/preventative treatment (primary/targeting underlying pathophysiology)</td><td>2b (4)</td></tr><tr><td></td><td>N-acetyl-glutamate synthetase deficiency</td><td>237310</td><td><i>NAGS (AR)</i></td><td>Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation)</td><td>Stabilizing/preventative treatment</td><td>4</td></tr></table>